

CURRICULUM VITAE

Kunle Odunsi, M.D., Ph.D., FRCOG, FACOG

PERSONAL INFORMATION

CITIZENSHIP: United States of America

PRIMARY APPOINTMENT: Cancer Center Director

ACADEMIC APPOINTMENTS: Obstetrics and Gynecology / Section of Gynecologic Oncology

PRESENT RANK: Professor

OFFICE ADDRESS: 5841 South Maryland Avenue, MC1140
Chicago, IL 60637

OFFICE PHONE: Tel: 773-702-5769

HOME ADDRESS: 1101 Northeast Avenue
Oak Park, IL 60302

MARITAL STATUS: Married with three daughters. Wife: Ayo

EDUCATION

MEDICAL SCHOOL: University of Ife
Ife - Ife, Nigeria
1977-1984
B.Sc. Health Sciences - 1981
MB Ch.B. - 1984

GRADUATE: Weatherall Institute of Molecular Medicine
John Radcliffe Hospital
Oxford, United Kingdom
1993-1995
Ph.D., Immunogenetics (Open University)
Thesis Advisors: T. S. Ganesan, M.D., Ph.D.
and John Bell, M.D., Ph.D.

RESIDENCY:

Department of Obstetrics & Gynecology
Yale University School of Medicine
New Haven, Connecticut
1995-1999

FELLOWSHIP:

Division of Gynecologic Oncology
Roswell Park Comprehensive Cancer Center,
Elm & Carlton Streets
Buffalo, NY
1999 – 2001

EXECUTIVE LEADERSHIP:

Executive Leadership for Healthcare Professionals
Cornell University
Ithaca, NY
2016

NATIONAL ACADEMY OF MEDICINE: Elected, October 2018

POSTDOCTORAL TRAINING:

- 1999 – 2001 CLINICAL INSTRUCTOR / FELLOW, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA, Department of Gynecologic Oncology
- 1995 – 1999 RESIDENT, EXECUTIVE CHIEF RESIDENT, Yale University School of Medicine, New Haven, CT, USA, Department of Obstetrics & Gynecology
- 1993 – 1995 RESEARCH FELLOW, Molecular Oncology Laboratories, Imperial Cancer Research Fund, Institute of Molecular Medicine, University of Oxford.
- 1993 – 1995 HONORARY REGISTRAR, Nuffield Department of Obstetrics & Gynecology, John Radcliffe Hospital, Headington, Oxford, United Kingdom.
- 1991 – 1993 REGISTRAR, South Tyneside District Hospital, University of Newcastle Upon-Tyne, South Shields, Tyne & Wear, U.K.
Department of Obstetrics & Gynecology
- 1990 – 1991 ACTING REGISTRAR (Senior SHO), The Rosie Maternity & Addenbrooke's Hospitals, University of Cambridge, Cambridge, United Kingdom
Department of Obstetrics & Gynecology
- 1988 – 1989 REGISTRAR, University Teaching Hospitals Complex, Ile-Ife, Nigeria
Department of Obstetrics & Gynecology
- 1986 – 1988 SENIOR HOUSE OFFICER, Ogun-State University Teaching Hospital, Nigeria
Department of Obstetrics & Gynecology
- 1985 – 1986 MEDICAL OFFICER (National Youth Service), Institute of Child Health and Primary Care, College of Medicine of the University of Lagos, Nigeria
- 1984 – 1985 HOUSE OFFICER, Military Hospital, Lagos, Nigeria
Rotating Internship

FACULTY / ACADEMIC APPOINTMENTS

- 2021 Cancer Center DIRECTOR
University of Chicago Medicine Comprehensive Cancer Center, Chicago, IL
- 2021 DEAN, for Oncology, Biological Sciences Division,
University of Chicago, Chicago, IL
- 2021 PROFESSOR, Department of Obstetrics and Gynecology,
University of Chicago, Chicago, IL
- 2015 - 2021 Cancer Center DEPUTY DIRECTOR
Roswell Park Comprehensive Cancer Center, Buffalo, NY
- 2010 - 2021 CHAIR, Department of Gynecologic Oncology
Roswell Park Comprehensive Cancer Center, Buffalo, NY
- 2009 - 2021 EXECUTIVE DIRECTOR, Center for Immunotherapy
Roswell Park Comprehensive Cancer Center, Buffalo, NY
- 2008 - 2021 PROFESSOR (Tenure), Department of Obstetrics and Gynecology
School of Medicine and Biomedical Sciences, State University of New York,
Buffalo, NY
- 2007 - 2021 PROFESSOR OF ONCOLOGY, Gynecologic Oncology
Roswell Park Comprehensive Cancer Center, Buffalo, NY
- 2006 – 2007 ASSOCIATE PROFESSOR OF ONCOLOGY, Gynecologic Oncology
Roswell Park Comprehensive Cancer Center, Buffalo, NY
- 2006 – 2008 ASSOCIATE PROFESSOR (Tenure), Department of Obstetrics and Gynecology
State University of New York at Buffalo, Buffalo, NY
- 2005 – 2011 DIRECTOR, United States of America, Cancer Vaccine Collaborative
Ludwig Institute for Cancer Research
- 2004 - 2019 RESEARCH PROGRAM DIRECTOR, Division of Gynecologic Oncology
Roswell Park Comprehensive Cancer Center, Buffalo NY
- 2001 – 2021 ATTENDING STAFF PHYSICIAN, Division of Gynecologic Oncology
Roswell Park Comprehensive Cancer Center, Buffalo, NY
- 2001 – 2006 ASSISTANT PROFESSOR, Department of Obstetrics and Gynecology
State University of New York at Buffalo, Buffalo, NY

LICENSURE AND CERTIFICATION

1991	Membership, Royal College of Obstetricians and Gynaecologists, London, United Kingdom (MRCOG)	(active)
1992	General Medical Council, United Kingdom	(active)
2001	State of New York 220316-1	(active)
2003	American Board of Obstetrics & Gynecology Parent Boards	(active)
2003	Fellow of The American College of Obstetricians and Gynecologists (FACOG)	(active)
2004	Gynecologic Oncology Subspecialty Board	(active)
2004	Fellow of The Royal College of Obstetricians and Gynecologists, London, United Kingdom (FRCOG)	(active)
2021	State of Illinois 036156037	(active)

HONORS AND AWARDS

- 2021 Illinois Science & Technology Coalition (ISTC) Researchers to Know 2021
- 2021 Society of Gynecologic Oncology (SGO) Innovation Award
- 2020 Society for Immunotherapy of Cancer (SITC) Team Science Award
- 2020 Buffalo Business First – 2020 C-Level Executives Award
- 2019 The Robert, Anne & Lew Wallace Endowed Chair in Cancer Immunotherapy
- 2019 Ovarian Cancer Research Alliance’s Rosalind Franklin Prize for Excellence in Ovarian Cancer Research
- 2018 Elected to the National Academy of Medicine, United States (formerly IOM)
- 2015 Medaille College 10th Annual Media Awards, Lifetime Achievement in Medicine and Research
- 2014 Institute of Medicine (IOM) of the United States National Academies, Committee on the State of the Science in Ovarian Cancer Research
- 2013 Fellow, Nigerian Academy of Science
- 2012 Thomas B. Tomasi, MD, PhD Hope Award
(Faculty member whose work has made significant advances in the fight against cancer and brought hope to cancer patients), Roswell Park Comprehensive Cancer Center, Buffalo, New York
- 2012 Great Ife Alumni Award for Excellence in the Sciences
- 2012 D’Youville College Achievement in Health Care Award
- 2007 The M. Steven Piver Endowed Professor of gynecologic Oncology
Roswell Park Cancer Institute, Buffalo, NY
- 2007 The Buffalo Medical Union, Buffalo, New York
- 2007 Epsilon of New York Chapter of Alpha Omega Alpha, Buffalo, New York
- 2005 Anna-Marie Kellen Clinical Investigator Award
Cancer Research Institute, New York, NY
- 2002 Best Teaching Faculty Award
University at Buffalo, Buffalo, NY
- 2000 Berlex Oncology Foundation Travel Award (Genetics in
Oncology Workshop)
Roswell Park Cancer Institute, Buffalo, NY
- 1999 Meehan-Miller Award to the graduating chief resident who most exemplifies the scholarly
attributes of Obstetrics and Gynecology

Yale University School of Medicine, New Haven, CT

- 1999 Irving Friedman Memorial Award for clinical excellence in Obstetrics and Gynecology
Yale University School of Medicine, New Haven, CT
- 1999 Peter A. Granuum Memorial Award, for the Chief Resident with a humanistic approach to medicine and dedicated to teaching medical students
Yale University School of Medicine, New Haven, CT
- 1999 American Society for Colposcopy and Cervical Pathology Award for the top resident in colposcopy and the study of lower genital tract disease
Yale University School of Medicine, New Haven, CT
- 1998 Award for Best presented paper in OBGYN
National Medical Association /NIH Scientific Assembly, New Orleans, USA
- 1998 Most Outstanding Senior Resident
Hospital of St Raphael / Yale University School of Medicine, New Haven, CT
- 1998 Temporary Adviser on Reproductive Health
World Health Organization, Geneva, Switzerland
- 1997 Berlex Laboratories Resident Teaching Award in Obstetrics & Gynecology, Yale University School of Medicine, New Haven, CT
- 1993 Wellbeing Research Fellowship
Royal College of Obstetricians and Gynecologists, London, United Kingdom
- 1981 Honors in Health Sciences, University of Ife

SCIENTIFIC AND PROFESSIONAL SOCIETIES

- 1991- Royal College of Obstetricians & Gynecologists, United Kingdom.
- 1996- American Association of Cancer Research
- 2001- American Society of Clinical Oncology
- 2002- 2012 Cancer Vaccine Collaborative, Ludwig Institute for Cancer Research
- 2003- American Congress of Obstetricians & Gynecologists
- 2003- Society for Reproductive Investigation
- 2004- Gynecologic Oncology Group, USA
- 2004- Society of Gynecologic Oncology
- 2007- Association of African Biomedical Scientists
- 2007- Cancer Immunotherapy Consortium
- 2009- American Gynecological and Obstetrical Society
- 2009- Ovarian Cancer Association Consortium
- 2010- Cancer Immunotherapy Trials Network, USA
- 2014-2021 Medical Society of the County of Erie and the Medical Society of the State of New York
- 2015- Society of Immunotherapy Cancer (SITC)
- 2016- European Network for Translational Research in Ovarian Cancer (EUTROC)

COMMITTEES

Roswell Park Cancer Institute

2020-2021 Epigenetics SPORE Internal Advisory Board
2020-2021 Buffalo Niagara COVID-19 Research Collaborative
2018-2021 Steering Committee of the Cancer Immunology Working Group (CIMM)
2016-2021 Finance Advisory Committee
2016-2021 Global Biotechnology and Cancer Therapeutics Scientific Advisory Board
2015-2021 Translational Research Committee
2015-2021 Roswell Park Board of Directors
2015-2021 Alliance Foundation Board of Directors
2014-2015 Roswell Park President/Chief Executive Officer Search Committee
2014-2021 Informatics Governance Steering Committee
2010-2021 BioMolecular Shared Resource Advisory Committee
2009-2021 Familial Ovarian Cancer Registry, Co-PI
2007-2010 cGMP Taskforce
2006-2021 Pathology Resource Network Steering Committee
2006-2012 Clinical Research Feasibility and Prioritization Committee
2006-2008 NMR Steering Committee
2006-2021 Hematopoietic Progenitor Cell (HPC) Medical Advisory Committee
2005-2021 Cancer Center Support Grant (CCSG) Steering Committee
2005-2021 Databank & Biorepository Shared Resource (DBBR) Steering Committee
2005-2021 Department of Medicine Search Committee
2005-2008 Surgical Oncology Chair Search Committee
2005-2021 Clinical/Translational Research Advisory Committee
2003-2021 Ethics Committee
2002-2021 Tumor Immunology Program Advisory Committee
2001-2021 Surgical Quality Assurance Committee
2001-2021 Utilization Review Committee
2001-2021 Advisory Committee, Laboratory of Immunological Monitoring

State University of New York at Buffalo, Buffalo, NY

2009-2021 Search Committee, for Chair, University at Buffalo, SUNY Department of Gynecology-Obstetrics
2007-2009 Admissions Committee, University at Buffalo Medical School

New York State

2006-2021 New York State Department of Health, Bureau of Chronic Disease Services, New York, NY, Ovarian Cancer Information Program Planning Committee
2007 Member, New York State Cancer Consortium
2015-2021 Board Member, Health Research Incorporated

Community

2005-2012 Member, Church Council, Evangel Assembly of God Church, Williamsville, NY
2005-2009 National Medical Association, Buffalo Chapter: Vice President
2004-2006 Erie Niagara Area Health Education Center Board of Directors, Buffalo, NY
2012-2013 BUILD of Buffalo, Board Member
2016-2021 Board Member, Hauptman-Woodward Institute, Buffalo, NY
2020-2021 HWI Long Range Planning Committee

Other

2014 Celsion-EGEN, Clinical Advisory Panel

2016-present Scientific Advisory Board, OmniSeq, LLC
2016-present Scientific Advisory Board, Triumvira Immunologics Inc.
2016-2021 Buffalo Translational Consortium Board, Clinical and Translational Research
Center (CTRC)

International

2020-Present Daiichi Sankyo Co., Ltd., External IO Steering Committee

Yale University School of Medicine, New Haven, CT

1998-1999 OB-GYN Residency Committee
1997-1999 Women's Center Task Force

South Tyneside District Hospital, South Shields, United Kingdom

1991-1993 Maternity Services Committee

NATIONAL COMMITTEES

Society for Immunotherapy of Cancer

2020-2023 Board of Directors, At-Large Director

National Academy of Medicine

2020-present 2020 NAM International Candidate Subcommittee

National Cancer Institute Study Sections

2017-present Permanent member, National Institutes of Health, Transplantation, Tolerance, and Tumor Immunology (TTT) Study Section

2017-2021 Member, NCI Cancer Center Subcommittee-A Initial Review Group

Institute of Medicine (IOM) of the United States National Academies

2014-2016 IOM's Committee on the State of the Science in Ovarian Cancer Research

National Institutes of Health/National Cancer Institute

2021- present Immunotherapy Task Force

2013-2019 Co-Chair, NCI Ovarian Task Force

2014-present Member, Gynecologic Cancer Steering Committee, Core Planning Committee

2015 Cancer Therapy Evaluation Program – Investigational Drug Steering Committee
PD-L1 Project Team

2020-Present Co-Chair, Immuno-Oncology Translational Network (IOTN) Steering
Committee

Ovarian Cancer Research Fund Alliance

2014-present Member, Scientific Advisory Committee

Cancer Research Institute

2013-present Member, Scientific Advisory Council

- CLIP Review Committee

- Clinical Accelerator Leadership Committee

2020-present Associate Director

Society for Gynecologic Oncology

2016-2018 Member, Program Committee

2021-2022 Member, Nominating Committee

American Society of Clinical Oncology

2013-2016 Member, Scientific Program Committee, Gynecologic Cancer Subcommittee

2017-2021 ASCO Representative, ASCO-SITC Clinical Immuno-Oncology Symposium
Program Committee

Cancer Immunotherapy Consortium, USA

2008-2014 Chair, Immunological Monitoring Committee

2012-2013 Member, Annual Scientific Meeting Planning Committee

2014-2017 Member, Scientific Advisory Council

Marsha Rivkin Center for Ovarian Cancer Research,

2008-present Scientific Advisory Board

2010-present Grant Programs Review Committee

2011-2014 Rivkin Symposium Planning Committee

Translational Research Cancer Center Consortium

2012-present Member, Program Committee

NRG Oncology (formerly Gynecologic Oncology Group, USA)

2001-2012 Immunotherapy Subcommittee

2004-present Co-Principal Investigator – Roswell Park Cancer Institute

2004-present Experimental Medicine Committee

2010-present Translational Research Co-Chair, GOG-0265: “A Phase II Evaluation of ADXS11-001 C (NSC 752718, IND#13,712) in the Treatment of Persistent or Recurrent Squamous or Non-Squamous Cell Carcinoma of the Cervix”

2011-2016 Translational Research Co-Chair, GOG-0271: “A Study of the Local and Systemic Effects of Intraperitoneal Chemotherapy in the Treatment of Previously-untreated, Invasive Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma”

2012-2015 Translational Research Co-Chair, GOG-9928: “A Phase I Study of Intraperitoneal Egen-001 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer) (IND #12,484) Administered in combination with Pegylated Liposomal-Doxorubicin (PDL, DOXIL (NSC# 712227 or LIPODOX (NSC# 673089 in Patients with Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer”

American Association for Cancer Research

2011-present Member, AACR-Minorities in Cancer Research Jane Cooke Wright Lectureship Selection Committee

2011-present Member, CIMM Nominating Committee

2016 – 2017 Member, 2017 AACR Annual Meeting Scientific Program Committee

2017 Chair, AACR-AstraZeneca Fellowship in Ovarian Cancer Research Scientific Review Committee

2018-2021 Member, CIMM; Member, Program Committee

2020-2022 Chairperson-elect, CIMM

2021-2023 Chairperson, CIMM

2021-Present Member, AACR Publications Committee

2023-2024 Past Chairperson, CIMM

MIATA-minimal information about T cell assays

2010-2012 Member, Core Team

National Ovarian Cancer Coalition

2011 Member, Medical and Scientific Advisory Board

Society for Gynecologic Investigation, USA

2005-2006 53rd Annual Meeting Program Committee

2005-2006 54th Annual Meeting Program Committee

2007-2008 55th Annual Meeting Program Committee

2008-2009 56th Annual Meeting Program Committee

2009-2010 57th Annual Meeting Program Committee

2010-2014 Member, Nomination Committee

Fox Chase Cancer Center/University of Pennsylvania

2010-2013 Member, External Advisory Board Ovarian SPORE

Seattle Ovarian Cancer SPORE/Fred Hutchinson Cancer Center

2014-2017 Member, External Advisory Board Ovarian SPORE

MD Anderson Cancer Center Ovarian Cancer SPORE

2015-present Member, External Advisory Board Ovarian SPORE

Mayo Clinic

2019-present Member, External Advisory Board Ovarian SPORE

Harvard Medical School – Dana-Farber Cancer Institute

2021-present Member, Ovarian Cancer SPORE External Advisory Board

Frontiers in Cancer Immunotherapy

2015-2017 Member, 2017 Frontiers in Cancer Immunotherapy Meeting, Scientific Organizing Committee

Society for Immunotherapy of Cancer

2016-present Reviewer, SITC Fellowship Review Task Force

2020-present Co-Chair, Diversity and Inclusion Task Force

ImmunoVaccine Technologies

2017-present Member, Scientific and Clinical Advisory Committee

Helen Harris Memorial Trust Ovarian Cancer Meeting, London, UK (Ovarian Cancer Action)

2018-2019 Member Organizing Committee

Memorial Sloan Kettering Cancer Center Uterine Cancer SPORE

2019 Member, External Advisory Board, Ovarian SPORE

2020-present External Advisory Board, MSK Human Oncology & Pathogenesis Program (HOPP)

Reproductive Scientist Development Program (RSDP)

2014-present Member, Selection Committee

Amgen, Inc.

2020-present Member, Ovarian Cancer Commercial Virtual Advisory Board

Case Comprehensive Cancer Center (Case CCC)

2021-present Member, External Advisory Committee

OVARCOME – Overcoming Cancer

2021-present Member, Ovarcome Advisory Board

Rutgers Cancer Institute of New Jersey

2021-present Member, External Advisory Board

UPMC Hillman Cancer Center

2021-present Member, External Advisory Board

UCLA Jonsson Comprehensive Cancer Center

2021-present Member, External Advisory Board

National Academy of Medicine

2021-present Vice Chair of Section 5

GRANTS REVIEW/STUDY SECTION

- 2021 Reviewer, International Review Committee, Terry Fox Marathon of Hope Cancer Centres
- 2020 Reviewer, Ontario Institute for Cancer Research (OICR)
- 2020 NCI Cancer Centers Subcommittee-A Initial Review Group: Standing Member
- 2020 Reviewer, NIH Transplantation, Tolerance, and Tumor (TTT) Immunology Study Section Peer Review Virtual Meeting.
- 2020 Reviewer, Data Visualization Tool Development Workshop for the NCI Cancer Moonshot
- 2020 T32 Advisory Committee, Rutgers Cancer Institute of New Jersey
- 2020- Reviewer, Ovarian Cancer Research Alliance, 2021 Research Grants
- 2020- Editorial Board Member, JITC Best Paper Award Overview 2020
- 2020- Moderator, AACR/Marsha Rivkin Virtual Ovarian Cancer Research Seminar Series – Immuno-oncology
- 2020- SGO 20/20 Vision for the Future - Annual Meeting on Women’s Cancer Series Education Webinar - Developmental Therapeutics in Gynecological Cancer, Panelist
- 2020- AACR Annual Meeting 2020 - Virtual Tumor Immunology and Immunotherapy for Nonimmunologists: Roundtable Discussions
- 2019- NIH External Advisory Board, Cancer Metabolism and Growth and Tumor Host Interactions Training Program
- 2019 Reviewer, NIH Reproductive Scientist Development Program (RSDP) Selection Committee, Washington, DC
- 2019- Endometrial Cancer SPORE External Advisory Board, Memorial Sloan Kettering Cancer Center, New York, NY
- 2019- Ovarian Cancer SPORE External Advisory Board, Harvard University.
- 2017- NCI Cancer Center Subcommittee-A Initial Review Group: Standing Member
- 2016- National Institutes of Health, Transplantation, Tolerance, and Tumor Immunology Study Section (TTT): Standing Member
- 2016- Chair, International Review Committee, Terry Fox Research Institute, immunoTherapy NeTwork(iTNT): Targeting ovarian cancer, Vancouver, BC Canada
- 2015- Reviewer, NIH Reproductive Scientist Development Program (RSDP), Standing Member.

- 2015-2017 P01 External Advisory Board, Memorial Sloan Kettering Cancer Center, New York, NY
- 2015- CRI Scientific Advisory Council, Translational Research Grants.
- 2015 FDA Public Workshop: Ovarian Cancer Endpoints Workshop
Silver Spring, MD
- 2015- Advisory Board Steering Committee, Seattle Ovarian Cancer SPORE (University of Washington / Fred Hutchinson Cancer Research Center)
- 2015 Scientific Advisory Board, Ontario Regional Biotherapeutics (ORBiT), Toronto, ON, Canada
- 2015 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, Breast and Ovarian Cancer Program CCSG renewal
- 2015 Scientific Advisory Committee, Ovarian Cancer Research Fund (OCRF)
Chicago, IL
- 2015 Gynecologic Cancer Steering Committee Strategic Planning Meeting
Rockville, MD
- 2015 Peer Review Panel, Terry Fox Research Institute, Program Project, Vancouver, BC
Canada
- 2015 NCI Site Review Panel, Cancer Center Support Grant (CCSG), Siteman Cancer Center, Washington University, St. Louis, MO
- 2014 T32 Advisory Board, UT MD Anderson Cancer Center
- 2014 Scientific Reviewer, Qatar Biomedical Research Institute, Qatar
- 2014 P01 External Advisory Board, University of Pittsburgh-University of Pittsburgh Cancer Institute
- 2014 P01 External Advisory Board, Memorial Sloan Kettering Cancer Center
- 2014 Chair, External Advisory Board, Seattle Ovarian Cancer SPORE (University of Washington / Fred Hutchinson Cancer Research Center)
- 2013 NCI Site Review Panel, Cancer Center Support Grant (CCSG), MD Anderson Cancer Center, Houston, TX
- 2013- Program Reviewer, Ontario Institute for Cancer Research (OICR) Ontario Regional Bio-Therapeutics Program (ORBiT)
- 2013 Program Reviewer, University of Washington, Seattle, Women's Reproductive Health Research (WRHR)
- 2013- Cancer Research Institute's Clinic and Laboratory Integration Program (CLIP)
- 2012 University of Chicago, External Advisory Board Breast Cancer SPORE
- 2012 Scientific Reviewer, Medical Research Council, United Kingdom

- 2012 Scientific Reviewer, European Commission, 7th Framework Program for HEALTH Research
- 2012 Scientific Reviewer, French National Institute for Cancer (Institut National du Cancer).
- 2012 Scientific Reviewer, Research Grants Council (RGC) of Hong Kong
- 2009 Scientific Reviewer, National Institutes of Health, NCI, PO1 Special Emphasis Panel, Cancer Prevention, Control and Population Sciences
- 2011, 2012
- 2009, Scientific Reviewer, Royal College of Obstetricians and Gynecologists (RCOG) Wellbeing of Women Research Grant
- 2010
- 2010 Scientific Reviewer, National Institutes of Health, P01 Clinical Studies Special Emphasis Panel
- 2009 Scientific Reviewer and Discussion Leader, NCI P01 Clinical Studies Special Emphasis Panel, Cell-Mediated Clinical Oncology Studies
- 2009 Scientific Reviewer, Italian Association for Cancer Research (AIRC -Associazione Italiana per la Ricerca sul Cancro)
- 2009 Scientific Reviewer, Swiss Cancer League, Bern Switzerland
- 2009 National Institutes of Health, NCI SPORE in Ovarian and Gynecologic Cancers
- 2008 Scientific Reviewer and Discussion Leader, NCI P01 Clinical Studies Special Emphasis Panel
- 2008 National Institutes of Health, Cancer Immunopathology and Immunotherapy Study Section
- 2007 Concept Panel Review, Department of Defense Ovarian Cancer Research Program
- 2006, Scientific Review Study Section, Department of Defense Ovarian Cancer Research Program
- 2005
- 2006 Marsha Rivkin Center for Ovarian Cancer Research, Pilot Study Program
- 2005 Cancer Research UK, Clinical Research Training Fellowship Section
- 2004 Sheffield Hospitals Charitable Trust, Medical Research Committee

EDITORIAL BOARDS

Ad Hoc Reviewer

Nature, Nature Medicine, Cancer Discovery, Proceedings of the National Academy of Sciences, U.S.A., BLOOD, Cancer Research, Clinical Cancer Research, BMC Cancer, Cancer Immunity, Cancer Immunology Immunotherapy, Journal of Clinical Investigation, Cancer Letters, Cancer Research, Expert Opinion on Biological Therapy, Fertility and Sterility, Future Oncology, Gynecologic Oncology, Gynecological Surgery, International Journal of Cancer, Journal of Cancer Immunology, Journal of Clinical Pathology, Journal of the Society for Gynecologic Investigation, The Lancet, Mayo Clinic Proceedings, Molecular Cancer Therapeutics, Oncogene, Oncology, PLoS One, American Journal of Obstetrics & Gynecology.

Editorial Board

2010- *BMC Cancer*, Associate Editor
2011-2013 *Cancer Immunity*
2011- *Journal of Translational Medicine, Clinical Translation Section*
2010- *OncoImmunology (Landes Bioscience)*
2013- *American Journal of Clinical and Experimental Obstetrics and Gynecology* –
Founding Editorial Board Member
2013- *Cancer Immunology Research (a journal of the AACR)* – Member
2013- *Cancer.Net* – Member, Advisory Panel for Gynecologic Cancers
2015- *Gynecologic Oncology*
2015- *Journal for ImmunoTherapy of Cancer (journal for SITC)*, Associate Editor
2016-2019 *Scientific Reports, Editorial Board*

VISITING PROFESSORSHIPS AND GUEST LECTURESHIPS

- 1998 *Current management of postpartum hemorrhage*
Annual meeting of the Society of Gynecology and Obstetrics of Nigeria (SOGON),
Benin City, Nigeria
- 2000 *New perspectives on the biology of human ovulation*
Frederick Naftolin Research Forum in Obstetrics and Gynecology,
Yale University School of Medicine
New Haven, CT
- 2001 *Evaluating evidence from the medical literature*
Obstetrics and Gynecology Journal Club
University at Buffalo, Buffalo, NY
- 2001 *Human papillomavirus and cervical cancer: A tale of David and Goliath*
Oxford Annual Gynecological Oncology Meeting,
Institute of Molecular Medicine
University of Oxford, Oxford, UK
- 2001 *New developments in the management of HPV and cervical dysplasia*
Comprehensive Update Course in Gynecological Oncology,
Roswell Park Cancer Institute, Buffalo, NY
- 2001 *Current management of the abnormal pap smear*
Family Medicine Grand Rounds
Niagara Falls Memorial Medical Center, Niagara Falls, NY
- 2001 *Analysis of NY-ESO-1 expression in epithelial ovarian cancer*
Ludwig Institute for Cancer Research,
New York, NY
- 2002 *Management of Abnormal Pap Smears*
Cancer 2002: Assessment & Therapeutics Update
Family Medicine Quarterly Grand Rounds,
University at Buffalo, Buffalo, NY
- 2002 *The abnormal pap smear: current treatment strategies*
The Witness Community Outreach Program
Roswell Park Cancer Institute, Buffalo, NY
- 2002 *Advances in antigen-specific immunotherapy for epithelial ovarian cancer*
Obstetrics and Gynecology Grand Rounds
University of Cincinnati, Cincinnati, OH
- 2003 *Current approaches to the management of adnexal masses*
Obstetrics and Gynecology Grand Rounds
University at Buffalo, Buffalo, NY
- 2003 *Controversies in the management of the abnormal pap smear*
Family Medicine Grand Rounds
Millard Fillmore Suburban Hospital
Williamsville, NY
- 2003 *Identification and characterization of target molecules for antigen-specific immunotherapy of ovarian cancer*
Guest Speaker, Institute of Molecular Medicine and Genetics
Medical College of Georgia
Augusta, GA
- 2003 *Current developments in antigen-specific immunotherapy for epithelial ovarian cancer*

- Obstetrics and Gynecology Grand Rounds
Medical College of Georgia
Augusta, GA
- 2003 *Advances in the identification and characterization of target molecules for the immunotherapy of ovarian cancer*
Guest Speaker, Tumor Immunology Program
Department of Immunology
Roswell Park Cancer Institute, Buffalo, NY
- 2003 *Antigen Specific Vaccine Therapy for Ovarian Cancer: Myth or Reality?*
Department of Gynecology-Obstetrics Grand Rounds
University of Buffalo, State University of New York
Buffalo, NY
- 2003 *Vaccine Therapy for Ovarian Cancer: An Evolving Paradigm to Prevent Recurrent Disease*
Breast & Gynecologic Cancers Update
Roswell Park Cancer Institute, Buffalo, NY
- 2004 *Phase I trial using NY-ESO 1 as a vaccine target in ovarian cancer*
Regional Cancer Center Consortium for the Biological Therapy of Cancer
7th Annual Meeting: Back to the Future
Roswell Park Cancer Institute, Buffalo, NY
- 2004 *Phase I trial using NY-ESO 1 as a vaccine target in ovarian cancer*
Regional Cancer Center Consortium for the Biological Therapy of Cancer
7th Annual Meeting: Back to the Future
Roswell Park Cancer Institute, Buffalo, NY
- 2004 *Cancer becomes a chronic disease*
2nd World Congress on Women's Mental Health
Washington, DC
- 2004 *Antigen Specific Vaccine Therapy for Ovarian Cancer: An Evolving Paradigm*
Surgical Oncology Core Curriculum Grand Rounds
Gynecologic Oncology
Roswell Park Cancer Institute, Buffalo, NY
- 2004 *New approaches for the early detection of epithelial ovarian cancer*
Wiser Lectureship in Gynecologic Surgery
University of Mississippi Medical Center, Jackson, MI
- 2004 *Antigen-specific vaccine therapy for ovarian cancer: an evolving paradigm*
Wiser Lectureship in Gynecologic Surgery
University of Mississippi Medical Center, Jackson, MI
- 2004 *Lessons from a pilot clinical trial of vaccine therapy with a NY-ESO-1 peptide of dual MHC class I and II specificities in ovarian cancer*
Cancer Vaccine 2004: The Next Decade Symposium
Ludwig Institute for Cancer Research, New York, NY
Cancer Immun [serial online] 2005; 5 Supp 1:22.
- 2005 *Phase I study of NY-ESO-1 DP4 peptide in patients with NY-ESO-1 or LAGE-1 expressing ovarian cancer*
Cancer Vaccine Collaborative
Ludwig Institute for Cancer Research, New York, NY
- 2005 *Immune surveillance and tolerance in a novel mouse model of ovarian cancer: lesson for human cancer vaccine development*
Society for Gynecologic Investigation 52nd Annual Meeting Symposium

- presentation
Los Angeles, CA
- 2005 *Vaccine therapy for ovarian cancer: Barriers and opportunities*
Obstetrics and Gynecology Grand Rounds
University of Vermont
Burlington, VT
- 2005 *Early Detection of Ovarian Cancer: New Avenues*
Breast & Gynecologic Cancers: 2005 Update
Roswell Park Cancer Institute
Buffalo, NY
- 2005 *Evolution of NY-ESO-1 cancer vaccines: Lessons learned*
Cancer Vaccine 2005: Barriers, Endpoints & Opportunities
Ludwig Institute for Cancer Research, New York, NY
Cancer Immun [serial online] 2006; 6 Suppl 1:12. URL:
http://www.cancerimmunity.org/v6suppl1p12/051026_abs.htm
- 2005 *Evolution of NY-ESO-1 Vaccine Therapy for Ovarian Cancer*
Ovarian Cancer: Prevention and Detection of the Disease and its Recurrence
Symposium
University of Pittsburgh
Pittsburgh, PA
- 2005 *Advances in Antigen Specific Immunotherapy for Ovarian Cancer*
Grand Rounds
Oregon Health & Science University
Portland, OR
- 2006 *Emerging Lessons from Clinical trials of Vaccine Therapy Targeting NY-ESO-1 in Ovarian Cancer*
9th Annual Meeting of the Regional Cancer Center Consortium for the Biological
Therapy of Cancer, University of Pittsburgh Medical Center
- 2006 *Moderator, Session on Stem Cells and Oncology*
53rd Annual Meeting of the Society for Gynecologic Investigation
Westin Harbour Castle, Toronto, Ontario, Canada
- 2006 *Immunologic Markers of Cancer Progression and Prognosis*
97th Annual Meeting of the American Association for Cancer Research
Washington DC
Am Assoc Cancer Res Educ Book 2006: 35-38
- 2006 *Identification of target molecules for antigen specific vaccine therapy of ovarian cancer*
Cornell University
Ithaca, NY
- 2006 *Immune responses to NY-ESO-1 in ovarian cancer*
Cancer Vaccines-Ovarian Cancer Symposium
University Hospital Zurich
Zurich, Switzerland
- 2006 *Translational Research, Bench Studies and Clinical Trials*
New York State Department of Health, Bureau of Chronic Disease Services,
Ovarian Cancer Program
New York Academy of Sciences
New York, NY
- 2007 *¹H-NMR Metabonomics for detecting epithelial ovarian cancer*

- Metabonomic Research Day
University at Buffalo
Buffalo, NY
- 2007 *Impact of regulatory T cells on spontaneous and vaccine induced anti-tumor immunity in human ovarian cancer*
Grand Rounds
Medical College of Georgia
Augusta, GA
- 2007 *Cancer Vaccines-Clinical Trials*
8th Charles Rodolphe Brupbacher Symposium-Cancer Immunology, Cancer Immunotherapy and Cancer Immunosurveillance
Charles Rodolphe Brupbacher Foundation
Zurich, Switzerland
- 2007 *Vaccine Therapy for ovarian cancer: Barriers and opportunities*
American Association for Cancer Research 98th Annual Meeting
Los Angeles, CA
April, 2007
- 2007 *Anatomy of Human Papillomavirus Vaccines: Past, Present and Future*
Breast & Gynecologic Cancers: 2007 Update
Roswell Park Cancer Institute
Buffalo, NY
- 2007 *Cancer Diagnostics Using ¹H-NMR-Based Metabonomics*
Ernst Schering Foundation Scientific Symposium on “Oncogenes meet Metabolism-From Deregulated Genes to a Broader Understanding of Tumour Physiology”
Ernst Schering Foundation
Berlin, Germany
- 2008 *Endometrial Cancer*
Department of Gynecology-Obstetrics Grand Rounds
University at Buffalo, The State University of New York
Buffalo, NY
- 2008 *Conventional, regulatory and “unconventional” T cell in the immunologic response to human ovarian cancer*
Immunology Department Seminar
Rush University Medical Center
Chicago, IL
- 2008 *Conventional & Regulatory Th17 Cells & Immunologic Response to Human Ovarian Cancer*
Gynecologic Cancer Interest Group
Mayo Clinic
Rochester, MN
- 2008 *Generation and regulation of Th17 cells in human ovarian cancer*
Department of OB/GYN/Reproductive Sciences
Magee Womens Research Institute
Pittsburgh, PA
- 2008 *Impact of regulatory T cells on spontaneous and vaccine induced anti-tumor immunity in human ovarian cancer*
Department of OB/GYN/Reproductive Sciences Grand Rounds
University of Pittsburgh School of Medicine

- Pittsburgh, PA
- 2008 *Harnessing the immune system for ovarian cancer therapy*
Chemotherapy Foundation Symposium XXVI
Mount Sinai School of Medicine
New York, NY
- 2009 *Lessons from Clinical Trials of Vaccine Therapy Targeting NY-ESO-1 in Ovarian Cancer*
12th Annual Translational Research Cancer Center Consortium Meeting: Therapies for Cancer
University of Pennsylvania
Philadelphia, PA
- 2009 *NY-ESO-1 Proficiency Panel*
Cancer Vaccine Consortium 8th Annual Meeting: Assessing the State of Cancer Vaccines
Bethesda, MD
- 2009 *HPV Vaccines for Cervical Cancer: Quo Vadis?*
Breast & Gynecologic Cancer: 2009 Update
Roswell Park Cancer Institute
Buffalo, NY
- 2009 *Recombinant Viral Vectors as a Platform for Cancer Vaccines: Updated Results from the Cancer Vaccine Collaborative*
XVII Meeting of International Cancer Immunotherapy Symposium Series, Control of Cancer Immunosuppression, The Challenge for Cancer Vaccine Development
The Cancer Research Institute
New York, NY
- 2009 *Vaccine Therapy for Ovarian Cancer: Barriers And Opportunities*
Obstetrics, Gynecology, and Women's Health: 40th Annual Autumn Seminar
University of Minnesota
Minneapolis, MN
- 2009 *Immunology & Cancer Vaccines*
Pharmacy Oncology Symposium 2009
Roswell Park Cancer Institute
Buffalo, NY
- 2010 *Conventional Regulatory & Th17 T cells in Human Ovarian Cancer*
Department of Microbiology and Immunology
Initiative of Maximizing Student Diversity Program
University of Arkansas for Medical Sciences
Little Rock, AK
- 2010 *Seronic and Metabonomic Profiling of Human Ovarian Cancer*
2010 Westlake International Medical Conference- Translational Medicine
Zhejiang-California Internal Nanosystem Institute
Hanzhou, China
- 2010 *The Race Between Ovarian Cancer and Immunity: How Hormones and Inhibitory Molecules Set the Pace*
2010 Society for the Study of Reproduction 43rd Annual Meeting
Milwaukee, WI
- 2010 *The Race Between Ovarian Cancer and Immunity: How Hormones and Inhibitory Molecules Set the Pace*
Tenth Annual Buffalo Conference on Immunology
Niagara Falls, NY
- 2010 *The Race Between Ovarian Cancer and Immunity: How Hormones and Inhibitory Molecules Set the Pace*
Oregon Health and Sciences University/Providence Hospital

- Portland, OR
- 2010 *Role of Cognate CD4⁺ Help in Promoting Antigen Specific CD8⁺ T Cell Mediated Tumor Regression in Human Ovarian Cancer*
Department of Pharmaceutical Sciences
State University of New York at Buffalo
Buffalo, NY
- 2010 *Role of Cognate CD4⁺ Help in Promoting Antigen Specific CD8⁺ T Cell Mediated Tumor Regression in Human Ovarian Cancer*
Roswell Park Cancer Institute/McMasters University Retreat
Lewiston, NY
- 2011 *Coordinate negative regulation of human ovarian tumor immunity by PD-1 and LAG-3*
Canadian Cancer Immunotherapy Consortium's 4th Annual Canadian Cancer Immune Therapy Symposium
Lake Louise, Alberta, Canada
- 2011 *New Approaches to Ovarian Cancer Treatment: Role of Immunology in Ovarian Cancer*
The 27th Ella T. Grasso Memorial Conference, University of Connecticut Health Center
Farmington, CT
- 2012 *Antibody Therapy*
IFReC-Sign Winter School on Advance Immunology
Awaji Island, Japan
- 2012 *New Developments in Vaccine Therapy for Ovarian Cancer*
Danbury Hospital
Danbury, CT
- 2012 *Molecular Mechanisms of Tumor Antigens and Vaccine Therapies*
Ovarian Cancer: Prevention, Detection and Treatment of the Disease and Its Recurrence
Magee-Womens Hospital of UPMC
Pittsburgh, PA
- 2012 *Ex vivo targeting of NY-ESO-1 to DEC-205 receptor for DC Vaccination in combination with mTOR blockade: a clinical trial update*
Roswell Park Cancer Institute Science Retreat
SUNY Geneseo
Geneseo, NY
- 2012 *Therapeutic Vaccines in Cancer*
Tenth International Congress on Targeted Therapies in Cancer
Washington, DC
- 2012 *Recent Advances in Immunotherapy for Ovarian Cancer*
Ovarian Cancer Research Symposium
The Marsha Rivkin Center for Ovarian Research
Seattle University
Seattle, WA
- 2012 *Harnessing the Immune System for Anti-Cancer Therapy*
Distinguished Speaker Series
Buffalo Club
Buffalo, NY
- 2012 *Lessons from clinical trials of vaccine therapy targeting NY-ESO-1 in human ovarian cancer*
McMasters University, Infection and Immunity Program Seminar
Hamilton, Ontario, Canada

- 2013 *Determining T cell fate and anti-tumor immunity in ovarian cancer by mTOR and co-inhibitory molecules*
University of Washington Women's Reproductive Health Research (WRHR)
Program Spring Symposium
Seattle, WA
- 2013 *Grand Rounds Presentation*
Oregon Health and Sciences University
Portland, OR
- 2013 *Determining T cell fate and anti-tumor immunity in ovarian cancer by mTOR and co-inhibitory molecules*
University of Pittsburgh Cancer Institute Seminar Series
Pittsburgh, PA
- 2013 *NY-ESO-1 Targeted Immunotherapy*
American Association for Cancer Research- Advances in Ovarian Cancer
Research: From Concepts to Clinic
Miami, FL
- 2013 *Determining T cell fate and anti-tumor efficacy in ovarian cancer by mTOR and epigenetic regulation*
International Symposium on Immunotherapy
Cancer Vaccine Institute
London, United Kingdom
- 2013 *New Approaches to Ovarian Cancer Treatment: Role of Immunotherapy in Ovarian Cancer*
Department of Gynecology-Obstetrics Grand Rounds
University at Buffalo, The State University of New York
Buffalo, NY
- 2013 *Recent Progress in Immunotherapy for Ovarian Cancer*
American Congress of Obstetricians & Gynecologists 2013 Annual District II
Meeting
New York, NY
- 2013 *Cancer vaccine development for ovarian cancer: trials and tribulations*
African Organization for Research and Training in Cancer
Durban, South Africa
- 2014 *Epigenetic and mTOR reprogramming for promoting vaccine efficacy in human ovarian cancer*
Cancer Vaccines and Immunomodulation: Harnessing patients' immune response.
Nantes, France
- 2014 *Immunotherapy-Implication for Prognosis and Treatment*
Survivorship Forum, Canadian Conference on Ovarian Cancer Research
Victoria, British Columbia, Canada
- 2014 *Tumor microenvironment and immunity: implications for prognosis and therapy*
Canadian Conference on Ovarian Cancer Research
Victoria, British Columbia, Canada
- 2014 *Epigenetic reprogramming of tumor antigens for promoting immunity in human ovarian cancer*
American Association for Cancer Research- Marsha Rivkin Research Foundation:
Advances in Ovarian Cancer Research
Seattle, WA
- 2015 *Fertility Preservation Surgery in Early stage Cervix Cancer*
Recent Advances in Immunotherapy for Ovarian Cancer
Apollo Cancer Conclave & Cancer CI – 2015
Hyderabad, India
- 2015 *Gynecologic Oncology: The Basics*

Department of Gynecology-Obstetrics Grand Rounds
University at Buffalo, The State University of New York
Buffalo, NY

- 2015 *A Novel CD4+ Th Subset Directly Recognizes Tumor in a Non-Classical Fashion: Implications for Ovarian Cancer Immunotherapy*
62nd SRI Annual Scientific Meeting
San Francisco, CA
- 2015 *Lessons from Clinical Trials of Vaccine Therapy Targeting NY-ES-1 in Human Ovarian Cancer*
Grand Rounds Lecture
Karmanos Cancer Institute
Detroit, MI
- 2015 *Immunotherapy in Ovarian Cancer*
Austrian Association of Gynecologic Oncology
Salzburg, Austria
- 2015 *Grand Rounds*
Sisters Hospital, Buffalo New York
- 2015 *Programming Hematopoietic Stem Cells for Long-Term T Cell Therapy of Patient with Relapsed Ovarian Cancer*
NYSTEM 2015, New York, NY
- 2015 *Progress in Immunotherapy for Ovarian Cancer*
Saul Gusberg Memorial Lecture
The Mount Sinai Medical Center
New York, NY
- 2015 *GYN Clinical Science Panel (Panel Chair)*
ASCO Highlights of the Day
American Society of Clinical Oncology
Chicago, IL
- 2015 *Overcoming Barriers to Immunotherapy in Ovarian Cancer*
Immunotherapy Conference (keynote speaker)
Huntsman Cancer Institute
Salt Lake City, UT
- 2015 *Overcoming Barriers to Immunotherapy of Ovarian Cancer*
Fred & Pamela Buffet Cancer Center and Olson Center Special Grand Rounds
University of Nebraska
Omaha, NE
- 2015 *Reprogramming T cells for adoptive immunotherapy of ovarian cancer*
American Association for Cancer Research: Advances in Ovarian Cancer Research: Exploiting Vulnerabilities
Immunotherapy for Ovarian Cancer session speaker
Orlando, FL
- 2015 *Cellular Immunotherapy for Cancer: Infrastructure for Current Approaches and the Future*
Association of American Cancer Institutes/Cancer Center Administrators Forum
Immunology 101: A Primer session speaker
Washington, DC
- 2015 *Emerging concepts in cancer immunotherapy*
African Organisation for Research and Training in Cancer (AORTIC)
Marrakech, Morocco

- 2016 *Epithelial Ovarian Cancer and Tubal Carcinoma*
Grand Rounds Speaker
Women & Children's Hospital, Buffalo, New York
- 2016 *New Advances in the Immunotherapy of Ovarian Cancer*
Eleventh International Regional Cancer Therapies Conference
Chandler, AZ
- 2016 *Reprogramming the Immunologic and Epigenetic Landscape of the Tumor Microenvironment: Applications in Ovarian Cancer (Symposia Chair)*
Deciphering and Overcoming Immune Checkpoint in Ovarian Cancer: Rationale, Evidence and Clinical Potential (Presenter)
63rd Annual Scientific Meeting, Society for Reproductive Investigations
Montreal, QC, Canada
- 2016 *Seminal presentation on ASCO abstracts*
Society of Gynecologic Oncology (SGO) Annual Meeting
San Diego, CA
- 2016 Cancer Immunology for the Non-Immunologist - Tutorial Session, Round-table
Faculty
AACR Annual Meeting
New Orleans, LA
- 2016 *Reprogramming T cells for Adoptive Immunotherapy of Ovarian Cancer*
Grand Rounds Speaker
Weill Cornell Medical College
New York, NY
- 2016 *Reprogramming hematopoietic stem cells for adoptive T cell immunotherapy in ovarian cancer*
SPORE Workshop on Translational Research in Ovarian/GYN Cancers
NCI Shady Grove, Rockville, MD
- 2016 *Granulosa Cell Tumors and Immunotherapy for Ovarian Cancer*
Granulosa Cell Tumor Survivor's Workshop
Niagara Fall, Ontario, Canada
- 2016 *Reprogramming T cells for adoptive immunotherapy of ovarian cancer*
Genomics Guiding Therapeutics
Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, PA
- 2016 Discussant, Clinical Science Symposium: Leveraging the Immuno-Molecular Landscape of Gynecologic Cancers
Chair & Discussant, Gynecologic Cancer Poster Discussion Session
Abstract Title: *Prognostic effects of peripheral and tumor-infiltrating T-cell repertoire diversity in ovarian cancer*
2016 ASCO Annual Meeting
Chicago, IL
- 2016 *Immunotherapy*
2016 Ovarian Cancer Research Symposium
Seattle, WA
- 2016 *Integration of Immunotherapies*
16th International Gynecologic Cancer Society
Lisbon, Portugal
- 2016 *Reprogramming T cells and tumor microenvironment for adoptive immunotherapy of ovarian cancer*
Capital Region Cancer Research (CRCR) symposium

- Albany, NY
- 2016 *IDO Inhibitor: Updated data with Nanostring data*
Cancer Immunotherapy Trials Network (CITN) Annual meeting
National Harbor, MD
- 2017 *What are the Best Antigens for Cancer Immunotherapy?*
ASCO-SITC Clinical Immuno-Oncology Symposium Program Committee
Orlando, FL
- 2017 *Targeting Tryptophan Metabolism to Overcome Negative Regulation of Antitumor Immunity in Ovarian Cancer*
Frontiers in Cancer Immunotherapy
New York, NY
- 2017 *Keynote lecture on Immunotherapy in Ovarian Cancer*
11th International Advanced Ovarian Cancer Optimal Therapy Update
Valencia, Spain
- 2017 *Immunotherapy in ovarian cancer: what is the evidence really? (Cautiously optimistic or recklessly pessimistic?)*
Society of Gynecologic Oncology (SGO) Annual Meeting
- 2017 *Programming Hematopoietic Stem Cells for Long-Term Targeted T cell Therapy of Patients with Relapsed Ovarian Cancer*
CYTO 2017
Boston, MA
- 2017 *Phase 1/2 study of in situ vaccination with tremelimumab + intravenous durvalumab + poly - ICLC in patients with select relapsed, advanced cancers with measurable, biopsy-accessible tumors.*
2017 CRI-CIMT-EATI-AAACR
Mainz, Germany
- 2017 *First-in-human neoadjuvant study of the immunogenomic impact of the oral IDO inhibitor epacadostat (INCB024360) on the tumor microenvironment of advanced ovarian cancer.*
SITC 32nd Annual Meeting
National Harbor, MD
- 2017 *Opportunities of immunotherapy in ovarian cancer*
1st ESMO Immuno Oncology Congress (speaker)
Geneva, Switzerland
Chair of Oral Abstract Session B: CAR-T cells
- 2018 ASCO-SITC Clinical Immuno-Oncology Symposium Program Committee
San Francisco, CA
Keynote lecture on Reprogramming the tumor microenvironment and T cells for ovarian cancer immunotherapy
- 2018 Dana-Farber/Harvard Cancer Center Breast and Gynecologic Cancer Symposium
Boston, MA
- 2018 *Basic Principles of Cancer Immunology*
SITC's Advances in Cancer Immunotherapy (ACI) Meeting (speaker)
Buffalo, NY
- 2018 Discussant, Clinical Trials Plenary, CTPL01 Multimodality Immuno-oncology Approaches
Abstract Title: *Intraperitonealradioimmunotherapy for desmoplastic small round cell tumor: Results of a Phase I*
2018 AACR Annual Meeting

- Chicago, IL
- 2018 *Reprogramming the Tumor Microenvironment to Enhance “Next-Generation” Adoptive Cellular Therapy*
Meet-the-expert Session (speaker)
2018 AACR Annual Meeting
- 2018 *Reprogramming the Tumor Microenvironment and T Cells for Ovarian Cancer Immunotherapy*
Seminar Speaker at Center for Research on Reproduction and Women’s Health
University of Pennsylvania
- 2018 *Chair of Engaging the Immune System in Ovarian Cancer*
2018 ASCO Annual Meeting
Chicago, IL
- 2018 *Current and Future Approaches to Gynecologic Cancers*
Latin American Current Trends in Immuno-oncology (speaker)
Sao Paulo, Brazil
- 2018 *Chair of Gynecology Oncology Oral Abstract Session*
Speaker: Novel Immunotherapy for Gynecologic Cancer: Introduction to the Future
2018 FIGO Congress
Rio de Janeiro, Brazil
- 2018 *Session Chair: Engaging the Immune System in Ovarian Cancer*
2018 ASCO Annual Meeting
Chicago, IL
- 2018 *Speaker: Ovarian Cancer Immunotherapy: Current Status and Future Directions*
NAM Interest Group
Washington, DC
- 2018 *Outsmarting Ovarian Cancer: Breaking IDO Mediated Immune Privilege and Engineering T cells to be Effective in Eradicating Tumors*
AGOS Meeting/RSDP Retreat
Philadelphia, PA
- 2018 *Reprogramming the Tumor Microenvironment and T cells for Ovarian Cancer Immunotherapy*
Annual Gynecologic Malignancies Retreat
Boston, MA
- 2018 *Status of Immunotherapy for Ovarian Cancer*
NRG Oncology Meeting/GOG Summer Symposium
Philadelphia, PA
- 2018 *Immunotherapy to Cure in the Primary Setting*
Towards a Cure for Advanced Stage Ovarian Carcinoma
The Banbury Center/Cold Spring Harbor Laboratory
Lloyd Harbor, NY
- 2019 *Current and Future Approaches to Gynecologic Cancers*
ASCO-SITC Clinical Immuno-Oncology Sumposium
San Francisco, CA
- 2019 *Immunotherapy: Treatment, Trials, Toxicity*
SGO 50th Annual Meeting on Women’s Cancer
Honolulu, HI
- 2019 *Reprograming the tumor microenvironment and T cells for ovarian cancer immunotherapy*

- MD Anderson Ovarian SPORE Seminar Series
Houston, TX
- 2019 *“Next-generation” adoptive cell immunotherapy with TCR-engineered T cells in ovarian cancer*
Helen Harris Memorial Trust Meeting, September 2019, London, UK
- 2019 *Immunotherapy in gynecologic cancers: immune checkpoint blockade and other targets*
International Gynecologic Cancer Society (IGCS 2019), Rio de Janeiro, Brazil
- 2019 *Where are we going with Immunotherapy for ovarian cancer?*
Immunotherapy Bridge, Naples, Italy
- 2019 *Immune Oncology and Gynecologic Cancers*
Westaway Scholars Program – Princess Margaret Cancer Center
Toronto, Canada
- 2020 *Developmental Therapeutics in Gynecologic Cancer*, Moderator
SGO 2020 Annual Meeting - Virtual
- 2020 *Overview of Immunotherapeutic Approaches in Ovarian Cancer*
ASCO20 Virtual Education Program – Faculty Presentation
- 2020 SPARCC Workshop: NCI R25 Pipeline Program to train students in clinical cancer research, Medical College of Wisconsin – Virtual
Immuno-Oncology
- 2020 AACR Virtual Ovarian Cancer Research Seminar Series, Moderator
Live Q&A
State of Immunotherapy in Ovarian Cancer
- 2020 OVARCOME Ovarcoming Cancer Virtual Annual Conference, Speaker
Immunotherapy for Ovarian Cancer
- 2020 Ovarian Cancer Research Alliance (OCRA) Virtual Ovarian Cancer National Conference, Speaker
Ovarian Cancer as a Silent Killer
- 2020 Lakeshore Cancer Center Oncology Webinar Series – The Essence of Gynecological Cancer, Presenter
Tumor Microenvironment to Overcome Multiple Primary and Acquired Immune Resistance Mechanisms in Ovarian Cancer
- 2020 Immuno-Oncology Translational Network (IOTN) Virtual Steering Committee, Immuno-Oncology Joint IOTN, PI-DDN, and PRECINCT Session, Presenter
Ovarian Cancer Breakout Session
- 2020 Cancer Research Institute (CRI) Virtual Immunotherapy Patient Summit, Presenter
Overcoming Immune Resistance in Ovarian Cancer: New Insights on Metabolic Adaptations of the Tumor Microenvironment
- 2021 Human Oncology and Pathogenesis Program (HOPP) Research Seminar Series (RSS) – Memorial Sloan Kettering Cancer Center, Presenter
- 2021 *New Insights on Overcoming Innate and Adaptive Immune Resistance in Ovarian Cancer* Sylvester Comprehensive Cancer Center Distinguished Lecture Series, Distinguished Lecture Presenter
Cancer Research Institute (CRI) Live Webinar
- 2021 *Reprogramming the Tumor Microenvironment and T Cells for Adoptive Immunotherapy of Ovarian Cancer*
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Director’s Visiting Professor Lecture Series, Presenter

- 2021 *The Future State of Immunotherapy for Ovarian Cancer*
European Association for Cancer Research (EACR) Defence is the Best Attack
Virtual Conference, Speaker
- 2021 *Immunotherapy in the treatment of Endometrial Cancer: Current state and future
opportunities* AACR Annual Meeting 2021, Advances in Edometrial Cancer,
Presenter
- 2021 *Overcoming Innate and Adaptive Immune Resistance in Ovarian Cancer*
Northshore Thomas W. McElin – David W. Cromer Lecture, Presenter
- 2021 *Overcoming Resistance to Immunotherapy in Ovarian Cancer*
Parker Institute for Cancer Immunotherapy Symposium, Presenter
- 2021 *Where are We Going with Immunotherapy for Ovarian Cancer?*
The University of Chicago, Presenter
- 2021 *Where are We Going with Immunotherapy for Ovarian Cancer?*
Washinton University School of Medicine, Grand Rounds Lecture
- 2021 *Lessons learned in developing a cancer immunotherapy research program*
RSDP Retreat, Chicago, IL, Presenter
- 2021 *Overcoming Tumor Immune Suppression to Enhance Immunotherapy for Ovarian
Cancer*
GYN Oncology Society, Republic of Korea, Virtual Presenter

PATENTS

PCT/US2014025673 – compositions and methods for use of recombinant T cell receptors for
direct recognition of tumor antigen

PCT/US2014025456 – enhancement of vaccines

GRANTS FUNDED

Current Awards

NATIONAL INSTITUTE OF HEALTH 2021-2026
P50 CA2P50CA159981-07A1
Roswell Park -University of Chicago Ovarian Cancer Specialized Program of Research Excellence (SPORE)
Annual Direct Costs: \$319,523
This SPORE grant pursues the translation of biological and technological advances into improvements in prevention, diagnostics, predictors of outcome, and advances in the treatment of ovarian cancer. The SPORE includes researchers from Roswell Park Comprehensive Cancer Center and the University of Chicago Comprehensive Cancer Center; and includes 2 major projects, 4 cores, a Developmental Projects Program and Career Development Award Program. The creation of this Ovarian Cancer SPORE at RPCCC and UCCCC combines researchers in basic, translational, and clinical sciences into a program that uniquely focuses on harnessing immunological approaches to advance the diagnosis, treatment, and prevention of ovarian cancer.
Role: Overall MPI, Co-Leader for Project 1, Co-Investigator Project 2, and Co-Leader Administration Core

NATIONAL INSTITUTE OF HEALTH 2021 -
5P30 CA016056-46
Cancer Center Support Grant, University of Chicago Medicine Comprehensive Cancer Center
The major goals of this Program are to support ongoing and stimulate and integrate new basic, translational, and clinical research throughout the University of Chicago Comprehensive Cancer Center.
Role: PI, Cancer Center Director

NATIONAL INSTITUTE OF HEALTH 2019 - 2024
1U01 CA233085-01A1
NCI Cancer Moonshot Immuno-Oncology Translation Network: “Reprogramming the tumor microenvironment to overcome multiple primary and acquired immune resistance mechanisms in ovarian cancer”
Annual Direct Costs: \$500,000
The overall goal of this project is to reprogram the ovarian tumor microenvironment with an “armed” oncolytic vaccinia virus delivering CXCR4, PD1, and LAG3 inhibitors, while minimizing the potential for high rates of systemic toxicities.
Role: MPI

NATIONAL INSTITUTE OF HEALTH 2019 - 2024
1U24 CA232979-01
NCI Cancer Moonshot Immuno-Oncology Translation Network (IOTN): “Immuno-Oncology Translation Network: Data Management and Resource-Sharing Center at RPCI (DMRC)
Annual Direct Costs: \$500,000
The overall goal of this project is to support the IOTN in discovering new immune targets and evaluate novel immune based therapies and combination approaches that eliminate established cancers in adults or prevent cancers before they occur. The DMRC strategy is to serve as an administrative and analytic hub at every step of IOTN’s

translational studies, focusing to reduce the barrier for access to analytic expertise, improve the productivity of IOTN investigators, maintain a high standard for data collection and management, design and perform rigorous analytical strategies, and foster a collaborative and supportive research community.

Role: MPI

DEPARTMENT OF DEFENSE
OC180397

2019-2021

DoD and SPORE Ovarian Cancer Omics Consortium (DSOCOC)
Annual Direct Costs \$200,000

The goal of our DSOCOC Team is to accelerate the discovery of biomarkers for the early detection of serous tubal intraepithelial carcinoma (STIC) or early stage high grade serous ovarian cancer (HGSOC) in the general and high-risk populations. We have assembled a unique multidisciplinary team that would align the three NCI ovarian cancer Specialized Programs of Research Excellence (SPORE) and the DoD Gynecologic Cancer Center of Excellence (GYN-COE) in an unprecedented consortium aimed at leveraging existing and new repositories of omics datasets and biospecimens to identify STIC biomarkers that would be subsequently validated during Phase II of the DoD Omics Consortium Program.

Role: Principal Investigator

NATIONAL INSTITUTE OF HEALTH
4 P50 CA159981-04

2013-2021

Roswell Park Cancer Institute-University of Pittsburgh Ovarian Cancer Specialized Program of Research Excellence (SPORE)
Annual Direct Costs: \$1,735,622

This SPORE grant pursues the translation of biological and technological advances into improvements in prevention, diagnostics, predictors of outcome, and advances in the treatment of ovarian cancer. The SPORE includes researchers from Roswell Park Cancer Institute and the University of Pittsburgh Cancer Institute; and includes 4 major projects, 4 cores, and a Developmental Projects Program and Career Development Award Program. The creation of this Ovarian Cancer SPORE at RPCI and UPCI combines leading researchers in basic, translational, and clinical sciences into a program that uniquely focuses on harnessing immunological approaches to produce meaningful advances in the diagnosis, treatment, and prevention of ovarian cancer.

Role: Overall Principal Investigator, Co-Leader for Projects 1, 2, and Administration Core

NATIONAL INSTITUTE OF HEALTH
1R01CA250412-01A1

2021-2025

Annual Direct Costs: \$429,260
MPI: Dr. Sharon Evans, Dr. Scott Abrams

Impact of Circulating Myeloid Cell Clusters on Anti-Tumor Immunity, Annual Direct Costs: \$500,000

Goal: Our laboratories discovered that myeloid cells, notably myeloid-derived suppressor cells (MDSCs), interact with antitumor immune cells within the blood, forming previously unrecognized circulating myeloid cell (CMC) clusters that we propose promote global immune suppression. The goals of our proposed research are to define CMC clusters as a novel mechanism of systemic immune suppression, with potential implications as a blood-based biomarker.

Role: Co-I

DEPARTMENT OF DEFENSE / HENRY M. JACKSON 2017 - 2021
HU0001-16-0006

“Gynecologic Cancer Center of Excellence”

Annual Direct Costs: \$75,000

Investigation of ovarian, uterine and cervical carcinogenesis and drug resistance in pre-clinical and clinical biospecimens. Development of clinical biomarkers and assays for gynecologic malignancies throughout spectrum of care. to advance goals and impact of applied proteogenomics and organizational learning and Cancer Moonshot, and ensure readiness, cost containment and improvements in clinical care and outcomes. Advance patient awareness, support and survivorship.

Role: Site PI

Prior Awards

1. Immunogenetic analysis of HLA class II antigens and their correlation with HPV status in premalignant and malignant disease of the cervix
WELLBEING RESEARCH TRAINING FELLOWSHIP, ROYAL COLLEGE OF OBSTETRICIANS AND GYNECOLOGISTS, LONDON, ENGLAND
\$90,000 1993 - 1995
Role: Principal Investigator
2. Audit into the management of ovarian, cervical and endometrial cancer
OXFORD HEALTH DISTRICT CLINICAL AUDIT GRANT, OXFORD, ENGLAND
\$15,000 1994-1995
Principal Investigator
3. Immunogenetic analysis of the HPV associated risk of cervical carcinogenesis.
ROSWELL PARK ALLIANCE FOUNDATION GRANT, BUFFALO, NY
\$105,000 2002 - 2003
Co-Principal Investigator with Dr. Yasmin Thanavala
4. Immunotherapy Program for Ovarian Cancer
ROSWELL PARK ALLIANCE FOUNDATION 2005-2006
Direct Costs: \$100,000
Principal Investigator
5. Ovarian Cancer Detection Using ¹H-NMR-Based Metabonomics
R21 CA106949-01A1
NATIONAL INSTITUTES OF HEALTH
Direct Costs: \$215,000 2005-2008
Principal Investigator
6. Identification and functional characterization of stomatic mutations in human microRNAs and their responsive elements in target genes in ovarian tumor tissues
DEPARTMENT OF DEFENSE
Direct Costs \$ 75,000 2008-2009
Co-investigator

7. Phase I study of standard chemotherapy combined with 5-aza-2-deoxycytidine (decitabine) and NY-ESO-1 vaccine therapy in patients with recurrent epithelial ovarian cancer
ROSWELL PARK ALLIANCE FOUNDATION
Direct Costs \$103,000 2007-2009
Principal Investigator
8. Development of $^1\text{H}/^{13}\text{C}$ -NMR based metabonomics for early diagnosis of epithelial ovarian cancer
JOHN H. OISHEI FOUNDATION 2006-2010
Direct Costs \$408,200
Principal Investigator
9. Development of a biorepository and databank for molecular analysis of ovarian cancer metastasis
LUDWIG INSTITUTE FOR CANCER RESEARCH
Direct Costs \$450,000 2007-2010
Principal Investigator
10. Analysis of protein expression changes in ovarian cancer metastasis
LUDWIG INSTITUTE FOR CANCER RESEARCH
Direct Costs \$150,000 2007-2010
Principal Investigator
11. Regulatory T Cells and Breast Cancer Risk
SUSAN G. KOMEN FOUNDATION
Direct Costs \$300,000 2007-2010
Co-Principal investigator
12. Ovarian Cancer Program Project Development Grant: Approaches for enhancing tumor immunity in ovarian cancer
OVARIAN CANCER RESEARCH FUND
Direct Costs \$900,000 2008-2011
Principal Investigator
13. Development of an Ovarian SPORE at RPCI
ROSWELL PARK ALLIANCE FOUNDATION
Annual direct costs \$150,000 2010-2011
Co-Investigator
14. Epigenetic regulation of cancer/germ-line antigen gene expression
1R01CA116674-01 A1
NATIONAL INSTITUTES OF HEALTH 2006-2012
\$887,500
Co-Investigator
15. Identification of targets for CD8+ T cell recognition in ovarian cancer
CANCER RESEARCH INSTITUTE/LUDWIG INSTITUTE FOR CANCER RESEARCH
Direct Costs: \$200,000 2005-2011
Principal Investigator
16. Expression and prognostic role of NY-ESO-1 cancer testis antigen in triple negative breast cancer

- 02-2010-080
AVON FOUNDATION FOR WOMEN
Annual direct costs \$130,000 2011-2012
Co-Investigator
17. Re-activating memory T cells in the microenvironment of human tumors
2R01CA131407-01
NATIONAL INSTITUTE OF HEALTH 2007-2012
\$338,070
Co-investigator
18. Granulopoietic growth factor secretion in ovarian carcinoma as a mechanism for the
emergence of immune suppressive myeloid subsets
OC100137
DEPT. OF DEFENSE (DOD) OVARIAN CANCER RESEARCP PROGRAM
Annual direct costs \$100,000 2011 - 2013
Co-Investigator
19. Anna-Marie Kellen Clinical Investigator Award
CANCER RESEARCH INSTITUTE
Direct Costs: \$600,000 2005-2014
Principal Investigator
20. CD4+ Memory T-Cells in Human Tumor Microenvironment
2R01CA108970-06 2010-2014
NATIONAL INSTITUTES OF HEALTH
Annual direct costs \$205,100
Co-Investigator
21. Re-activating Memory T Cells in the Microenvironment of Human Tumors
2R01CA131407-06
NATIONAL INSTITUTE OF HEALTH 2013-2014
Annual direct costs \$16,000
Co-Investigator
22. Regulatory T cell Function in Ovarian Cancer
1R01CA126841-01A2
NATIONAL INSTITUTES OF HEALTH
Direct Costs \$2,110,434 2009-2014
Co-investigator
23. Antigen specific vaccine therapy for ovarian cancer utilizing NY-ESO-1 as target
CANCER RESEARCH INSTITUTE/LUDWIG INSTITUTE FOR CANCER
RESEARCH CANCER VACCINE COLLABORATIVE PROGRAM GRANT
Direct Costs: \$2,450,000 2002-2015
Principal Investigator
The goals of this project are to identify the targets of immune recognition in human
ovarian cancer and develop clinical applications of the targets for vaccine therapy.
24. Cancer Immunotherapy Trials Network (CITN) 2011-2015
NATIONAL INSTITUTES OF HEALTH
Annual direct costs dependent upon enrollment in clinical trials

Site Principal Investigator

The goal of CITN is to conduct single-site and multi-institutional Phase I and early Phase II cancer immunotherapy clinical trials focusing on NCI-designated “high priority” agents and combinations of these and other agents and immunotherapy modalities.

25. Cancer Research Institute Clinical Strategy Team Grant 2015-2016
Enhancing T-cell homing to solid cancers by stimulating proper chemokines
Annual Direct: \$15,790
The overall goal of this grant is to develop effective and clinically applicable regimens to promote intratumoral accumulation of CTLs and CAR-T-cells, while inhibiting local accumulation of myeloid-derived suppressor cells (MDSCs) and regulatory T(reg) cells.
Role: Co-Investigator

26. mTOR inhibition for generating memory T cells to enhance ovarian tumor immunity
NATIONAL INSTITUTES OF HEALTH 2011-2019
5R01CA158318-05
Annual direct costs \$217,201 (NCE)
The goals of this project are to test whether mTOR inhibition will alter lineage fate of vaccine induced T-cells, and endow the cells for enhanced persistence, antigen recall and tumor efficacy in ovarian cancer patients.
Role: MPI

27. SPORE Supplement – NIH Diversity supplement for PhD student, Adaobi Amobi
NATIONAL INSTITUTES OF HEALTH 2015-2019
3P50CA159981-04S1
Annual Direct Cost: \$44,235
This study will focus on addressing the hypothesis that IDO1 mediates T cell exhaustion and inhibition of IDO1-mediated tryptophan catabolism will augment anti-tumor immune responses in ovarian cancer. This study complements Project 1 of the parent SPORE grant (P50CA159981) and allows Adaobi to utilize a murine model of ovarian cancer to delineate molecular mechanisms that direct amino acid metabolism in tumor-mediated immune suppression.
Role: PI/Mentor

28. CXCR4 antagonist as an adjuvant in immunotherapy of epithelial ovarian cancer
Department of Defense 2016-2019
OC150418
Direct Cost: \$771,750
This application proposes to test the hypothesis that differences in the level of CXCR4 antagonists in the tumor and lymphoid/non-lymphoid tissues after the targeted versus soluble form of delivery will affect efficacy of immunotherapeutic intervention by modulating the recruitment and survival of immune cells in tumor sites.
Role: Co-Investigator

29. NATIONAL INSTITUTES OF HEALTH 2016 –2021
3P30 CA016056-39S6 (Johnson)
Total Direct Cost: \$62,570 Supplement Grant (PI: Odunsi)

Roswell Park Cancer Center Support Grant: Administrative Supplement Investigator-
Initiated Trial Utilizing CTEP IND Agents in the ETCTN
Role: Principal Investigator

30. NATIONAL INSTITUTES OF HEALTH 2004-2021
2T32 CA108456-11
Postdoctoral Research Training in Surgical Oncology
Annual Direct Cost: \$215,562
The overall objective of the program is to develop career research skills in basic science and translational research from the pool of talented Fellows in general surgical oncology, urologic oncology and gynecologic oncology. The proposed laboratory research program will provide the training necessary for these fellows to develop their research expertise skills central to academic development in surgical oncology.
Role: Principal Investigator

31. NATIONAL INSTITUTES OF HEALTH 2019-2025
UG1CA233191
Network Lead Academic Participating Site Grant from the Roswell Park Cancer Inst.
Annual Direct \$263,679
National cooperative group clinical trials for advancing novel therapies in cancer patients.
Role: Co-Investigator

32. Buffalo Clinical and Translational Research Center 2015-2024
1UL1TR001412-02
SUNY at Buffalo/NCATS
Annual Direct Cost: \$24,931
Aims include facilitating new strategies that will promote novel drug development through greater access of BTC investigators to the RPCI Center for Immunotherapy and the Tumor Immunology and Immunotherapy Program
Role: Co-Investigator

33. NIH/NCI 2020 - 2025
1 P01CA234212-01A1
“Targeting the Chemokine System to Sensitize Tumors to Immunotherapy”
Annual Direct Costs: \$1,855,805
The goal of this project is to test novel strategies to promote selective CTL entry into tumor microenvironments and sensitize “cold” tumors to immunotherapy.
Role: Co-Investigator

34. DEPARTMENT OF DEFENSE 2016 - 2020
OC150418
“CXCR4 antagonist as an adjuvant in immunotherapy of epithelial ovarian cancer”
Annual Direct Costs: \$166,495
This application proposes to test the hypothesis that differences in the level of CXCR4 antagonists in the tumor and lymphoid /non-lymphoid tissues after the targeted versus soluble form of delivery will affect efficacy of immunotherapeutic intervention by modulating the recruitment of immune cells in tumor sites.
Role: Co-Investigator

35. New York State Stem Cell Science Program (NYSTEM) 2015-2021
C030158
Programing Hematopetic Stem Cells for Long Term Targeted T Cell Therapy of Patients with Relapsed Ovarian Cancer
Annual Direct Costs \$2,497,464
The overall goal of this grant is to genetically re-program human hematopoietic stem/progenitor cells (hHSC) for continuous generation of long lived and durable antigen-specific T cells for a sustained anti-tumor response. We propose that T cells produced *de novo* from hHSCs will continuously replenish anti-tumor T cells that have become anergic or exhausted from exposure to the intratumoral microenvironment.
Role: Principal Investigator
36. NATIONAL INSTITUTES OF HEALTH 2017 - 2021
3P50CA159981-04S2
Annual Direct Cost: \$317,128 Supplement Grant (PI: Odunsi)
The goal of this administrative supplement to the RPCI-UPCI Ovarian Cancer SPORE (P50CA159981) is to conduct a multi-parametric, clinically translatable biomarker study of IDO1-immunomodulation utilizing bio specimens collected from two NCI-supported clinical trials of immunotherapy.
Role: Principal Investigator
37. LUDWIG INSTITUTE FOR CANCER RESEARCH 2014 - 2021
LUD2013-003
“A Phase 1 Study to Evaluate the Safety and Tolerability of Anti-PD-L1, MEDI4736, in Combination with Tremelimumab in Subjects with Advanced Solid Tumors (I2438-13)”
Annual Direct Costs: \$369,794
This is a multicenter, open-label study with a standard 3+3 dose-escalation phase, followed by an expansion phase in subjects with solid tumors.
Role: PD/PI
38. CELYAD SA 2017 - 2021
CYAD-N2T-002
“A Multinational, Open-Label, Dose Escalation Phase 1 Study to Assess the Safety and Clinical Activity of Multiple Administrations of NKR-2 in Patients with Different Metastatic Tumor Types (P352-16)”
Annual Direct Costs: \$153,061
THINK (THERapeutic Immunotherapy with NKR-2) is a multinational (EU/US) open-label Phase I study to assess the safety and clinical activity of multiple administrations of autologous NKR-2 cells in seven refractory cancers, including five solid tumors (colorectal, ovarian, bladder, triple-negative breast and pancreatic cancers) and two hematological tumors (acute myeloid leukemia and multiple myeloma).
Role: Site PD/PI
39. ASTRAZENECA PHARMACEUTICAL LP 2017 - 2020
ESR-16-11751/D4191L00035
“A Phase 1/2 Dose Escalation Study with Expansion Cohorts to Investigate the Safety, Biologic and Anti-Tumor Activity of ONCOS-102 in Combination with Durvalumab in Subjects with Advanced Peritoneal Malignancies (P397-16)”
Annual Direct Costs: \$500,000
This is a two-part Phase 1/2 dose escalation and dose expansion study of the GMCSF-encoding adenovirus, ONCOS-102, in combination with anti-programmed death ligand-

1 (PDL1) antibody, durvalumab, in adult subjects with peritoneal disease who have failed prior standard chemotherapy and have histologically confirmed platinum-resistant or refractory epithelial ovarian cancer or colorectal cancer.
Role: Site PD/PI

DIRECTION OF FELLOW, RESIDENT, AND STUDENT RESEARCH

Fellows in Gynecologic Oncology are requested to publish a “Masters” Quality thesis to qualify for Board exam

Fellows

- Yvonne Collins, M.D. – *Identification of differentially expressed genes in clinically distinct groups of serous ovarian carcinomas using cDNA microarray: 2003*
- Jonathan Tammela, M.D. – *Expression and immunogenicity of OY-TES-1 cancer testis antigen in epithelial ovarian cancer: 2005.*
- Sameer Sharma, M.D. – *Isolation of human scFv fragments by panning a synthetic phage-display library with cultured ovarian carcinoma cells: 2005*
- Jeannine Villella, D.O. – *Role of indoleamine 2,3-dioxygenase as a mechanism of immune escape in epithelial ovarian cancer: 2006*
- Pankaj Singhal, M.D. – *A murine model of epithelial ovarian cancer for the study of the adjuvant properties of α -C-galactosylceramide for promoting ovarian tumor immunity: 2008*
- Stacey South, M.D. – *Characterization of side population stem cells in human ovarian cancer: 2008*
- Nana Tchabo, M.D. – *Molecular and functional characterization of human ovarian cancer stem cells: 2009*
- Joshua Kesterson, M.D. – *Inhibition of IDO for enhancing antigen-specific CD8+T cell responses for promoting durable immunity against ovarian cancer: 2009*
- Heidi Godoy, D.O. - *A murine model for generating WT1 immunity in ovarian cancer: 2010*
- Sayeema Daudi, M.D. – *Calcitriol promoted TLR9/NOD2 mediated memory and Th1 differentiation of antigen specific CD8+ T cells in ovarian tumor bearing mice: 2011-2012*
- Nonna Kolomeyevskaya, M.D. 2011-2012 - *The role of Indoleamine-2,3 dioxygenase (IDO) in regulating ovarian cancer-associated dendritic cells; 2012-2013 Expression Pattern of TGIF2Ix (TGFB-induced factor homeobox 2-like, X-linked) Gene in Ovarian Cancer; Targeting Myeloid Cells in the Epithelial Ovarian Cancer Tumor Microenvironment as a Strategy to Enhance MIS-416 Vaccine Efficacy*
- Rachel Brightwell, M.D. – 2012-2014 - *Lymphocyte reconstitution kinetics and chemotherapy: A window into future endeavors in the study of cancer vaccination; Developing Combinatorial Approaches for Durable Cancer Treatment*
- Kassandra S. Grzankowski, M.D. – 2013-2015 – *Mitochondrial DNA found in cell-free ascites and serum in advance ovarian cancer patients induces NETosis and is associated with shorter progression free and overall survival.*
- James Brian Szender, M.D. – 2014-2016 - *Overcoming Immune Tolerance in Ovarian Cancer: Investigating the Role of Arginine Metabolism in Anti-tumor Immunity*
- Kristen Starbuck, MD - 2015-2017
- Paul Mayor, MD - 2015-2019
- Jaron Mark, MD - 2016-2020
- Sarah Lynam, MD - 2017-2021

Residents

- Victor Moneke, M.D. – *Efficacy of adjuvant CYVADIC chemotherapy in early stage uterine sarcomas: results of long-term follow-up. Awarded best OBGYN resident research presentation, University at Buffalo, 2001*

- Uche Ezeh, M.D. – *Differential gene expression profiling in tissues of women with endometriosis compared to normal endometrium using oligo-arrays*. Awarded best OBGYN resident research presentation, University at Buffalo, 2002
- Alyssa Ta, M.D. – *Investigation of CD44, v5, and v6 as prognostic indicators for vulvar cancer*. Resident research day presentation, University at Buffalo, 2002
- Tunde Olatinwo, M.D. - *Uterine papillary serous carcinoma: evaluation of prognostic factors and treatment modalities*. Resident Research Day presentation, University at Buffalo, 2002
- LaSonya Roberts, M.D. – *Analysis of short and long-term complications of ileal conduits in patients with gynecologic malignancies*. Resident Research Day presentation, University at Buffalo, 2003
- Abeer Eddib, M.D. – *HLA expression in epithelial ovarian cancer*. Resident Research Day presentation, University at Buffalo, 2003
- Alex Olawaiye, M.D. – *Analysis of the Time Interval between Diagnoses in Women with Double Primary Cancers of Breast and Ovarian or Primary Peritoneal Cancer*. Awarded best OBGYN resident research presentation, University at Buffalo, 2004
- Peter Frederick, M.D. – *Prognostic significance of cytologic washings in low malignant potential ovarian tumors*. Resident Research Day presentation, University at Buffalo, 2006
- Mian M. Shahzad, M.D. – *The role of chemotherapy in advanced and recurrent endometrial cancer*. Resident Research Day presentation, University at Buffalo, 2006
- Prethi Vaddadi, M.D. – *XAGE cancer testis antigens in ovarian cancer*. Research elective, 2011; Resident Research Day presentation, 2012
- Cici Liu, M.D. – Research elective. May 2012; 2014-2015.

Medical Students

- Lori S. Caesar - *Analysis of the Time Interval between Diagnoses in Women with Double Primary Cancers of Breast and Ovarian or Primary Peritoneal Cancer*. Clinical / Research elective, University of Rochester Medical School, Rochester, NY. 2002
- Peter Frederick – *The potential role of indoleamine 2, 3-dioxygenase as a mechanism of immune escape in epithelial ovarian cancer*. Research elective, University at Buffalo, 2003
- Sarah Thomas – *Identification of novel tumor antigens in ovarian cancer by serological analysis of recombinant complementary DNA expression libraries (SEREX)*. Research elective, University at Buffalo, 2003
- Celines Morales – *Expression of cancer testis antigen CT 46 in epithelial ovarian cancer*. University at Buffalo, 2005
- Eun (Amy) Beattie – *Investigating MIS416 as a vaccine adjuvant for the treatment of ovarian cancer* – University at Buffalo, 2015

Graduate Students

- Kyle Runkel – University at Buffalo, 2011
- Jie Gong – University at Buffalo, 2012
- Adaobi Amobi – University at Buffalo, 2013 - *Overcoming tumor-mediated catabolism of tryptophan for augmenting immunity against ovarian cancer: PhD Thesis*
- Aimee Stablewski – University at Buffalo 2016 - *Differential activation of specific transcriptional pathways alters T cell infiltration and/or function in chemoresistant*

ovarian cancer: PhD Thesis

- Brendan Zangari - University at Buffalo, 2017 – *PhD Thesis*

High School Students

- Nwamaka Iloabachie, 2003
- Dordi, Rushad, 2004
- Remy S. Bizimungu, 2005
- Jola Obiesesan, 2008
- Adebukola Abiola, 2009
- Jillian Piaggione, 2009
- Michael Timi Sosanya, 2010
- Olurotimi Owolabi, 2011
- Matthew Withiam-Leitch, 2012
- Ajay Kolli, 2012
- Oluwagbemisola Abiola, 2012
- Zikun (Steven) Qian, 2013
- Olorunfemi (Femi) Adetola, 2015
- Elise Yu, 2018

College Students

- Ademola Osundeko, 2014
- Adeiyewunmi Osinubi, 2015
- Anish Mahadeo, 2018

Research Trainees

- Feng Qian, Ph.D., Postdoctoral Research Fellow, 2002 – Present. Supported by CRI/LICR Cancer Vaccine Collaborative Grant. *Approach for counteracting regulatory T cells to enhance ovarian tumor immunity.*
- Chalong Cheewakriangkrai, M.D., Postdoctoral Research Fellow, 2002 – 2004. Supported by a grant from the University Hospital, Republic of Thailand. *Identification of HLA-2 restricted epitopes from PDEF.*
- Junko Matsuzaki, Ph.D., Postdoctoral Research Fellow, 2006-2011. Supported by a grant from LICR/NIH. (1) *Immunologic analysis of clinical trials targeting NY-ESO-1 for ovarian tumor immunity;* (2) *Roles of PD-1 and LAG-3 in negative regulation of ovarian tumor immunity.*
- Axel Mischo, M.D., Postdoctoral Research Fellow, 2006-2007. Supported by a grant from Stiftung für Onkologie, Zurich, Switzerland.
- Manoj Mehta, Ph.D., Postdoctoral Research Fellow, 2006-2007. Supported by a grant from the John R. Oishei Foundation, Buffalo, NY.
- Takemasa Tsuji, PhD, Postdoctoral Research Fellow, 2012-2014
- A.J. Robert McGray, PhD, Postdoctoral Research Fellow, 2012-2017

PhD Thesis Committee Advisor

- Anna Woloszynska-Read – *Cancer/germline (CG) Antigens and Epigenetic Deregulation in Human Epithelial Ovarian Cancer (EOC)*. Department of Molecular Pharmacology and Cancer Therapeutics, Roswell Park Cancer Institute, Buffalo, NY.
- Joseph Tario, Jr. – *Targeting NY-ESO-1 to Dendritic Cells as a Vaccine for Ovarian Cancer*. Department of Flow and Image Cytometry, Roswell Park Cancer Institute,

Buffalo, NY.

- Wa Zhang – *Molecular Characterization of Global DNA Hypomethylation Phenotype in ovarian cancer*. Department of Molecular Pharmacology and Cancer Therapeutics, Roswell Park Cancer Institute, Buffalo, NY
- Clara Maria Scarlata - *Human natural and induced regulatory CD4 T cells (Treg): ontogeny and differential function*, University of Nantes, Nantes, France
- Amy Ku – *Thermal regulation of myeloid derived suppressor cells*. Department of Immunology, Roswell Park Cancer Institute, Buffalo, NY
- Kelly Singel - *Targeting myeloid cells in the tumor microenvironment enhances vaccine efficacy in epithelial ovarian cancer*. Department of Immunology, Roswell Park Cancer Institute, Buffalo, NY
- Shivana Maharaj – Department of Immunology, Roswell Park Cancer Institute, Buffalo, NY

Doctoral Dissertation External Reviewer

- Spencer David Martin, Doctor of Philosophy, in the faculty of graduate and postdoctoral studies (interdisciplinary oncology) The University of British Columbia, Vancouver, BC, Canada – *Identifying and Targeting Immunogenic Mutations in Ovarian Cancer*

PUBLISHED ABSTRACTS AND PRESENTATIONS

1. Imperial Cancer Research Fund Annual Colloquium. Warwick, United Kingdom, 1994
Odunsi K, Terry G, Ho L, Cusack J, Ganesan TS. The role of the Human papillomavirus in the HLA associated risk of cervical carcinogenesis.
2. Oxford Regional Health Authority Scientific Forum in Obstetrics and Gynecology, Northampton, United Kingdom, 1994
Odunsi K, Terry G, Ho L, Cusack J, Bell J, Ganesan TS. Determination of the HLA Class II susceptibility to cervical cancer using a novel PCR-RFLP (ARFLP) approach.
3. British Association for Cancer Research, Annual Meeting, Birmingham, United Kingdom, 1994
Odunsi A, Terry G, Ho L, Cuzick J, Ganesan TS. Association between HLA-DQB1*03, Human papillomavirus and cervical intraepithelial neoplasia. *Brit J Cancer* 1994; 69:56.
4. British Gynecological Cancer Society, Annual Meeting, Glasgow, United Kingdom, 1994
Odunsi K, Terry G, Ho L, Cusack, Bell J, Ganesan TS. HLADQB1*03 increases the risk for human papillomavirus infection and cervical intraepithelial neoplasia.
5. 12th European Immunology Meeting, Barcelona, Spain, 1994
Odunsi K, Terry G, Ho L, Cusack J, Bell J, Ganesan TS. HLADQB1*03 is associated with increased risk of HPV infection, CIN and cervical cancer.
6. American Association of Cancer Research, Annual Meeting, Toronto, Canada. 1995
Odunsi A, Terry G, Ho L, Cuzick J, Ganesan TS. Association between HLA DQB1*03 and cervical intra-epithelial neoplasia. *Proc Amer Assis Cancer Res* 1995; 36:634.
7. American Association of Cancer Research, Annual Meeting, Washington, DC, 1996
Odunsi K, Terry G, Ho L, Bell J, Cuzick J, Ganesan TS. Susceptibility and protection to human papillomavirus associated cervical intra-epithelial neoplasia is related to specific HLA DR-DQ alleles. *Proc Amer Assoc Cancer Res* 1996; 37:598.
8. 1st International Conference on Maternal Mortality (Auspices of Cornell University, New York), Marakesh, Morocco, 1997.
Schiffer M and **Odunsi K**. Maternal mortality in New York City.
9. Annual Meeting of the American College of Obstetricians and Gynecologists, District I, Puerto Rico, USA, 1997.
Odunsi K, Terry G, Ho L, Cuzick J, Bell J, Ganesan TS. HLA Class II plays an important role in determining the HPV associated risk of cervical carcinogenesis.
10. 18th Annual Meeting of the Society of Perinatal Obstetricians, Orlando, FL, USA, 1998
Rebarber A, **Odunsi K**, Baumgarten A, Copel J, Sipes S. An in-vitro assessment of fetal contamination of human blood processed through the cell-saver (CS5) at Cesarean Section. *Am J Obstet Gynecol* 1998; 178: S80.
11. International Gynecological Cancer Society, 7th Biennial Meeting, Rome, Italy, 1999
Odunsi K, Terry G, Ho L, Cuzick J, Ganesan TS. Motif analysis of HLA class II

molecules that determine susceptibility to HPV associated cervical cancer. *Int J Gynecol Cancer* 1999;9: 146.

12. Society of Gynecologic Oncologists, Annual Meeting, San-Diego, USA, 2000
Odunsi K, Ganesan T, Shelling A. Evaluation of the possible protective role of adeno-associated virus in HPV associated cervical neoplasia. *Gynecol Oncol* 2000; 76:268.
13. Society for Gynecologic Investigation, Annual Meeting, Chicago, USA, 2000
Odunsi K, Kidd JR, Okonofua FE, Speed B, Pakstis AJ, Ossier M, Kidd KK, Naftolin F. Nuclear DNA polymorphisms among the Yorubas of southwestern Nigeria: comparison with eight other human populations and implications for reproductive biology. *J Soc Gynecol Investig* 2000;7(1Suppl Scientific):43A-379A.
14. Society of Gynecologic Oncologists, Annual Meeting, Nashville, TN, USA., 2001
Odunsi K, Lee S, Ganesan TS. Motif analysis of HLA class II molecules that determine the HPV associated risk of cervical carcinogenesis. *Gynecol Oncol* 2001; 80:292.
15. Society of Gynecologic Oncologists, Annual Meeting, Nashville, TN, USA, 2001
Odunsi K, Lele S, Ghamande S, Seago P, Driscoll D. The impact of pre-therapy extra-peritoneal surgical staging on the evaluation and treatment of patients with locally advanced cervical cancer. *Gynecol Oncol* 2001; 80:296.
16. Society of Gynecologic Oncologists, Annual Meeting, Nashville, TN, USA, 2001
Odunsi K, Chandrasekaran E, Ghamande S, Ta A, O'Donnell A, Driscoll D, Seago P, Lele S, Matta K. Evaluation of galactosyl transferase as a potential biomarker for ovarian cancer *Gynecol Oncol* 2001;80:330.
17. Society of Gynecologic Oncologists, Annual Meeting, Nashville, TN, USA, 2001
Ghamande S, Anupol N, **Odunsi K**, Seago P, Driscoll D, Lele S. Evaluation of prognostic factors and treatment modalities in ovarian cancer patients with brain metastases. *Gynecol Oncol* 2001; 80:327.
18. American Society of Clinical Oncology, Annual Meeting, San Francisco, USA, 2001
Odunsi K, Moneke V, Ghamande S, Seago DP, Driscoll D, Marchetti D, Baker T, Lele S. Adjuvant CYVADIC chemotherapy in early stage uterine sarcomas: results of long-term follow-up. *Proc Amer Soc Clin Oncol* 2001; 20:184b.
19. Society of Gynecologic Oncologists, Annual Meeting, Miami Beach, FL, USA, 2002
Collins Y, Lele S, **Odunsi K**, Pejovic T, Mor G, Rutherford T, McQuaid D, Nowak N. Molecular profiling of serous ovarian carcinomas by cDNA microarray reveals clinically distinct groups that correlate with altered expression of multiple genes. *Gynecol Oncol* 2002;84(3):496-7.
20. Society of Gynecologic Oncologists, Annual Meeting, Miami Beach, FL, USA, 2002
Collins Y, DiCioccio R, Keitz B, Lele S, **Odunsi K**. The role of DAP kinase hypermethylation in ovarian carcinoma. *Gynecol Oncol* 2002; 84:488
21. American Society of Clinical Oncology, Annual Meeting, Orlando, FL, 2002
Seago DP, Hoskins E, Chessner C, **Odunsi K**, Lele S. The use of body mass index as a

- predictor of surgical complications in patients with uterine cancer. Proc Amer Soc Clin Oncol 2002; 21:256a.
22. American Society of Clinical Oncology, Annual Meeting, Orlando, FL, USA, 2002
Koutras A, Lele S, Intengan M, Habib F, Driscoll D, **Odunsi K**. CD44 exon v7-8 is a prognostic marker in cervical cancer. Proc Amer Soc Clin Oncol 2002; 21:218a.
 23. American Society of Clinical Oncology, Annual Meeting, Orlando, FL, USA, May 2002
Odunsi K, Ghadersohi A, Chitta K, Lele S, Keitz B, Collins Y, Driscoll D, Sood A. Prostate epithelium derived Ets transcription factor (PDEF): a candidate tumor associated antigen in ovarian cancer Proc Amer Soc Clin Oncol 2002;21:206a.
 24. American Society of Clinical Oncology, Annual Meeting, Orlando, FL, USA, May 2002
Collins Y, **Odunsi K**, Driscoll D, Lele S. Risk factors for recurrence and survival in endometrial stromal sarcoma: a thirty-year experience at the Roswell Park Cancer Institute Proc Amer Soc Clin Oncol 2002;21:174b.
 25. American Society of Clinical Oncology, Annual Meeting, Orlando, FL, USA, May 2002
Ta A, **Odunsi K**, Intengan M, Driscoll S, Baker T, Lele S. Investigation of CD44, v5, and v6 as prognostic indicators for vulvar cancer. Proc Amer Soc Clin Oncol 2002; 21:172b.
 26. Society of Gynecologic Oncologists, Annual Meeting, New Orleans, LA, USA, 2003
Lele S, Jungbluth A, Beck A, Sood A, Williamson B, Keitz B, Driscoll D, Stockert E, Qian F, **Odunsi K**, Old L, Intengan M. NY-ESO-1 and LAGE-1 cancer-testis antigens: targets for immunotherapy in epithelial ovarian cancer. Gynecol Oncol 2003;88(2):253.
 27. Society of Gynecologic Oncologists, Annual Meeting, New Orleans, LA, USA, 2003
Pejovic T, Ladner D, Intengan M, Zheng K, Fairchild T, Easley S, Dillon D, Dillon D, Schwartz PE, Marchetti D, Lele S, **Odunsi K**. Somatic D-loop mitochondrial DNA mutations are frequent in uterine papillary serous carcinoma. Gynecol Oncol 2003; 88:188.
 28. American Association of Cancer Research, 94th Annual Meeting, Washington, D.C, USA, 2003
Qian F, Tammela J, Rodabaugh K, Keitz B, Wu Y, Driscoll D, Lele S, Old L, **Odunsi K**. Expression of the SSX “cancer-testis” antigens in epithelial ovarian cancer. Proc Amer Assoc Cancer Res 2003;(1st ed)44: Abstract 476.
 29. American Society of Clinical Oncology, Annual Meeting, Chicago, IL, USA, 2003
Tammela JE, Qian F, Keitz B, Driscoll D, Sood A, Lele S, Old L, **Odunsi K**. SCP-1 “Cancer / Testis” antigen is a candidate target for immunotherapy in epithelial ovarian cancer. Proc Am Soc Clin Oncol 2003; 22:469.
 30. American Society of Clinical Oncology, Annual Meeting, Chicago, IL, USA, 2003
Ghadersohi A, **Odunsi K**, Cheewakriang C, Lele S, Sood A. PDEF, a candidate molecular target in human cancer. Proc Am Soc Clin Oncol 2003; 22:903.
 31. Society for Gynecologic Investigation, Annual Meeting, Washington D.C., USA, 2003

- Schwartz P, Easley S, Lele S, Pejovic T, Fairchild T, Ladner D, Marchetti D, Dillion D, Dillon D, Zheng K, **Odunsi K**, Intengan M. Somatic D-loop mitochondrial DNA mutations are frequently in uterine papillary serous carcinoma. *J Soc Gynecol Investig* 2003;10(2) Supplement:296A.
32. American Society for Reproductive Medicine, 59th Annual Meeting, San Antonio, TX, USA, 2003
Ezeh U, Yeh J, Dillon D, Easley S, Ram V, **Odunsi K**. *Gene expression profiling of the endometrium of women with endometriosis using microarray*. *Fertil Steril* 2003;80: S219.
33. Cancer Research Institute, Cancer Vaccines 2003, Cancer & HIV Vaccines: Shared Lessons, New York City, NY, USA, 2003
Sato E, Jungbluth AA, Ahn J, Qian F, Gnjatic S, Santiago D, Ambrosone C, Keitz B, Ritter G, Lele S, Chen YT, Old LJ, **Odunsi K**. Prognostic Significance of Tumor Infiltrating Lymphocytes and CT Antigen Expression in Epithelial Ovarian Cancer. *CRI Abstract #45*.
34. Cancer Research Institute, Cancer Vaccines 2003, Cancer & HIV Vaccines: Shared Lessons, New York City, NY, USA, 2003
Qian F, Gnjatic S, Santiago D, Grande C, Schneider S, Keitz B, Ritter G, Lele S, Sood A, Old LJ, **Odunsi K**. T Helper Type1 (Th1)/Th2 CD4⁺ T Cell Responses Against NY-ESO-1 In HLA-DPB1*0401/0402 Patients With Epithelial Ovarian Cancer. *CRI Abstract #46*.
35. Society of Gynecologic Oncologists, Annual Meeting, San Diego, CA, USA, 2004
Anupol N, Hylander B, Lele S, **Odunsi K**, Repasky E. Effects of Apo2L/TRAIL combined with chemotherapy on ovarian tumor-SCID mouse xenograft. *Gynecol Oncol* 2004;92(1):497.
36. Society of Gynecologic Oncologists, Annual Meeting, San Diego, CA, USA, 2004
Odunsi K, Wollman R, Ambrosone C, Huston A, McCann S, Tammela J, Geisler J, Qian F, Keitz B, Intengan M, Lele S, Alderfer J. Detection of epithelial ovarian cancer using 1H-NMR- based metabonomics. *Gynecol Oncol* 2004; 92:497.
37. Society of Gynecologic Oncologists, Annual Meeting, San Diego, CA, USA, 2004
Sharma S, Qian F, Keitz B, Driscoll D, Lele S, **Odunsi K**. A-Kinase Anchoring Protein 3 Messenger RNA expression correlates with poor prognosis in epithelial ovarian cancer. *Gynecol Oncol* 2004; 92:464.
38. Society of Gynecologic Oncologists, Annual Meeting, San Diego, CA, USA, 2004
Tammela J, Wang X, Thomas S, Intengan M, Keitz B, Lele S, **Odunsi K**. Isolation of an ovarian tumor specific human scFv fragment bypanning a synthetic phage-display scFv library with cultured human ovarian cancer cells. *Gynecol Oncol* 2004; 92:461.
39. Society of Gynecologic Oncologists, Annual Meeting, San Diego, CA, USA, 2004
Olawaiye A, Caesar L, Walsh D, Yeh J, Rodabaugh R, Lele S, **Odunsi K**. Analysis of the time interval between diagnoses of double primary breast and ovarian carcinomas. *Gynecol Oncol* 2004; 92:399.
40. Society for Gynecologic Investigation, 51st Annual Meeting, Houston, TX, USA, 2004

Odunsi K, Sato E, Jungbluth AA, Ahn J, Qian F, Gnjatic S, Santiago D, Ambrosone C, Keitz B, Ritter G, Lele S, Chen TY, Old LJ. Prognostic significance of tumor infiltrating lymphocytes and ‘cancer-testis’ antigen expression in epithelial ovarian cancer. *J Soc Gynecol Invest* 2004;11(2) Supplement: Abstract No. 986

41. Society for Gynecologic Investigation, 51st Annual Meeting, Houston, TX, USA, 2004
Odunsi K, Wollman RM, Ambrosone CB, Hutson A, McCann SE, Tammela J, Geisler JP, Miller G, Sellers T, Cliby W, Qian F, Keitz B, Intengan M, Lele S, Alderfer JL. Use of ¹H-NMR- based metabonomics for detecting epithelial ovarian cancer. *J Soc Gynecol Invest* 2004;11(2) Supplement: Abstract No. 4.
42. American Association of Cancer Research, 95th Annual Meeting, Orlando, FL, USA, 2004
Tammela J, Wang X, Thomas S, Intengan M, Keitz B, Lele S, **Odunsi K**. Isolation of an ovarian tumor specific human scFv fragment by panning a synthetic phage-display scFv library with cultured human ovarian cancer cells. *Proc Amer Assoc Cancer Res* 2004;45: Abstract 5473.
43. American Association of Cancer Research, 95th Annual Meeting, Orlando, FL, USA, 2004
Qian F, Gnjatic S, Santiago D, Grande C, Schneider S, Keitz B, Ritter G, Lele S, Sood A, Old LJ, **Odunsi K**. T helper type1 (Th1)/Th2 CD4⁺ Tcell responses against NY-ESO-1 in HLA-DPB1*0401/0402 patients with epithelial ovarian cancer. *Proc Amer Assoc Cancer Res* 2004; 45: Abstract 1276.
44. American Society of Clinical Oncology, 40th Annual Meeting, New Orleans, LA, USA, 2004
Sabbatini P, Aghajanian C, Dupont J, Derosa F, Anderson S, McGuire W, Rodabaugh K, Ferrone S, Lele S, **Odunsi K**. Phase I trial of the anti-idiotypic monoclonal antibody (mAb) ACA-125 in patients with epithelial ovarian, fallopian tube or primary peritoneal cancer. *J Clin Oncol* 2004; ASCO Annual Meeting Proceedings 22(14S):453.
45. American Society of Clinical Oncology, 40th Annual Meeting, New Orleans, LA, USA, 2004
Sharma S, **Odunsi K**, Lele S. Pelvic exenterations for gynecologic malignancies: 20-year experience at a cancer institute. *J Clin Oncol* 2004; ASCO Annual Meeting Proceedings 22(14S):483.
46. United States and Canada Academy of Pathology, 94th Annual Meeting, San Antonio, TX, USA, 2005.
Sato E, Jungbluth AA, **Odunsi K**, Old LJ. Prognostic significance of tumor infiltrating lymphocytes (TILs) in ovarian cancer and their relationship to cancer-testis (CT) antigen expression. Abstract 132.
47. Society of Gynecologic Oncologists, 36th Annual Meeting, Miami Beach, FL, USA, March 2005
Villeglia JA, Driscoll D, Rodabaugh K, **Odunsi K**, Lele S. Outcome of patients with mucinous ovarian carcinoma. *Gynecol Oncol* 2005; 96:1018

48. Society of Gynecologic Oncologists, 36th Annual Meeting, Miami Beach, FL, USA, March 2005
Sharma S, Driscoll D, **Odunsi K**, Lele S. Safety and efficacy of cytoreductive surgery for epithelial ovarian cancer in elderly and complicated patients. *Gynecol Oncol* 2005; 96:956.
49. Society of Gynecologic Oncologists, 36th Annual Meeting, Miami Beach, FL, USA, March 2005
Sharma S, Driscoll D, **Odunsi K**, Lele S. Characterization of neutropenic fever in patients receiving first-line adjuvant chemotherapy of epithelial ovarian cancer. *Gynecol Oncol* 2005; 96:960.
50. Society for Gynecologic Investigation, 52nd Annual Meeting, Los Angeles, CA, USA, March 2005.
Vilella JA, Qian F, Keitz B, Driscoll D, Skipper J, Simpson A, Old L, Lele S, **Odunsi K**. BORIS, a novel cancer-testis antigen is a potential target for immunotherapy in epithelial ovarian cancer. *J Soc Gynecol Invest* 2005(2) Supplement; 12:286A.
51. Society for Gynecologic Investigation, 52nd Annual Meeting, Los Angeles, CA, USA, March 2005
Anderson ML, Tan DF, Yang A, Goode S, **Odunsi K**. Transcriptional coactivator SRC3/AIB1 is consistently overexpressed in ovarian and primary peritoneal cancers: implications for pathogenesis. *J Soc Gynecol Invest* 2005(2) Supplement; 12:370A.
52. Society of Gynecologic Surgeons, 31st Annual Meeting, Rancho Mirage, CA, USA, April 2005
Sharma S, Driscoll D, **Odunsi K**, Lele S. Safety and efficacy of cytoreductive surgery for epithelial ovarian cancer in elderly and complicated patients.
53. American Association for Cancer Research, 96th Annual Meeting, Anaheim, CA, USA, April 2005
Qian F, Gnjatic S, Hoffman E, Skipper J, Ritter G, Lele S, Old L, **Odunsi K**. Identification of a novel HLA-A24-restricted CTL epitope from NY-ESO-1 following immunization of ovarian cancer patients with a peptide of dual MHC Class I and II specificities. *Proc Amer Assoc Cancer Res* 2005;46: Abstract 5134.
54. American Society of Clinical Oncology, 41st Annual Meeting, Orlando, FL, USA, May 2005
Singhal P, Qian F, Keitz B, Driscoll D, Skipper J, Simpson A, Old L, Lele S, **Odunsi K**. TPTE "Cancer/Testis" antigen is a candidate target for immunotherapy in epithelial ovarian cancer. *J Clin Oncol* 2005; ASCO Annual Meeting Proceedings (16S) 23:2583.
55. American Society of Clinical Oncology, 41st Annual Meeting, Orlando, FL, USA, May 2005
Vilella J, Qian F, Keitz B, Driscoll D, Skipper J, Simpson A, Old L, Lele S, **Odunsi K**. BORIS, a novel cancer-testis antigen is a potential target for immunotherapy in epithelial ovarian cancer. *J Clin Oncol* 2005; ASCO Annual Meeting Proceedings (16S) 23:9673.

56. American Society of Clinical Oncology, 41st Annual Meeting, Orlando, FL, USA, May 2005
Sharma S, Driscoll D, **Odunsi K**. The oncogene longation factor 1 Alpha-2 mRNA expression in epithelial ovarian cancer. J Clin Oncol 2005; ASCO Annual Meeting Proceedings 23(16S):5034.
57. American Society of Clinical Oncology 41st Annual Meeting, Orlando, FL, USA, May 2005
Rodabaugh K, Wu Y, Driscoll D, **Odunsi K**, Lele S, Singhal PK. Real time PCR quantification of COX-2 mRNA in human ovarian epithelial neoplasm and its correlation with clinical outcome. J Clin Oncol 2005; ASCO Annual Meeting Proceedings;23(16S):5055.
58. American Society of Clinical Oncology, 41st Annual Meeting, Orlando, FL, USA, May 2005
Odunsi K, Qian F, Gnjjatic S, Jungbluth A, Hoffman E, Ritter G, Kepner J, Skipper J, Lele S, Old L. Immunization of ovarian cancer patients with an NY-ESO-1 peptide of dual MHC class I and II specificities plus incomplete Freund adjuvant induces simultaneous humoral, CD4+ and CD8+ T-cell responses. J Clin Oncol 2005; ASCO Annual Meeting Proceedings 23(16S):5040.
59. Ovarian Cancer: Prevention and Detection of the Disease and its Recurrence, International Symposium, Pittsburg, PA, USA, October 2005
Odunsi K, Wollman R, Ambrosone C, Hutson A, McCann S, Tammela J, Geisler JP, Miller G, Sellers T, Cliby W, Qian F, Lele S, Alderfer JL. ¹H-NMR- based metabonomics for the detection of epithelial ovarian cancer.
60. American Society of Human Genetics, 55th Annual Meeting, Salt Lake City, UT, USA, October 2005
Tayo AO, DiCioccio RA, Liang Y, Trevisan M, Piver MS, **Odunsi K**. Complex segregation analysis of 1919 pedigrees with ovarian cancer from the Gilda Radner Familial Ovarian Cancer Registry.
61. Society of Gynecologic Oncologists, 37th Annual Meeting, Palm Springs, CA, USA, March 2006
Rodabaugh K, **Odunsi K**, Lele S, Booker B, Smith P. Chemosensitivity testing in primary ovarian cancer: comparison of primary and Metastatic tumor. Gynecol Oncol 2006;101: S124.
62. Society of Gynecologic Oncologists, 37th Annual Meeting, Palm Springs, CA, USA, March 2006
Singhal P, Sharma S, Tan I, **Odunsi K**, Lele S. Can preoperative EMB/D&C predict final pathology results in patients with endometrial carcinoma? Gynecol Oncol 2006;101: S146.
63. American Society of Clinical Oncology, 42nd Annual Meeting, Atlanta, GA, USA, June 2006
Sharma S, Singhal P, **Odunsi K**, Lele S, Stroger, Jr. JH. Is there a CA-125 level that predicts negative second look surgery (SLS) in patients with advanced epithelial ovarian cancer (EOC)? J Clin Oncol 2006 ASCO Annual Meeting Proceedings Part I.

24(18S):15042.

64. American Society of Clinical Oncology, 42nd Annual Meeting, Atlanta, GA, USA, June 2006
Singhal PK, Sharma S, Benitez M, **Odunsi K**, Lele S. Efficacy of a gemcitabine based multiagent chemotherapy regimen of advanced uterine sarcomas. J Clin Oncol 2006 ASCO Annual Meeting Proceedings Part I. 24(18S):15047.
65. Society of Gynecologic Oncologists, 38th Annual Meeting, San Diego, CA, USA, March 2007
Odunsi K, Matsuzaki J, Qian F, Gnjjatic S, Andrews C, Hoffman E, Pan L, Ritter E, Ritter G, Rodabaugh KJ, Lele S, Old LJ. Diversified prime and boost vaccination using recombinant vaccinia and fowl pox expressing NY-ESO-1 efficiently induce antibody, CD4⁺ and CD8⁺ anti-tumor immune responses in ovarian cancer patients. Gynecol Oncol 2007;104: S49.
66. Society of Gynecologic Oncologists, 38th Annual Meeting, San Diego, CA, USA, March 2007
Odunsi K, Ghamande S, Andrews C, Strychor S, DeLoia J, Thomas B, Rodabaugh KJ, Macfee MS, Lele S, Zamboni W. Pharmacokinetic (PK) study of weekly docetaxel (DOC) in patients with platinum resistant ovarian cancer. Gynecol Oncol 2007; 104: S49
67. Society of Gynecologic Oncologists, 38th Annual Meeting, San Diego, CA, USA, March 2007
South S, Mhawech-Fauceglia P, Andrews C, Beck A, Lele S, **Odunsi K**. XAGE-1a cancer/testis antigen expression favors a high intratumoral CD8⁺/Treg ratio and predicts improved prognosis in epithelial ovarian cancer. Gynecol Oncol 2007; 104: S38.
68. Society of Gynecologic Oncologists, 38th Annual Meeting, San Diego, CA, USA, March 2007
South S, Huang R, Lele S, **Odunsi K**. Nitrogen permease regulator 2 confers resistance to doxorubicin in *Saccharomyces cerevisiae* and a novel isoform of the human homologue is frequently expressed in ovarian cancer. Gynecol Oncol 2007;104: S41.
69. Society of Gynecologic Oncologists, 38th Annual Meeting, San Diego, CA, USA, March 2007
Singhal P, Andrews C, Lele S, **Odunsi K**. Expression of testis specific “Transmembrane phosphatase with tensin homology” (TPTE) along with high intraepithelial CD8⁺/CD4⁺ T cell ratio predicts improved prognosis in ovarian cancer. Gynecol Oncol 2007; 104: S55.
70. Society of Gynecologic Oncologists, 38th Annual Meeting, San Diego, CA, USA, March 2007
Singhal P, Mischo A, Li Q, Eppolito C, Tsuji M, Franke M, Lele S, **Odunsi K**, Shrikant P. The natural killer T cell ligand alpha-C-Galactosylceramide promotes ovarian cancer survival by dual regulation of the adaptive host immunity. Gynecol Oncol 2007; 104: S21-2.

71. Society for Gynecologic Investigation, 54th Annual Meeting, Reno NV, USA, March 2007
Villega J, Andrews C, Sato E, Frederick PJ, Cheney R, Pilotte L, Lele S, Qian F, **Odunsi K**. Indolamine 2, 3 Dioxygenase: A potential mechanism of tolerance in ovarian cancer. *Reprod Sci* 2007; 14:133A, Abstract 269.
72. Society for Gynecologic Investigation, 54th Annual Meeting, Reno NV, USA, March 2007
Singhal P, Mischo A, Li Q, Eppolito C, Tsuji M, Lele S, **Odunsi K**, Shrikant P. The one-two punch by alpha-C-Galactosylceramide promotes ovarian tumor immunity. *Reprod Sci* 2007; 14:216A, Abstract 562.
73. American Association for Cancer Research, 98th Annual Meeting, Los Angeles, CA, USA, April 2007
Ghadersohi A, **Odunsi K**, Fayazi Z, Zhang S, Azrak RG, Pan D, Keitz B, Bundy BN, Rustum YM, Li F. Prostate-derived Ets transcription Factor (PDEF) is a favorable prognostic marker for ovarian cancer patients. In: *Proc Amer Assoc Cancer Res* 2007; Abstract 1695.
74. American Association for Cancer Research, 98th Annual Meeting, Los Angeles, CA, USA, April 2007
Mhaweche-Fauceglia P, Bshara W, Andrews C, South S, Lele S, **Odunsi K**. PSMA mRNA and Protein Expression are Potential Prognostic Markers in Endometrial Adenocarcinoma. In: *Proc Amer Assoc Cancer Res* 2007; Abstract 399.
75. American Association for Cancer Research, 98th Annual Meeting, Los Angeles, CA, USA, April 2007
Moysich KB, Weiss JR, Baker JA, Davis W, Carter L, **Odunsi K**. High Concordance between Pharmacogenetic Analysis of Tumor and Blood Samples from Patients with Ovarian Cancer. In: *Proc Amer Assoc Cancer Res* 2007; Abstract 3415.
76. American Association for Cancer Research 98th Annual Meeting, Los Angeles, CA, USA, April 2007
Woloszynska-Read A, Mhaweche-Fauceglia P, Yu J, **Odunsi K**, Karpf AR. Epigenetic regulation of NY-ESO-1 in ovarian cancer. In: *Proc Amer Assoc Cancer Res* 2007; Abstract 2854.
77. American Society of Clinical Oncology 43rd Annual Meeting, Chicago, IL. June 2007
Riebandt G, South SA, **Odunsi K**, Lele, Rodabaugh K. Limited value of routine iron studies prior to initiation of erythropoietin therapy in patients with ovarian cancer. *J Clin Oncol* 2007; ASCO Annual Meeting Proceedings 25(18S):19677
78. American Society of Clinical Oncology 43rd Annual Meeting, Chicago, IL. June 2007
Iyer RV, Tennant B, Ruiz M, Szyperski T, Trump D, **Odunsi K**, Wollman R. Can ¹H-Nuclear magnetic resonance (NMR) be used for early detection of hepatocellular cancer (HCC)? *J Clin Oncol* 2007; ASCO Annual Meeting Proceedings 25(18S):15107
79. Hematology Oncology Pharmacy Association, Annual Meeting, Denver, CO, USA, June 2007
Riebandt G, South S, Kossoff E, DelMonte J, Lele S, **Odunsi K**, Rodabaugh K. The impact of clinical pharmacist and anemia management service initiative on the response to erythropoietic growth factors (EGFs) in patients with gynecological malignancies. *J*

Oncol Pharm Practice 2007; 13:169-70. Abstract PR 09

80. European Society of Gynecologic Oncology, 15th International Meeting, Berlin, Germany, October/November 2007
Ghamande SA, Zamboni W, Lele S, Macfee M, Rodabaugh K, Thomas B, **Odunsi K**. Phase II trial of weekly docetaxel in patients with platinum resistant ovarian carcinoma.
81. Society for Biological Therapy (SBT), 22nd Annual Meeting, Boston, MA, USA, November 2007
Simpson-Abelson MR, Broderick L, Yokota SJ, **Odunsi K**, Conway TF, Kelleher Jr. RJ, Bankert RB. Re-activation of Memory T Cells in the Microenvironment of Human Tumors.
82. American Association for Cancer Research 99th Annual Meeting, San Diego CA Minisymposium April 2008
Odunsi K, Moysich K. Genetic variability in regulatory T (Treg) cell function in ovarian carcinogenesis. In: Proc Amer Assoc Cancer Res 2008; Abstract 2476.
83. Society of Gynecologic Oncologists, 39th Annual Meeting, Tampa, FL, March 2008
Odunsi K, Qian F, Villella J, Mhaweche-Fauceglia P, Andrews C, Matsuzaki J, Frederick PJ, Wallace P, Cheney R, Shrikant P, Lele S, Old LJ. Tryptophan degradation by indoleamine 2, 3-dioxygenase promotes induction of CD4+CD25+ High Foxp3+ regulatory T cells in human ovarian cancer. Gynecol Oncol 2008; 108: S147.
84. Society of Gynecologic Oncologists, 39th Annual Meeting, Tampa, FL, March 2008
South SA, Asubonteng KO, Andrews C, Rodabaugh K, **Odunsi K**, Shashikant Lele S. Weight loss after surgery impacts overall survival in epithelial ovarian cancer. Gynecol Oncol 2008;108: S151
85. Society of Gynecologic Oncologists, 39th Annual Meeting, Tampa, FL, March 2008
Singhal P, Villella J, Andrews C, Lele S, **Odunsi K**. BORIS and FATE Co-expression is a prognostic indicator in patients with epithelial ovarian cancer. Gynecol Oncol 2008;108: S87.
86. American Society of Clinical Oncology, 44th Annual Meeting, Chicago, IL, May 30-June 3, 2008
Riebandt G, South S, DelMonte J, Lele S, **Odunsi K**, Rodabaugh K Venous thromboembolism in Ovarian Cancer Patients Receiving Erythropoietin (epo)/darbepoetin (Darbe) for chemotherapy-induced anemia (CIA) J Clin Oncol 2008;26 May 20 suppl; abstr 16514. 2008 ASCO publication only.
87. American Society of Clinical Oncology, 44th Annual Meeting, Chicago, IL, May 30-June 3, 2008
Tchabo NE, Beck AF, Miliotto AJ, Sato E, Andrews C, Lele S, **Odunsi K**. Correlation of Wilms' tumor 1 (WT1) expression predicts high infiltration by regulatory T cells (Tregs) in epithelial ovarian cancer. J Clin Oncol 2008;26 May 20 suppl, abstr 5578.
88. American Society of Clinical Oncology, 44th Annual Meeting, Chicago, IL, May 30-June 3, 2008
Odunsi K, Tchabo NE, Beck AF, Miliotto AJ, Cabellero O, Sato E, Mhaweche-Fauceglia P,

Andrews C, Lele S. Developmentally restricted differentiation antigens in human ovarian cancer. *J Clin Oncol* 2008;26 May 20 suppl; abstr 16523.

89. American Society of Clinical Oncology, 44th Annual Meeting, Chicago, IL, May 30-June 3, 2008
Mhaweche-Fauceglia P, Herrmann FR, Andrews C, Lele S, **Odunsi K**. 14-3-3 sigma expression and prognostic value in patients with epithelial ovarian carcinoma. *J Clin Oncol* 2008;26 May 20 suppl; abstr 16597.
90. Hematology/Oncology Pharmacy Association/International Society of Oncology Pharmacy Practitioners Meeting, Anaheim, CA, June 2008
Rieband G, Macri D, Rodabaugh K, **Odunsi K**, Lele S. Evaluation of Medication Reconciliation Process in Gynecology Oncology Ambulatory Clinic. Presented at the. *J Oncol Pharm Practice* 2008; 14:90 #PR4.
91. American Society for Therapeutic Radiology and Oncology 50th Annual Meeting. Boston, MA. Sept 2008
Jaggernauth WA, Tchabo N, Yang G, Yap K, **Odunsi K**, Rodabaugh K, Lele S, Singh A, McCluskey S. High distant failure rate despite good local control in high risk early stage endometrial cancer. *Int J Radiat Oncol Biol Phys* 2008;72: S366. Abstract 2439.
92. National Institutes of Health/National Cancer Institute, Cancer Immunology and Immunotherapy: Realizing the Promise Meeting, Bethesda, MD, September 2008
Ramakrishna V, Takemasa T, Cohen L, Vitale L, O'Neill T, Sundarapandiyam K, Gnjatich S, **Odunsi K**, Ritter G, Old LJ, Keler T. Cross presentation of NY-ESO-1 to T cells by professional and non-professional APCs via a common DEC-205 receptor.
93. Hematology/Oncology Pharmacy Association 5th Annual Conference, Miami, FL, June 17-20, 2009
Riebandt G, Shao M, Miller A, duPont NC, **Odunsi K**, Lele S. Evaluation of Medication Reconciliation Process in Gynecologic Oncology Ambulatory Clinic.
94. Hematology/Oncology Pharmacy Association 5th Annual Conference, Miami, FL, June 17-20, 2009
Glode A, Riebandt G, Mackey M, Miller A, Kesterson J, Lele S, **Odunsi K**, duPont NC. Evaluation of Carboplatin Dosing Using Various Methods of Calculating Glomerular Filtration Rate (GFR) in Patients with Gynecologic Malignancies
95. African Society of Human Genetics 2009 Conference: Human Origins, Genetic Diversity and Health, Yaounde, Cameroon, March 13-15, 2009
Moysich K, Rodabaugh K, Sucheson L, Ness R, Baker J, **Odunsi K**. Genetic Variability in Regulatory T Cell Function in Ovarian Carcinogenesis.
96. Society for Gynecologic Investigation 56th Annual Scientific Meeting, Glasgow, Scotland. March 2009
Odunsi K, Kesterson J, Qian F, Lele S, Shrikant P. Inhibition of IDO Abrogates Induction of Tregs and Promotes Survival of Ovarian Tumor Bearing Hosts. *Reprod Sci* 2009;16; S89A. Abstract 71

97. Society for Gynecologic Investigation 56th Annual Scientific Meeting, Glasgow, Scotland. March 2009
Odunsi K, Kowalski D, Mhawech-Fauceglia P, South S, Andrews C, Lele S, Simpson AJG, Black JD, Rueda-Yea Huang RY. Inhibition of Serine–Arginine Protein Kinase 1 (SRPK1) Overcomes Platinum Resistance in Ovarian Cancer. *Reprod Sci* 2009; 16:151A. Abstract 283.
98. Society for Gynecologic Investigation 56th Annual Scientific Meeting, Glasgow, Scotland. March 2009
Pejovic T, Pande NT, Mori M, **Odunsi K**. Expression Profiling on the Ovarian Surface Kinome Reveals Candidate Genes for Early Neoplastic Changes. *Reprod Sci* 2009; 16:154A. Abstract 297.
99. American Society of Clinical Oncology, 45th Annual Meeting, Orlando, FL, May 29-June 2, 2009
Odunsi K, Ghamande S., Macfee M, Yin Chieh Yu A., Lele SB, Rodabaugh KJ, Thomas B, Zamboni WC. A phase II, pharmacokinetic (PK), and pharmacodynamic (PD) study of weekly docetaxel (DOC) in patients with platinum resistant ovarian cancer. *J Clin Oncol* 2009;27 suppl Abstract ID: e16531
100. Keystone Symposia on Molecular and Cellular Biology Meeting, Banff, Alberta, March 29-April 3, 2009
Ramakrishna V, Tsuji T, Cohen L, Vitale L, O'Neill T, Sundarapandiyam K, He LZ, Gnjatich S, Old LJ, **Odunsi K**, Ritter G, Keler T. Development of a novel vaccine that targets NY-ESO-1 to the dendritic cell receptor DEC-205. Abstract 260
101. Society for Gynecologic Investigation 57th Annual Scientific Meeting, Orlando, FL, March 2010.
Godoy H, Eppolito C, Balu-Iyer S, Lele S, **Odunsi K**. Dendritic Cells Loaded with WT-1 and Lipid A in a Cationic Liposome Promote Tumor Immunity in a Mouse Model of Ovarian Cancer. *Reprod Sci*. 2010; 17:356A. Abstract 1013
102. Society for Gynecologic Investigation 57th Annual Scientific Meeting, Orlando, FL, March 2010.
Fadiel A, Ulukus E, Ohtani K, Huang K, Scalise T, **Odunsi K**, Naftolin F. Transformed Human Ovarian Surface Epithelial Cells Express Ezrin and an Invasive Phenotype. *Reprod Sci*. 2010; 17:113A. Abstract 169.
103. Society for Gynecologic Oncologists 41st Annual Meeting, San Francisco, CA, March 2010.
Kesterson J, Weiss J, Rodabaugh K, Snowell S, **Odunsi K**, Zirpoli G, Grasela M, Sucheston L, Moysich K. An assessment of the concordance of pharmacogenetic polymorphisms between tumor and germline specimens in ovarian cancer patients. *Gynecol Oncol*. 2010; 116: S135. Abstract 348.
104. American Association for Cancer Research 101st Annual Meeting, Washington, D.C., April 2010.
Kesterson J, Lele S, **Odunsi K**, Liu S, Mhawech-Fauceglia P Distinct gene expression signatures for endometrial cancer predict for subtype, stage and prognosis. *Cancer Res*

2010;70(8 Suppl) Abstract LB-124.

105. American Association for Cancer Research 101st Annual Meeting, Washington, D.C., April 2010.
Godoy H, Mhaweche-Fauceglia P, Beck A, Miller A, Lele S, **Odunsi K**. Expression of Poly (Adenosine Diphosphate-ribose) Polymerase (PARP) and p53 in Epithelial Ovarian Cancer. *Cancer Res* 2010;70(8 Suppl). Abstract 803.
106. American Association for Cancer Research 101st Annual Meeting, Washington, D.C., April 2010.
Akers S, Link P, Zhang W, Miller A, Collamat G, **Odunsi K**, Lele S, Karpf A. Association between global DNA hypomethylation in leukocytes and risk of ovarian cancer. *Cancer Res* 2010;70(8 Suppl). Abstract LB-87.
107. American Association for Cancer Research 101st Annual Meeting, Washington, D.C., April 2010.
Moysich, KB, Nesline MK, Davis W, Wallace PK, Grasela MT, Hampras SS, Chennamaneni R, **Odunsi KO**. The influence of regulatory T cells on breast cancer risk and clinical characteristics. *Proc Amer Assoc Cancer Res* 2010; 51:1288.
108. CIMT/MASIR 8th Annual Meeting, Mainz, Germany, May 2010.
Attig S, Price L, Janetzki S, Kalos M, Pride M, Mc Neil L, Clay T, Yuan J, **Odunsi K**, Hoos A, Romero P, Britten CM, CRI-CIC Assay Working Group. Positive impact of dump channel use in HLA-peptide multimer staining - Results from the second HLA-peptide multimer proficiency phase organized by the Cancer Immunotherapy Consortium
109. Society for Gynecologic Oncologists 42nd Annual Meeting, Orland FL, March 2011.
Akers S, Moysich K, Zhang S, Link PA, Miller A, Lele S, **Odunsi K**, and Karpf AR - Association between global DNA hypomethylation in leukocytes and risk of ovarian cancer.
110. Society for Gynecologic Investigation 58th Annual Scientific Meeting, Miami Beach, FL, March 2011.
Godoy H, Kesterson JP, Eppolito C, Vethanayagam RR, Grimm MJ, Abrams S, Lele S, Segal BH, **Odunsi K**. NADPH Oxidase Modulates the Development of Myeloid-Derived Suppressor Cells (MDSCs) in Ovarian Cancer Tumor-Bearing Hosts.
111. American Association for Cancer Research 102nd Annual Meeting, Orlando, FL. April 2011.
Huang, RY, **Odunsi K**, Wong MKK. Identification of factors secreted by melanoma exhibiting propensity for lung metastasis. *Cancer Res* 2011;71(8 Suppl). Abstract 5170
112. American Society of Clinical Oncology 47th Annual Meeting, Chicago, IL. June 2011.
Berinstein NL, Morse M, Kaufman H, Nemunaitis JJ, **Odunsi K**, Chatta GS, Weir G, MacDonald L, Stanford M, Karkada M, Nigam R, Mansour M. A phase I study of the safety and immunogenicity of a therapeutic vaccine, DPX-0907 in patients with advanced-stage ovarian, breast, or prostate cancer. *J Clin Oncol* 2011;29 (suppl; abstr e13050)

113. American Society of Clinical Oncology 47th Annual Meeting, Chicago, IL. June 2011.
Riebandt G, Rodabaugh KJ, Pietkiewicz J, Fong M, Groman AE, Lele SB, **Odunsi K**, Akers S. Prospective analysis of chemotherapy-induced neuropathy in patients with gynecologic malignancies. *J Clin Oncol.* 2011;29 (suppl; abstr e19737)
114. Cancer Research Institute International Cancer Immunotherapy Symposium Series, Cancer Immunotherapy 2011; Immune Effector Mechanisms in Tumor Immunity. New York, NY. Oct 2011
Matsuzaki J, Sabado R, Gnjjatic S, Blank S, Lele S, Mhawech-Fauceglia P, duPont N, Muggia F, Holman RM, Siedlecki F, Escalon J, Ritter E, Ritter G, Old LJ, Shrikant P, Bhardwaj N, **Odunsi K**. Vaccination with recombinant canarypox expressing NY-ESO-1/TRICOM generates high avidity multifunctional CD8⁺ and CD4⁺ T cells in ovarian cancer patients.
115. Translational Research Cancer Centers Consortium 15th Annual Meeting, Silver Springs, PA. February 2012.
Huang RY, Eppolito C, Matsuzaki J, **Odunsi K**. Direct interaction of inhibitory molecules LAG-3 and PD-1 in murine CD8⁺ T cell signaling.
116. Translational Research Cancer Centers Consortium 15th Annual Meeting, Silver Springs, PA. February 2012.
Matsuzaki, J, Qian F, Scherle PA, **Odunsi K**. A potent small molecule inhibitor of IDO promotes NY-ESO-1-specific CD8⁺ T cell expansion, polyfunctionality, and tumor recognition in human ovarian cancer.
117. Translational Research Cancer Centers Consortium 15th Annual Meeting, Silver Springs, PA. February 2012.
Daudi S, Eppolito C, Matsuzaki J, Lele S, **Odunsi K**. Calcitriol Promotes TLR9/NOD2 Mediated Memory and Th1 Differentiation of Antigen Specific CD8⁺ T-Cells in Ovarian Tumor Bearing Mice.
118. Society for Gynecologic Investigation 59th Annual Scientific Meeting, San Diego, CA. March 2012.
Daudi S, Eppolito C, Matsuzaki J, Lele S, **Odunsi K**. Calcitriol Promotes TLR9/NOD2 Mediated Clonal Expansion, Survival and Th1 Differentiation of Antigen Specific CD8⁺ T-Cells for Ovarian Tumor Control
119. Society for Gynecologic Investigation 59th Annual Scientific Meeting, San Diego, CA. March 2012.
Daudi S, Millioto A, Beck A, Groman A, Lele S, **Odunsi K**. MAGE Antigens: Potential Targets for Immunotherapy with Co-ordinate Expression that Predicts Poor Survival in Epithelial Ovarian Cancer
120. Society for Gynecologic Investigation 59th Annual Scientific Meeting, San Diego, CA. March 2012.
Godoy H, Beck A, Miliotto A, Miller, Mhawch-Fauceglia P, **Odunsi K**. Developmentally restricted differentiation antigens are a target for immunotherapy in epithelial ovarian carcinoma.

121. Society of Gynecologic Oncology 43rd Annual Meeting, Austin, TX. March 2012.
Vaddadi P, Godoy H, Kesterson J, Tolentino, Frederick P, DuPont N, Lele S, **Odunsi, K.** Identification of a subset of Stage IV ovarian carcinomas with improved overall survival. *Gyne Onc* 2012;125(S1): S102. Abstract 243
122. Society of Gynecologic Oncology 43rd Annual Meeting, Austin, TX. March 2012.
Godoy H, Vaddadi P. Cooper M, Frederick P. **Odunsi K**, Lele S. Photodynamic therapy effectively palliates gynecologic malignancies. *Gyne Onc* 2012;125(S1): S81. Abstract 195
123. Society of Gynecologic Oncology 43rd Annual Meeting, Austin, TX. March 2012.
Akers SN, Khulpateea B, Groman A, Kesterson JP, **Odunsi K.** Lele S, Frederick PJ. Adjuvant treatment for uterine leiomyosarcoma. *Gyne Onc* 2012;125(S1): S159. Abstract 391
124. Society of Gynecologic Oncology 43rd Annual Meeting, Austin, TX. March 2012.
Simons E, Kiet T, Amanam I, Ho M, Fuh J, Kapp D, **Odunsi K**, Chan J. Immune biomarkers predictive of survival in epithelial ovarian cancer. *Gyne Onc* 2012;125(S1): S45. Abstract 106
125. Society of Gynecologic Oncology 43rd Annual Meeting, Austin, TX. March 2012.
Simons E, Kiet T, Amanam I, Ho M, Fuh J, Fuh K, Kapp D, **Odunsi K**, Chan J. Immune signatures predictive of optimal cytoreduction in ovarian cancer. *Gyne Onc* 2012;125(S1): S46. Abstract 107
126. American Association for Cancer Research 103rd Annual Meeting, Chicago, IL. March 2012.
Huang RY, Eppolito C, Matsuzaki J, **Odunsi K.** Direct interaction of inhibitory molecules LAG-3 and PD-1 in murine CD8⁺ T cell signaling. *Cancer Res* 2012;72(8 Suppl). Abstract 5398
127. American Association for Cancer Research 103rd Annual Meeting, Chicago, IL. March 2012.
Shen J, Wang D, Gregory S, Medico L, Hu Q, Lele S, **Odunsi K**, Ambrosone C, Liu S, Zhao H. Evaluation of microRNA expression profiles and their associations with risk alleles in lymphoblastoid cell lines of familial ovarian cancer. *Cancer Res* 2012;72(8 Suppl). Abstract 1659
128. American Society of Clinical Oncology 48th Annual Meeting, Chicago, IL. June 2012.
Tykodi SS, Brahmer JR, Hwu W-J, Chow LQ, Topalian SL, Hwu P, **Odunsi K**, Camacho LH, Kauh JS, Pitot HC, Hamid O, Pardoll DM, Agrawal S, Parker S, Goldberg S, Gupta AK, Wigginton J. PD-1/PD-L1 pathway as a target for cancer immunotherapy: Safety and clinical activity of BMS-936559, an anti-PD-L1 antibody, in patients with solid tumors.
129. American Society of Clinical Oncology 48th Annual Meeting, Chicago, IL. June 2012.
Berinstein NL, Karkada M, Nigam R, Morse M, Nemunaitis JJ, Chatta GS, Kaufman H, **Odunsi K**, Weir G, MacDonald L, Stanford M, Mansour M. A novel therapeutic cancer vaccine formulation DPX-0907 induces multifunctional T cell responses in ovarian, breast and prostate cancer patients.

130. American Society of Clinical Oncology 48th Annual Meeting, Chicago, IL. June 2012.
Mansour M, Hrytsenko O, Nigam R, Stanford M, Karkada M, Weir G, MacDonald L, **Odunsi K**, Berinstein NL. DPX-survivac: An enhanced peptide vaccine targeting survivin for cancer immunotherapy in ovarian cancer.
131. Eighth International Symposium on Regional Cancer Therapies, Indian Wells, CA. Feb 2013.
Kalinski P, Obermajer N, Muthuswamy R, **Odunsi K**, Edwards RP. Disruption of the positive feedback between PGE2 and COX2 blocks tumor accumulation and immunosuppressive functions of ovarian cancer associated MDSCs.
132. Society of Gynecologic Oncology's 44th Annual Meeting on Women's Cancer. Los Angeles, CA. March 2013.
Brightwell R, Miller A, Poblete S, **Odunsi K**, Lele S. Frequencies of non-ovarian cancers within the Gilda Radner Familial Ovarian Cancer Registry. *Gyne Onc* 2013;130(1); e106. Abstract 251
133. Society of Gynecologic Oncology's 44th Annual Meeting on Women's Cancer. Los Angeles, CA. March 2013.
Daudi S, Brady M, Lele S, **Odunsi K**. Human leukocyte antigen polymorphism predicts NY-ESO-1 serology and overall survival in epithelial ovarian cancer. *Gyne Onc* 2013;130(1): e134. Abstract 323
134. Society of Gynecologic Oncology's 44th Annual Meeting on Women's Cancer. Los Angeles, CA. March 2013.
Liu C, Miliotto A, Daudi S, Beck A, Groman A, Mhaweche-Fauceglia P, Lele S, **Odunsi K**. Expression and Serum Immunoreactivity Identify Cancer / Testis Genes 55 and 57 as Immunotherapy Targets in Ovarian Cancer. *Gyne Onc* 2013;130(1): e120-e121. Abstract 288
135. Society of Gynecologic Oncology's 44th Annual Meeting on Women's Cancer. Los Angeles, CA. March 2013.
Mori K, Akers SN, Bshara W, Burrin B, Freserieck P, Helenowski I, Morrison C, **Odunsi K**. Gamma synuclein expression in ovarian cancer. *Gyne Onc* 2013;130(1):272.
136. Society for Gynecologic Investigation 60th Annual Scientific Meeting, San Diego, CA. March 2013
Daudi S, Brady M, Miliotto A, Matsuzaki J, Lele S, **Odunsi K**. HLA Polymorphisms predict NY-EO-1 Tumor antigen serology and overall survival in epithelial ovarian cancer.
137. Society for Gynecologic Investigation 60th Annual Scientific Meeting, San Diego, CA. March 2013
Daudi S, Miliotto A, Groman A, Lele S, **Odunsi K**. Potential targest for immunotherapy in epithelial ovarian cancer.

138. American Association for Cancer Research 104th Annual Meeting, Washington, DC. April 2013.
Charbonneau B, Knutson K, Vierkant RA, Cunningham JM, Fogarty ZC, Kalli KR, Maurer MJ, Oberg AL, Fridley BL, Preston CC, Pharoah PDP, Ramus SJ, Phelan CM, **Odunsi K**, Moysich K, Goode EL. Polymorphisms in regulatory T cell related genes and ovarian cancer survival. *Cancer Res* 2013;73(8 Suppl): Abstract nr 4844
139. American Association for Cancer Research 104th Annual Meeting, Washington, DC. April 2013.
Amsler ME, Chmiel KA, Yaremko O, Carroll C, Yin J, Mashtare T, Miliotto A, Brightwell R, **Odunsi K**, Ceacareanu AC. Statins use prevents ovarian cancer recurrence in women with diabetes mellitus. *Cancer Res* 2013;73(8 Suppl): Abstract nr LB-18
140. Measuring Antigen Specific Immune Response (MASIR) Conference, Dubrovnik, Croatia. May 2013
McNeil LK, Price L, Britten CM, Jaimes M, Maecker H, **Odunsi K**, Matsuzaki J, Staats JS, Thorpe J, Yuan J, Janetzki S. A harmonized approach to intracellular cytokine staining gating: results from an international multi-consortia proficiency panel.
141. American Association for Cancer Research Special Conference on Advances in Ovarian Cancer Research: From Concept to Clinic, Miami, FL. September 2013
Sharma A, Zhang W, James S, Kufel C, Klinkebiel D, **Odunsi K**, Karpf AR. POTE gene expression, epigenetic regulation, and oncogenic functions in human epithelial ovarian cancer. *Clin Cancer Res* 2013;19(19 Suppl): Abstract nr B80
142. American Association for Cancer Research Special Conference on Advances in Ovarian Cancer Research: From Concept to Clinic, Miami, FL. September 2013
Zhang W, Klinkebiel D, Pandey S, Wang D, Liu S, Guda C, **Odunsi K**, Karpf AR. Genomic and epigenomic characterization of global DNA hypomethylation in human epithelial ovarian cancer. *Clin Cancer Res* 2013;19(19 Suppl): Abstract nr B12.
143. Society for Immunotherapy of Cancer 28th Annual Meeting, National Harbor, MD. November 2013.
Tsuji T, Eng K, Gnjjatic S, Matsuzaki J, Brightwell R, Miliotto A, Emerson R, Demarais C, Rubinstein E, Rubinstein J, Wang J, Liu S, Robins H, **Odunsi K**. Tumor-infiltrating T lymphocytes clonality predicts prognosis in human ovarian cancer. *J Immunother Cancer*. 2013;1(Suppl 1): P64
144. Society for Immunotherapy of Cancer 28th Annual Meeting, National Harbor, MD. November 2013.
Obermajer N, Wong JL, Edwards RP, Chen K, Scott M, Khader S, Kolls JK, **Odunsi K**, Billiar TR, Kalinski P. Development and stability of Th17 cells in ovarian cancer requires nitric oxide and endogenous NOS2 activity in cancer-associated CD4⁺ T cells. *J Immunother Cancer*. 2013;1(Suppl 1): P146
145. Keystone Symposia: Cancer Epigenetics. Santa Fe, NM. February 2014
Zhang W, Klinkebiel D, Pandey S, Guda C, Miller A, Akers S, **Odunsi K**, and AR Karpf. The molecular pathology of DNA hypomethylation in epithelial ovarian cancer

(EOC).

146. Society of Gynecologic Oncology's 19th Annual Winter Meeting- New Paradigms in Gynecologic Oncology, Breckenridge, CO, February 2014.
Brightwell R, Eng K, Lele S, **Odunsi K**. Duration of intrachemotherapy anemia is associated with prognosis and survival in epithelial ovarian cancer.
147. Society for Gynecologic Oncology's 45th Annual Meeting on Women's Cancer, Tampa FL, March 2014.
Kolomeyevskaya NV, Khan N, Dolnick R, Abrams S, **Odunsi KO**, Lele SB, Segal BH. Cytokine profiling of ascites identifies Macrophage inflammatory protein- beta and Tumor necrosis factor –alpha as predictors of progression-free survival in patients with epithelial ovarian cancer. *Gyne Onc.* 2014;133(S1):113.
148. Society for Gynecologic Oncology's 45th Annual Meeting on Women's Cancer, Tampa FL, March 2014.
Kolomeyevskaya NV, Lele SB, Miller A, Riebandt G, Blum B, Hacker K, Akers SN, **Odunsi KO**, Frederick PJ. *Oxaliplatin is a safe alternative for patients with recurrent gynecologic cancers following hypersensitivity reaction to carboplatin.* *Gyne Onc.* 2014;133(S1):70. PMID: 25356535
149. Society for Gynecologic Oncology's 45th Annual Meeting on Women's Cancer, Tampa FL, March 2014.
Dubil EA, Bshara W, **Odunsi KO**, Morrison C, Tian C,4, Risinger JI, Maxwell GL, Hamilton CA, Darcy KM, W. Consortium. Ovarian cancers with nuclear special AT-rich sequence-binding protein 1 and cytoplasmic AT-rich interactive domain-containing protein 1A are rare, drug-resistant, and deadly. *Gyne Onc.* 2014;133(S1):114.
150. Society for Gynecologic Oncology's 45th Annual Meeting on Women's Cancer, Tampa FL, March 2014.
Byrd KA, Maxwell GL, Bshara W, Risinger JI, Tian C, Omilian AR, **Odunsi KO**, Morrison C, Conrads TP, W. Consortium. Subcellular localization of AT-rich interactive domain1A protein expression is associated with survival in epithelial ovarian and peritoneal carcinoma. *Gyne Onc.* 2014;133(S1):93.
151. Society for Gynecologic Oncology's 45th Annual Meeting on Women's Cancer, Tampa FL. March 2014.
Kolomeyevskaya NV, Khan N, Grimm M, Singel K, Grzankowski KS, Abrams S, **Odunsi KO**, Segal BH. Targeting myeloid cells in the tumor microenvironment as a strategy to enhance vaccine efficacy in the epithelial ovarian cancer. *Gyne Onc.* 2014;133(S1):113.
152. Society for Gynecologic Oncology's 45th Annual Meeting on Women's Cancer, Tampa FL, March 2014.
Szender JB, Frederick PJ, Akers SN, Lele SB, **Odunsi KO**. Evaluation of a Universal Surgical Risk Calculator for quality improvement on a gynecologic oncology service. *Gyne Onc.* 2014;133(S1):149.
153. Society for Gynecologic Oncology's 45th Annual Meeting on Women's Cancer, Tampa FL, March 2014.

- Liu C, Friel G, Kolomeyevskaya NV, Lele SB, **Odunsi KO**, Moysich K. Aspirin and acetaminophen decrease the risk of cervical cancer in long-term users. *Gyne Onc.* 2014;133(S1):42.
154. American Society of Clinical Oncology's 50th Annual Meeting, Chicago, IL. May 2014. Wilson MK, Vilella JA, Berinstein NL, Brown J, Lheureux S, Haley A, **Odunsi K**, Karkada M, Nemunaitis JJ, Morse M, Pejovic T, Bentley J, Weir G, MacDonald L, Sattamur L, Stanford M, Burzykowski T, Nigam R, Mansour M, Oza AM. Phase I/Ib clinical and immunologic assessment of immunotherapeutic vaccine, dpx-survivac in women with ovarian, fallopian tube, or peritoneal cancer. *J Clin Oncol.* 2014; 32(15s) (suppl; abstr 5555)
155. American Society of Clinical Oncology's 50th Annual Meeting, Chicago, IL. May 2014. Grzankowski KS, Khan ANH, Grimm M, Hylander B, Singel KL, Moysich KB, Kolomeyevskaya N, **Odunsi K**, Segal BH. Effect of cell-free ascites containing mitochondrial DNA (mtDNA) from ovarian cancer (OC) patients on human neutrophils and neutrophil extracellular traps (NETs). *J Clin Oncol.* 2014; 32(15). (suppl; abstr e22087
156. American Society of Clinical Oncology's 50th Annual Meeting, Chicago, IL. May 2014. Callahan MK, Patrick Ott A, **Odunsi K**, Bertolini SV, Pan LS, Venhaus RR, Karakunne JJ, Hodi FS, Wolchok JD. A phase 1 study to evaluate the safety and tolerability of MEDI4736, an anti-PD-L1 antibody, in combination with tremelimumab in patients with advanced solid tumors. *J Clin Oncol.*2014;32(15s) Abstract No: TPS3120
157. American Society of Clinical Oncology's 50th Annual Meeting, Chicago, IL. May 2014. Grzankowski KS, Khan ANH, Eng KH, Melissa M, Singel KL, Kolomeyevskaya N, Moysich KB, **Odunsi K**, Segal BH. Pretreatment serum mitochondrial DNA (mtDNA) correlates with shorter progression-free and overall survival in patients with advanced ovarian cancer (OC). *J Clin Oncol.*2014;32(15s) (suppl; abstr 5545)
158. Society for Gynecologic Oncology's 2015 Annual Meeting on Women's Cancer, Chicago IL, March 2015
Brightwell RM, Eng K, Lele SB, **Odunsi KO**, P.J. Frederick PJ. Lymphocyte Nadir and Reconstitution During Chemotherapy Predicts Survival in Ovarian Cancer Patients
159. Society for Gynecologic Oncology's 2015 Annual Meeting on Women's Cancer, Chicago IL, March 2015
Kolomeyevskaya NV, Lele SB, **Odunsi KO**, Minlikeeva A, Friel G, Cannioto RA, Grzankowski, KS, Szender JB, Brightwell RM, Moysich KB. Oral contraceptive use and reproductive characteristics affect survival in patients with epithelial ovarian cancer..
160. Society for Gynecologic Oncology's 2015 Annual Meeting on Women's Cancer, Chicago IL, March 2015
Grzankowski KS, Segal, B, Kahn N, Grimm M, Singel K, Kolomeyevskaya N, Eng K, Moysich K, **Odunsi K**. Serum Mitochondrial DNA Shows a Greater Effect Size than CA-125 in Predicting Survival in Epithelial Ovarian Cancer.
161. Society for Gynecologic Oncology's 2015 Annual Meeting on Women's Cancer,

Chicago IL, March 2015

Grzankowski KS, Szender JB, Lele SB, **Odunsi KO**. Limited Training Exposure In Intraoperative Radiotherapy May Result In Omission Of Its Use In Treating Locally Advanced Gynecologic Malignancies.

162. American Society of Clinical Oncology's 51st Annual Meeting, Chicago, IL May 2015. Villella J, Wilson M, Berinstein N, Brown J, Lheureux S, Butler M, Ramsahai J, **Odunsi K**, Karkada M, Nemunaitis J, Morse M, Pejovic T, Bentley J, Weir G, MacDonald L, Stanford M, Burzykowski T, Nigam R, Mansour M, Oza A. Safety, immunogenicity and clinical activity of the immunotherapeutic vaccine, DPX-Survivac in a Phase 1/1b trial of women with ovarian, fallopian tube or peritoneal cancer.
163. American Society of Clinical Oncology's 51st Annual Meeting, Chicago, IL May 2015. Mahipal A, **Odunsi K**, Gnjatic S, Kim-Schulze S, Kenney R, Ejadi S. A First-in-Human Phase 1 Dose-escalating Trial of G305 in Patients with Solid Tumors Expressing NY-ESO-1.
164. American Society of Clinical Oncology's 51st Annual Meeting, Chicago, IL May 2015. Ott PA, Callahan MK, **Odunsi K**, Park A, Pan LS, Venhaus RR, Karakunnel JJ, Hodi FS, Wolchok JD. A Phase 1 Study to Evaluate the Safety and Tolerability of MEDI4736, an Anti-PD-L1 Antibody, in Combination with Tremelimumab in Patients with Advanced Solid Tumors.
165. American Society of Clinical Oncology's 51st Annual Meeting, Chicago, IL May 2015. Merchant M, Cristea M, Stadtmayer E, Tap W, D'Angelo S, Grupp S, Holdich T, Binder-Scholl G, Jakobsen B, **Odunsi K**, Rapoport A, Mackall C. Genetically Engineered NY-ESO-1 Specific T cells in HLA-A201+ Patients with Advanced Cancers.
166. Society for Immunotherapy of Cancer (SITC) 30th Annual Meeting, National Harbor, MD, November 2015. Dennis L, Fling SP, Beechem JM, Danaher P, D'Amico L, Disis ML, Elliot N, Geller MA, Jacquemont C, Kussick SJ, Shine R, **Odunsi K**. Preliminary validation of nCounter® PanCancer Immune Profiling of FFPE slides and PBMC in CITN-05, A CITN Study of the Immunological Effects of an IDO1 inhibitor in Patients with Ovarian Carcinoma.
167. American Society of Hematology 57th Annual Meeting, Orlando, FL, December 2015. Srivastava P, Matsuzaki J, Paluch B, Brumberger Z, Karpf A, **Odunsi K**, Austin Miller, Justin Kocent, Michael J. Nemeth, Elizabeth A. Griffiths. NY-ESO-1 vaccination in combination with decitabine for patients with MDS induces CD4+ and CD8+ T-cell responses.
168. American Association of Cancer Research: Advances in Ovarian Cancer Research: Exploiting Vulnerabilities, Orlando, FL, October 2015. McGray AJR, Eppolito C, Pol J, Stephenson K, Lichty B, **Odunsi K**. Combining Oncolytic virotherapy with immunotherapy for ovarian cancer treatment.
169. American Association of Cancer Research: Advances in Ovarian Cancer Research: Exploiting Vulnerabilities, Orlando, FL, October 2015. Huang R, McGray AJ and

- Odunsi K.** Combinatorial blockade of PD-1, CTLA-4, and LAG-3 pathways inhibits murine ovarian tumor growth.
170. BRCA: Challenges and Opportunities - The Sixth International Symposium on Hereditary Breast and Ovarian Cancer, May 2016. Ramus, S, Dicks E, Song H, Gronwald J, Poblete S, Zhu Q, Lele S, Campbell L, Moysich K, **Odunsi K**, Pharoah P, Gayther S. Session 10: New genes, old genes and modifiers.
 171. American Society of Clinical Oncology 2016 Annual Meeting, Chicago, IL, June 2016. Takemasa Tsuji, Kevin Eng, Brian Szender, Junko Matsuzaki, Anthony Miliotto, Sacha Gnjatic, Wiam Bshara, Angela Omilian, Carl Morrison, Shashikant Lele, Ryan Emerson, Cindy Desmarais, Jianmin Wang, Song Liu, Harlan Robins, Amit Lugade, Richard Koya, **Kunle Odunsi**. Prognostic effects of peripheral and tumor-infiltrating T cell V β repertoire diversity in ovarian cancer
 172. 2016 ACS NSQIP® Annual Conference, San Diego, CA, July 2016. The Impact of Hyperglycemic Intensity on Post-Operative Outcomes for a Gynecologic Oncology Service: a Cohort Study.
 173. Annals of Oncology: 11th International Symposium on Advanced Ovarian Cancer: Optimal Therapy, Valencia, Spain, March 2017. Immunotherapy in Ovarian Cancer
 174. American Society of Clinical Oncology 2017 Annual Meeting, Chicago, IL, June 2017. Comprehensive genomic profiling (CGP) with loss of heterozygosity (LOH) to identify therapeutically relevant subsets of ovarian cancer (OC). (Abstract 5512) J. A. Elvin, Y. He, J. Sun, **K. Odunsi**, J. B. Szender, K. N. Moore, L. M. Gay, G. M. Frampton, J. Vergilio, J. Suh, S. Ramkissoon, E. A. Severson, S. Daniel, K. K. Lin, J. Y. Hou, C. C. Gunderson, L. L. Holman, P. Stephens, M. Raponi, J. S. Ross
 175. Phase 1 study to evaluate the safety and tolerability of MEDI4736 (durvalumab, DUR) + tremelimumab (TRE) in patients with advanced solid tumors. (Abstract 3069) M. K. Callahan, **K. Odunsi**, M. Sznol, J. J. Nemunaitis, P. A. Ott, P. M. Dillon, A. J. Park, P. Schwarzenberger, T. Ricciardi, M. J. Macri, A. Ryan, R. R. Venhaus, J. D. Wolchok
 176. A NKG2D-based CAR-T therapy in a multinational phase I dose escalation and expansion study targeting multiple solid and hematologic tumor types. (Abstract TPS3093) B. Verma, P. G. Aftimos, A. Awada, J. H. Machiels, J. B. Brayer, D. A. Sallman, T. Kerre, **K. Odunsi**, C. Loney, D. E. Gilham, F. Lehmann
 177. A phase I/IIa, open label, clinical trial evaluating the safety and efficacy of autologous T cells expressing enhanced TCRs specific for NY-ESO-1 in patients with recurrent or treatment refractory ovarian cancer (NCT01567891). (Abstract TPS3094) **K. Odunsi**, M. C. Cristea, O. Dorigo, A. A. Jazaeri, B. M. Slomovitz, K. Chagin, E. Van Winkle, G. Kari, M. Iyengar, E. Norry, A. N. Bartlett-Pandite, R. G. Amado
 178. CD40 signaling is required for expansion of terminally differentiated CX3CR1⁺ CD8⁺ T cells. Fumito Ito, Toshifumi Hoki, Cheryl A. Eppolito, BS, Ariel J. Francois, MS Takayoshi Yamauchi, and **Kunle Odunsi**

179. Defining CD8 T-cell Subsets that are rescued by PD-1/PD-L1 Blockade in the Tumor Microenvironment. Takayoshi Yamauchi, Toshifumi Hoki, Cheryl A. Eppolito, BS, Ariel J. Francois, MS, Fumito Ito and **Kunle Odunsi**
180. SGO Annual Meeting on Women’s Cancer. Honolulu, HI, March 2019. Breaking the silence: Burnout among gynecologic oncology trainees is an impending crisis.
181. European Meeting on Complement in Human Disease, 2019. The Alternative and Classical Pathways of Complement Activation are Involved in Neutrophil-Mediated T-Cell Suppression in the Ovarian Cancer Microenvironment. Tiffany R. Emmons, Kelly L. Singel, ANM Nazmul H. Khan, Emad Alqassim, Sanjay Ram, Viviana Ferreira, Steven M. Holland, **Kunle Odunsi**, Emese Zsiros, and Brahm H. Segal
182. European Society of Medical Oncology (ESMO) 2019 Congress. ADP-A2M4 (MAGE-A4) in patients with Synovial Sarcoma. Brian A. Van Tine, Marcus Butler, Dejka Araujo, Melissa Johnson, Jeffrey Clarke, David Liebner, **Kunle Odunsi**, Anthony Olszanski, Samik Basu, Francine Brophy, Tom Holdrck, Trupti Trivedi, Rafael Amado, David S. Hong
183. Connective Tissue Oncology Society (CTOS) Meeting June 2019. The Synovial Sarcoma Subset Analysis of the Multi-histology Phase I Trial of ADP-A2M4 (MAGE-A4). Brian A. Van Tine, David S. Hong, Melissa L. Johnson, David Liebner, **Kunle Odunsi**, Trupti Trivedi, Quan Lin, Swethajit Biswas, Erica Elefant, Jean-Marc Navenot, Joana Senra, Zohar Wolchinsky, Robyn Broad, Gareth Betts, Natalie Bath, Will Spinner, Alex Tipping, Svetlana Fayngerts, Karen Miller, Amy Sun, Dennis Williams, Paula M. Fracasso, Elliot Norry, Marcus O. Butler
184. Society of Immunotherapy Cancer (SITC) Meeting November 2019. The Cancer Moonshot Immuno-Oncology Translational Network. Alan D. Hutson, Song Liu, Martin Morgan, **Kunle Odunsi**
185. Overcoming Ovarian Cancer Chemoresistance, 2020. **Kunle Odunsi**, Goli Samimi, Christina Annunziata
186. Connective Tissue Oncology Society (CTOS) Virtual Meeting November 2020. Durable Responses in Patients with Synovial Sarcoma in the Phase I Trial of ADP-A2M4 (MAGE-A4) (Abstract 3463188). Brian A. Van Tine, David S. Hong, David Liebner, **Kunle Odunsi**, Marcus Butler
187. European Association for Cancer Research (EACR) Virtual Conference – Defence is the Best Attack: Immuno-Oncology Breakthroughs, February 2021. The Future State of Immunotherapy for Ovarian Cancer. **Kunle Odunsi**
188. CCAF/CCAF-IT 2021 Annual Meeting, University of Michigan Rogel Cancer Center - Panel Discussion, “Diversity, Equity and Inclusion: How Cancer Centers are Creating a More Inclusive Future,” March 16, 2021. **Kunle Odunsi**
189. SGO 2021 Focused Plenary V: Ovary – Time to Return to the Drawing Board (Panelist), March 21, 2021. **Kunle Odunsi**

PUBLICATIONS

1. Ding L, Odunsi K. *RNA Splicing and Immune-Checkpoint Inhibition*. N Engl J Med. 2021 Nov 4;385(19):1807-1809. doi: 10.1056/NEJMcibr2110736.PMID: 34731541
2. Mistarz A, Graczyk M, Winkler M, Singh PK, Cortes E, Miliotto A, Liu S, Long M, Yan L, Stablewski A, O'Loughlin K, Minderman H, Odunsi K, Rokita H, McGray AJR, Zsiros E, Kozbor D. *Induction of cell death in ovarian cancer cells by doxorubicin and oncolytic vaccinia virus is associated with CREB3L1 activation*. Mol Ther Oncolytics. 2021 Apr 29; 23:38-50. doi: 10.1016/j.omto.2021.04.014. eCollection 2021 Dec 17. PMID: 34632049
3. Muthuswamy R, McGray AR, Battaglia S, He W, Miliotto A, Eppolito C, Matsuzaki J, Takemasa T, Koya R, Chodon T, Lichty BD, Shrikant P, **Odunsi K**. *CXCR6 by increasing retention of memory CD8⁺ T cells in the ovarian tumor microenvironment promotes immunosurveillance and control of ovarian cancer*. J Immunother Cancer. 2021 Oct;9(10): e003329. doi: 10.1136/jitc-2021-003329.PMID: 34607898
4. Bhatta M, Shenoy GN, Loyall JL, Gray BD, Bapardekar M, Conway A, Minderman H, Kelleher RJ Jr, Carreno BM, Linette G, Shultz LD, **Odunsi K**, Balu-Iyer SV, Pak KY, Bankert RB. *Novel phosphatidylserine-binding molecule enhances antitumor T-cell responses by targeting immunosuppressive exosomes in human tumor microenvironments*. J Immunother Cancer. 2021 Oct;9(10): e003148. doi: 10.1136/jitc-2021-003148.PMID: 34599030
5. Buas MF, Drescher CW, Urban N, Li CI, Bettcher L, Hait NC, Moysich KB, **Odunsi K**, Raftery D, Yan L. *Quantitative global lipidomics analysis of patients with ovarian cancer versus benign adnexal mass*. Sci Rep. 2021 Sep 13;11(1):18156. doi: 10.1038/s41598-021-97433-x.PMID: 34518593
6. Yao S, Cheng TD, Elkhanany A, Yan L, Omilian A, Abrams SI, Evans S, Hong CC, Qi Q, Davis W, Liu S, Bandera EV, Odunsi K, Takabe K, Khoury T, Ambrosone CB. *Breast Tumor Microenvironment in Black Women: A Distinct Signature of CD8⁺ T-Cell Exhaustion*. J Natl Cancer Inst. 2021 Aug 2;113(8):1036-1043. doi: 10.1093/jnci/djaa215.PMID: 33395700
7. Thaker PH, Bradley WH, Leath CA, Gunderson Jackson C, Borys N, Anwer K, Musso L, Matsuzaki J, Bshara W, Odunsi K, Alvarez RD. *GEN-1 in Combination with Neoadjuvant Chemotherapy for Patients with Advanced Epithelial Ovarian Cancer: A Phase I Dose-Escalation Study*. Clin Cancer Res. 2021 Jul 29: clincanres.0360.2021. doi: 10.1158/1078-0432.CCR-21-0360. Online ahead of print. PMID: 34326131
8. Hunt AL, Bateman NW, Barakat W, Makohon-Moore S, Hood BL, Conrads KA, Zhou M, Calvert V, Pierobon M, Loffredo J, Litzi TJ, Oliver J, Mitchell D, Gist G, Rojas C, Blanton B, Robinson EL, Odunsi K, Sood AK, Casablanca Y, Darcy KM, Shriver CD, Petricoin EF, Rao UNM, Maxwell GL, Conrads TP. *Extensive three-dimensional intratumor proteomic heterogeneity revealed by multiregion sampling in high-grade serous ovarian tumor specimens*. iScience. 2021 Jun 21;24(7):102757. doi: 10.1016/j.isci.2021.102757. eCollection 2021 Jul 23. PMID: 34278265

9. Ascierto PA, Bifulco C, Ciardiello F, Demaria S, Emens LA, Ferris R, Formenti SC, Galon J, Khleif SN, Kirchhoff T, McQuade J, **Odunsi K**, Patnaik A, Paulos CM, Taube JM, Timmerman J, Fox BA, Hwu P, Puzanov IJ *Perspectives in immunotherapy: meeting report from the immunotherapy bridge* (December 2nd-3rd, 2020, Italy). *Transl Med*. 2021 Jun 2;19(1):238. doi: 10.1186/s12967-021-02895-2.PMID: 34078406
10. Emmons TR, Giridharan T, Singel KL, Khan ANH, Ricciuti J, Howard K, Silva-Del Toro SL, Debreceni IL, Aarts CEM, Brouwer MC, Suzuki S, Kuijpers TW, Jongerius I, Allen LH, Ferreira VP, Schubart A, Sellner H, Eder J, Holland SM, Ram S, Lederer JA, Eng KH, Moysich KB, **Odunsi K**, Yaffe MB, Zsiros E, Segal BH. *Mechanisms driving neutrophil-induced T-cell immunoparalysis in ovarian cancer*. *Cancer Immunol Res*. 2021 May 14: canimm.0922.2020. doi: 10.1158/2326-6066.CIR-20-0922. Online ahead of print. PMID:33990375
11. Oba T, Makino K, Kajihara R, Yokoi T, Araki R, Abe M, Minderman H, Chang AE, **Odunsi K**, Ito F. *In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models*. *J Immunother Cancer*. 2021 May;9(5): e002432. doi: 10.1136/jitc-2021-002432.PMID: 34049930
12. Barger CJ, Chee L, Albahrani M, Munoz-Trujillo C, Boghean L, Branick C, **Odunsi K**, Drapkin R, Zou L, Karpf AR. *Co-regulation and function of FOXM1/RHNO1 bidirectional genes in cancer*. *Elife*. 2021 Apr 23;10: e55070. doi: 10.7554/eLife.55070.PMID: 33890574
13. McGray AJR, Eppolito C, Miliotto A, Singel KL, Stephenson K, Lugade A, Segal BH, Keler T, Webster G, Lichty B, Kozbor D, **Odunsi K**. *A prime/boost vaccine platform efficiently identifies CD27 agonism and depletion of myeloid-derived suppressor cells as therapies that rationally combine with checkpoint blockade in ovarian cancer*. *Cancer Immunol Immunother*. 2021 Apr 20:1-10. doi: 10.1007/s00262-021-02936-1. Online ahead of print. PMID:33880648
14. Amobi-McCloud A, Muthuswamy R, Battaglia S, Yu H, Liu T, Wang J, Putluri V, Singh PK, Qian F, Huang RY, Putluri N, Tsuji T, Lugade AA, Liu S, Odunsi K. *IDO1 Expression in Ovarian Cancer Induces PD-1 in T Cells via Aryl Hydrocarbon Receptor Activation*. *Front Immunol*. 2021 Apr 16; 12:678999. doi: 10.3389/fimmu.2021.678999. eCollection 2021.PMID: 34025677
15. Yamauchi T, Hoki T, Oba T, Jain V, Chen H, Attwood K, Battaglia S, George S, Chatta G, Puzanov I, Morrison C, **Odunsi K**, Segal BH, Dy GK, Ernstoff MS, Ito F. *T-cell CX3CR1 expression as a dynamic blood-based biomarker of response to immune checkpoint inhibitors*. *Nat Commun*. 2021 Mar 3;12(1):1402. doi: 10.1038/s41467-021-21619-0. PMID: 33658501
16. Fu Z, Kelley JL, **Odunsi K**, Edwards RP, Moysich K, Modugno F. *Gestational weight gain and risk of epithelial ovarian cancer*. *Cancer Causes Control*. 2021 Feb 22. doi: 10.1007/s10552-021-01405-5. Online ahead of print. PMID: 33616777
17. Want MY, Tsuji T, Singh PK, Thorne JL, Matsuzaki J, Karasik E, Gillard B, Cortes Gomez E, Koya RC, Lugade A, **Odunsi K**, Battaglia S. *WHSC1/NSD2 regulates immune*

infiltration in prostate cancer. J Immunother Cancer. 2021 Feb;9(2): e001374. doi: 10.1136/jitc-2020-001374. PMID: 33589522

18. Alqassim EY, Sharma S, Khan ANMNH, Emmons TR, Cortes Gomez E, Alahmari A, Singel KL, Mark J, Davidson BA, Robert McGray AJ, Liu Q, Lichty BD, Moysich KB, Wang J, **Odunsi K**, Segal BH, Baysal BE. *RNA editing enzyme APOBEC3A promotes pro-inflammatory M1 macrophage polarization.* Commun Biol. 2021 Jan 22;4(1):102. doi: 10.1038/s42003-020-01620-x. PMID: 33483601
19. Chen M, Brackett CM, Burdelya LG, Punnanitinont A, Patnaik SK, Matsuzaki J, **Odunsi K**, Gudkov AV, Singh AK, Repasky EA, Gurova KV. *Stimulation of an anti-tumor immune response with "chromatin-damaging" therapy.* Cancer Immunol Immunother. 2021 Jan 13. doi: 10.1007/s00262-020-02846-8. Online ahead of print. PMID: 33439292
20. Ascierto PA, Butterfield LH, Campbell K, Daniele B, Dougan M, Emens LA, Formenti S, Janku F, Khleif SN, Kirchhoff T, Morabito A, Najjar Y, Nathan P, **Odunsi K**, Patnaik A, Paulos CM, Reinfeld BI, Skinner HD, Timmerman J, Puzanov I. *Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge" (December 4th-5th, 2019, Naples, Italy).* J Transl Med. 2021 Jan 6;19(1):13. doi: 10.1186/s12967-020-02627-y. PMID: 33407605
21. Yao S, Cheng TD, Elkhanany A, Yan L, Omilian A, Abrams SI, Evans S, Hong CC, Qi Q, Davis W, Liu S, Bandera EV, **Odunsi K**, Takabe K, Khoury T, Ambrosone CB. *Breast Tumor Microenvironment in Black Women: A Distinct Signature of CD8+ T Cell Exhaustion.* J Natl Cancer Inst. 2021 Jan 5: djaa215. doi: 10.1093/jnci/djaa215. Online ahead of print. PMID: 33395700
22. Zsiros E, Lynam S, Attwood KM, Wang C, Chilakapati S, Gomez EC, Liu S, Akers S, Lele S, Frederick PJ, **Odunsi K**. *Efficacy and Safety of Pembrolizumab in Combination With Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Ovarian Cancer: A Phase 2 Nonrandomized Clinical Trial.* JAMA Oncol. 2021 Jan 1;7(1):78-85. doi: 10.1001/jamaoncol.2020.5945. PMID: 33211063 PMCID: PMC7677872
23. Gastman B, Agarwal PK, Berger A, Boland G, Broderick S, Butterfield LH, Byrd D, Fecci PE, Ferris RL, Fong Y, Goff SL, Grabowski MM, Ito F, Lim M, Lotze MT, Mahdi H, Malafa M, Morris CD, Murthy P, Neves RI, **Odunsi K**, Pai SI, Prabhakaran S, Rosenberg SA, Saoud R, Sethuraman J, Skitzki J, Slingsluff CL, Sondak VK, Sunwoo JB, Turcotte S, Yeung CC, Kaufman HL. *Defining best practices for tissue procurement in immunoncology clinical trials: consensus statement from the Society for Immunotherapy of Cancer Surgery Committee.* J Immunother Cancer. 2020 Nov;8(2): e001583. doi: 10.1136/jitc-2020-001583. PMID: 33199512
24. **Odunsi K**, McGray AJR, Miliotto A, Zhang Y, Wang J, Abiola A, Eppolito C, Huang RY. *Fidelity of human ovarian cancer patient-derived xenografts in a partially humanized mouse model for preclinical testing of immunotherapies.* J Immunother Cancer. 2020 Nov;8(2): e001237. doi: 10.1136/jitc-2020-001237. PMID: 33177175
25. Glubb DM, Thompson DJ, Aben KKH, Alsulimani A, Amant F, Annibali D, Attia J,

- Barricarte A, Beckmann MW, Berchuck A, Bermisheva M, Bernardini MQ, Bischof K, Bjorge L, Bodelon C, Brand AH, Brenton JD, Brinton LA, Bruinsma F, Buchanan DD, Burghaus S, Butzow R, Cai H, Carney ME, Chanock SJ, Chen C, Chen XQ, Chen Z, Cook LS, Cunningham JM, De Vivo I, deFazio A, Doherty JA, Dörk T, du Bois A, Dunning AM, Dürst M, Edwards T, Edwards RP, Ekici AB, Ewing A, Fasching PA, Ferguson S, Flanagan JM, Fostira F, Fountzilas G, Friedenreich CM, Gao B, Gaudet MM, Gawełko J, Gentry-Maharaj A, Giles GG, Glasspool R, Goodman MT, Gronwald J, Harris HR, Harter P, Hein A, Heitz F, Hildebrandt MAT, Hillemanns P, Høgdall E, Høgdall CK, Holliday EG, Huntsman DG, Huzarski T, Jakubowska A, Jensen A, Jones ME, Karlan BY, Karnezis A, Kelley JL, Khusnutdinova E, Killeen JL, Kjaer SK, Klapdor R, Köbel M, Konopka B, Konstantopoulou I, Kopperud RK, Koti M, Kraft P, Kupryjanczyk J, Lambrechts D, Larson MC, Le Marchand L, Lele S, Lester J, Li AJ, Liang D, Liebrich C, Lipworth L, Lissowska J, Lu L, Lu KH, Macciotta A, Mattiello A, May T, McAlpine JN, McGuire V, McNeish IA, Menon U, Modugno F, Moysich KB, Nevanlinna H, **Odunsi K**, et al. *Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers*. *Cancer Epidemiol Biomarkers Prev*. 2021 Jan;30(1):217-228. doi: 10.1158/1055-9965.EPI-20-0739. Epub 2020 Nov 3. PMID: 33144283
26. Stenzel AE, Abrams SI, Joseph JM, Goode EL, Tario JD Jr, Wallace PK, Kaur D, Adamson AK, Buas MF, Lugade AA, Laslavic A, Taylor SE, Orr B, Edwards RP, Elishaev E, **Odunsi K**, Mongiovi JM, Etter JL, Winham SJ, Kaufmann SH, Modugno F, Moysich KB. *Circulating CD14⁺ HLA-DR^{low} monocytic cells as a biomarker for epithelial ovarian cancer progression*. *Am J Reprod Immunol*. 2021 Mar;85(3): e13343. doi: 10.1111/aji.13343. Epub 2020 Sep 21.
27. Martins FC, Couturier DL, Paterson A, Karnezis AN, Chow C, Nazeran TM, **Odunsi K**, et al. *Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium*. *Br J Cancer*. 2020 Sep;123(5):793-802. doi: 10.1038/s41416-020-0900-0. Epub 2020 Jun 18.
28. Song H, Dicks EM, Tyrer J, Intermaggio M, Chenevix-Trench G, Bowtell DD, Traficante N, Group A, Brenton J, Goranova T, Hosking K, Piskorz A, van Oudenhove E, Doherty J, Harris HR, Rossing MA, Duerst M, Dork T, Bogdanova NV, Modugno F, Moysich K, **Odunsi K**, et al. *Population-based targeted sequencing of 54 candidate genes identifies PALB2 as a susceptibility gene for high-grade serous ovarian cancer*. *J Med Genet*. 2020 Jun 16: jmedgenet-2019-106739. doi: 10.1136/jmedgenet-2019-106739. Online ahead of print.
29. Tsuji T, Eng K, Matsuzaki J, Battaglia S, Szender B, Miliotto A, Gnjatich S, Bshara W, Morrison C, Lele S, Emerson R, Wang J, Liu S, Robins H, Lugade A, **Odunsi K**. *Clonality and antigen-specific responses shape the prognostic effects of tumor-infiltrating T cells in ovarian cancer*. *Oncotarget*. 2020 Jul 7; 11(27): 2669-2683. Published online 2020 July 7. Doi: 10.18632/oncotarget.27666. PMCID: PMC7343634
30. Khan ANH, Emmons TR, Wong JT, Alqassim E, Singel KL, Mark J, Smith BE, Tario JD, Eng KH, Moysich KB, **Odunsi K**, Abrams SI, Segal BH. *Quantification of Early-Stage Myeloid-Derived Suppressor Cells in Cancer Requires Excluding Basophils*. *Cancer*

Immunol Res. 2020 Jun;8(6):819-828. doi: 10.1158/2326-6066.CIR-10-0556. Epub 2020 Apr 1.

31. Annapragada A, Sikora A, Bollard C, Conejo-Garcia J, Cruz C, Demehri S, Demetriou M, Demirdjian L, Fong L, Horowitz M, Hutson A, Kadash-Edmondson K, Kufe D, Lipkin S, Liu S, McCarthy C, Morgan M, Morris Z, Pan Y, Pasquini M, Schoenberger S, Van Allen E, Vilar E, Xing Y, Zha W, the IOTN Consortium, **Odunsi K**. *Cancer Moonshot Immuno-Oncology Translational Network (IOTN); accelerating the clinical translation of basic discoveries for improving immunotherapy and immunoprevention of cancer*. J Immunother Cancer. 2020; 8(1): e000796. Published online 2020 June 17. doi: 10.1136/jitc-2020-000796. PMCID: PMC7304845
32. Kandalaft LE, **Odunsi K**, Coukos G. *Immune Therapy Opportunities in Ovarian Cancer*. Am Soc Clin Oncol Educ Book. 2020 May; 40:1-13. doi: 10.1200/EDBK_280539. PMID: 32412818
33. Yamauchi T, Hoki T, Oba T, Saito H, Attword K, Sabel M, Chang A, **Odunsi K**, Ito F. *CX3CR1-CD8+ T cells are critical in antitumor efficacy but functionally suppressed in the tumor microenvironment*. JCI Insight. 2020 April 23; 5(8): e133920. doi: 10.1172. PMCID: PMC7205436
34. Punnanitinont A, Kannisto E, Matsuzaki J, **Odunsi K**, Yendamuri S, Singh A, Patnaik S. *Sublethal Radiation Affects Antigen Processing and Presentation Genes to Enhance Immunogenicity of Cancer Cells*. Int J Mol Sci. 2020 Apr; 21(7): 2573. Published online 2020 Apr 7. doi: 10.3390/ijms21072573. PMCID: PMC7178186
35. Zhu Q, Zhang J, Chen Y, Hu Q, Shen H, Huang RY, Liu Q, Kaur J, Long M, Battaglia S, Eng KH, Lele SB, Zsiros E, Vilella J, Lugade A, Yao S, Liu S, Moysich K, **Odunsi K**. *Whole-exome sequencing of ovarian cancer families uncovers putative predisposition genes*. Int J Cancer, 2020 Apr 15; 146(8):2147-2155. doi: 10.1002/ijc.32545. Epub 2019 Jul 16. PMID: 31265121.
36. Lynam S, Lugade A, **Odunsi K**. *Immunotherapy for Gynecologic Cancer: Current Applications and Future Directions*. Clin Obstet Gynecol. Author manuscript; available in PMC 2020 Jun 17. Published in final edited form as: Clin Obstet Gynecol. 2020 Mar; 63(1): 48-63. doi: 10.1097/GRF.0000000000000513. PMCID: PMC7298668
37. Zhang W, Klinkebiel D, Barger C, Pandey S, Guda C, Miller A, Akers S, **Odunsi K**, Karpf A. *Global DNA Hypomethylation in Epithelial Ovarian Cancer: Passive Demethylation and Association with Genomic Instability*. Cancers (Basel) 2020 Mar; 12(3); 764. Published online 2020 Mar 24. doi: 10.3390/cancers12030764. PMCID: PMC7140107
38. Etter J, Moysich K, Kohli S, Lele S, **Odunsi K**, Eng K. *Transmission of X-linked Ovarian Cancer: Characterization and Implications*. Diagnostics (Basel) 2020 Feb; 10(2): 90. Published online 2020 Feb 7. doi: 10.3390/diagnostics10020090. PMCID: PMC7167857
39. Ascierto P, Bifulco C, Buonaguro L, Emens L, Ferris R, Fox B, Delgoffe G, Galon J, Gridelli C, Merlano M, Nathan P, **Odunsi K**, Okada H, Paulos C, Pignata S, Schalper K, Spranger S, Tortora G, Zarour H, Butterfield L, Puzanov I. *Perspectives in immunotherapy:*

meeting report from the “Immunotherapy Bridge 2018” (28-29 November, 2018, Naples, Italy). *J Immunother Cancer*. 2019; 7: 332. Published online 2019 Nov 29. doi: 10.1186/s40425-019-0798-3. PMCID: PMC6884742

40. McGray AJR, Huang RY, Battaglia S, Eppolito C, Miliotto A, Stephenson KB, Lugade AA, Webster G, Lichty BD, Seshadri M, Kozbor D, **Odunsi K**. *Oncolytic Maraba virus armed with tumor antigen boosts vaccine priming and reveals diverse therapeutic response patterns when combined with checkpoint blockade in ovarian cancer*. *J Immunother Cancer*. 2019 Jul 17;7(1):189. doi: 10.1186/s40425-019-0641-x. PMID: 31315674
41. Liu S, Matsuzaki J, Wei L, Tsuji T, Battaglia S, Hu Q, Cortes E, Wong L, Yan L, Long M, Miliotto A, Bateman NW, Lele SB, Chodon T, Koya RC, Yao S, Zhu Q, Conrads TP, Wang J, Maxwell GL, Lugade AA, **Odunsi K**. *Efficient identification of neoantigen-specific T-cell responses in advanced human ovarian cancer*. *J Immunother Cancer*. 2019 Jun 20;7(1):156. doi: 10.1186/s40425-019-0629-6. PMID: 31221207
42. **Odunsi K**, Pejovic T. *Immune Checkpoint and Poly (ADP-Ribose) Polymerase Inhibition for Recurrent Platinum-Resistant Ovarian and Metastatic Triple-Negative Breast Cancers*. *JAMA Oncol*. 2019 Jun 13. doi: 10.1001/jamaoncol.2019.1009. [Epub ahead of print] No abstract available. PMID: 31194214
43. Mahipal A, Ejadi S, Gnjjatic S, Kim-Schulze S, Lu H, Ter Meulen JH, Kenney R, **Odunsi K**. *First-in-human phase I dose-escalating trial of G305 in patients with advanced solid tumors expressing NY-ESO-1*. *Cancer Immunol Immunother*. 2019 May 8. doi: 10.1007/s00262-019-02331-x [Epub ahead of print] PMID: 31069460
44. Zhu Q, Zhang J, Chen Y, Hu Q, Shen H, Huang RY, Liu Q, Kaur J, Long M, Battaglia S, Eng KH, Lele SB, Zsiros E, Vilella J, Lugade A, Yao S, Liu S, Moysich K, **Odunsi KO**. *Whole-exome sequencing of ovarian cancer families uncovers putative predisposition genes*. *Int J Cancer*. 2019 Jul 2. doi: 10.1002/ijc.32545. [Epub ahead of print] PMID: 31265121
45. Kandalaf LE, **Odunsi K**, Coukos G. *Immunotherapy in Ovarian Cancer: Are We There Yet?* *J Clin Oncol*. 2019 Sept 20;37(27):2460-2471. Doi: 10.1200/JCO.1900508 PMID: 31403857
46. Mistarz A, Komorowski MP, Graczyk MA, Gil M, Jiang A, Opyrchal M, Rokita H, **Odunsi K**, Kozbor D. *Recruitment of Intratumoral CD103+ Dendritic Cells by a CXCR4 Antagonist-Armed Virotherapy Enhances Antitumor Immunity*. *Mol Ther Oncolytics*. 2019 Jul 3; 14:233-245. doi: 10.1016/j.omto.2019.06.003. eCollection 2019 Sep 27. PMID: 31384667
47. Nesline MK, DePietro P, Dy GK, Early A, Papanicolau-Sengos A, Conroy JM, Lenzo FL, Glenn ST, Chen H, Grand'Maison A, Boland P, Ernstoff MS, Puzanov I, Edge S, Akers S, Opyrchal M, Chatta G, **Odunsi K**, Frederick P, Lele S, Gardner M, Morrison C. *Oncologist uptake of comprehensive genomic profile guided targeted therapy*. *Oncotarget*. 2019 Jul 23;10(45):4616-4629. doi: 10.18632/oncotarget.27047. eCollection 2019 Jul 23 PMID: 31384390

48. Springuel L, Lonez C, Alexandre B, Van Cutsem E, Machiels JH, Van Den Eynde M, Prenen H, Hendlisz A, Shaza L, Carrasco J, Canon JL, Opyrchal M, **Odunsi K**, Rottey S, Gilham DE, Flament A, Lehmann FF. *Chimeric Antigen Receptor-T Cells for Targeting Solid Tumors: Current Challenges and Existing Strategies*. *BioDrugs*. 2019 Jul 30. doi: 10.1007/s40259-019-00368-z. [Epub ahead of print] Review. PMID: 31363930
49. Meagher NS, Wang L, Rambau PF, Intermaggio MP, Huntsman DG, Wilkens LR, El-Bahrawy MA, Ness RB, **Odunsi K**, et al. *A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases*. *Mod Pathol*. 2019 Jun 25. doi: 10.1038/s41379-019-0302-0. [Epub ahead of print] PMID: 31239549
50. Want MY, Konstorum A, Huang RY, Jain V, Matsueda S, Tsuji T, Lugade A, **Odunsi K**, Koya R, Battaglia S. *Neoantigens retention in patient derived xenograft models mediates autologous T cells activation in ovarian cancer*. *Oncoimmunology*. 2019 Mar 30;8(6): e1586042. doi: 10.1080/2162402X.2019.1586042. eCollection 2019. PMID: 31069153
51. Grant DJ, Manichaikul A, Alberg AJ, Bandera EV, Barnholtz-Sloan J, Bondy M, Cote ML, Funkhouser E, Moorman PG, Peres LC, Peters ES, Schwartz AG, Terry PD, Wang XQ, Keku TO, Hoyo C, Berchuck A, Sandler DP, Taylor JA, O'Brien KM, Velez Edwards DR, Edwards TL, Beeghly-Fadiel A, Wentzensen N, Pearce CL, Wu AH, Whittemore AS, McGuire V, Sieh W, Rothstein JH, Modugno F, Ness R, Moysich K, Rossing MA, Doherty JA, Sellers TA, Permuth-Way JB, Monteiro AN, Levine DA, Setiawan VW, Haiman CA, LeMarchand L, Wilkens LR, Karlan BY, Menon U, Ramus S, Gayther S, Gentry-Maharaj A, Terry KL, Cramer DW, Goode EL, Larson MC, Kaufmann SH, Cannioto R, **Odunsi K**, Etter JL, Huang RY, Bernardini MQ, Tone AA, May T, Goodman MT, Thompson PJ, Carney ME, Tworoger SS, Poole EM, Lambrechts D, Vergote I, Vanderstichele A, Van Nieuwenhuysen E, Anton-Culver H, Ziogas A, Brenton JD, Bjorge L, Salvensen HB, Kiemeny LA, Massuger LFAG, Pejovic T, Bruegl A, Moffitt M, Cook L, Le ND, Brooks-Wilson A, Kelemen LE, Pharoah PDP, Song H, Campbell I, Eccles D, DeFazio A, Kennedy CJ, Schildkraut JM. *Evaluation of vitamin D biosynthesis and pathway target genes reveals UGT2A1/2 and EGFR polymorphisms associated with epithelial ovarian cancer in African American Women* *Cancer Med* 2019 Apr 18. doi: 10.1002/cam4.1996. [Epub ahead of print] PMID: 31001917
52. Minlikeeva AN, Cannioto R, Jensen A, Kjaer SK, Jordan SJ, Diergaarde B, Szender JB, **Odunsi K**, Almohanna H, Mayor P, Starbuck K, Zsiros E, Bandera EV, Cramer DW, Doherty JA, DeFazio A; Australian Ovarian Cancer Study Group, Edwards R, Goode EL, Goodman MT, Høgdall E, Matsuo K, Mizuno M, Nagle CM, Ness RB, Paddock LE, Pearce CL, Risch HA, Rossing MA, Terry KL, Wu AH, Modugno F, Webb PM, Moysich KB; Ovarian Cancer Association Consortium. *Joint exposure to smoking, excessive weight, and physical inactivity and survival of ovarian cancer patients, evidence from the Ovarian Cancer Association Consortium* *Cancer Causes Control*. 2019 May;30(5):537-547. Doi: 10.1007/s10552-019-01157-3. Epub 2019 Mar 23. PMID: 30905014
53. Bast RC Jr, Matulonis UA, Sood AK, Ahmed AA, Amobi AE, Balkwill FR, Wielgos-Bonvallet M, Bowtell DDL, Brenton JD, Brugge JS, Coleman RL, Draetta GF, Doberstein K, Drapkin RI, Eckert MA, Edwards RP, Elias KM, Ennis D, Futreal A, Gershenson DM, Greenberg RA, Huntsman DG, Ji JXY, Kohn EC, Iavarone C, Lengyel ER, Levine DA,

Lord CJ, Lu Z, Mills GB, Modugno F, Nelson BH, **Odunsi K**, Pilsworth JA, Rottapel RK, Powell DJ Jr, Shen L, Shih IM, Spriggs DR, Walton J, Zhang K, Zhang R, Zou L. *Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference*. Cancer. 2019 Mar 5 doi: 10.1002/cncr.32004 [Epub ahead of print] PMID: 30835824

54. Matsuzaki J, Tsuji T, Chodon T, Ryan C, Koya RC, **Odunsi K**. *A rare population of tumor antigen-specific CD4+CD8+ double-positive $\alpha\beta$ T lymphocytes uniquely provide CD8-independent TCR genes for engineering therapeutic T cells*. J Immunother Cancer, 2019 Jan 9;7(1):7. doi: 10.1186/s40425-018-0467-y.PMID: 30626427
55. Singel KL, Emmons TR, Khan ANH, Mayor PC, Shen S, Wong JT, Morrell K, Eng KH, Mark J, Bankert RB, Matsuzaki J, Koya RC, Blom AM, McLeish KR, Qu J, Ram S, Moysich KB, Abrams SI, **Odunsi K**, Zsiros E, Segal BH. *Mature neutrophils suppress T cell immunity in ovarian cancer microenvironment*. JCI Insight. 2019 Feb 7. pii: 122311. doi: 10.1172/jci.insight.122311. [Epub ahead of print] PMID: 30730851
56. Sharma A, Albahrani M, Zhang W, Kufel CN, James SR, **Odunsi K**, Klinkebiel D, Karpf AR. *Epigenetic activation of POTE genes in ovarian cancer*. Epigenetics. 2019 Feb 14. doi: 10.1080/15592294.2019.1581590. [Epub ahead of print] PMID: 30764732
57. Pabla S, Conroy JM, Nesline MK, Glenn ST, Papanicolau-Sengos A, Burgher B, Hagen J, Giamo V, Andreas J, Lenzo FL, Yirong W, Dy GK, Yau E, Early A, Chen H, Bshara W, Madden KG, Shirai K, Dragnev K, Tafe LJ, Marin D, Zhu J, Clarke J, Labriola M, McCall S, Zhang T, Zibelman M, Ghatalia P, Araujo-Fernandez I, Singavi A, George B, MacKinnon AC, Thompson J, Singh R, Jacob R, Dressler L, Steciuk M, Binns O, Kasuganti D, Shah N, Ernstoff M, **Odunsi K**, Kurzrock R, Gardner M, Galluzzi L, Morrison C. *Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients*. J Immunother Cancer. 2019 Feb 1;7(1):27. doi: 10.1186/s40425-019-0506-3 PMID: 30709424
58. Modugno F, Goughnour SL, Wallack D, Edwards RP, **Odunsi K**, Kelley JL, Moysich K, Ness RB, Brooks MM. *Breastfeeding factors and risk of epithelial ovarian cancer*. Gynecol Oncol. 2019 Jan 25. pii: S0090-8258(19)30060-5. doi: 10.1016/j.ygyno.2019.01.017.
59. Dy GK, Nesline MK, Papanicolau-Sengos A, DePietro P, LeVeae CM, Early A, Chen H, Grand'Maison A, Boland P, Ernstoff MS, Edge S, Akers S, Opyrchal M, Chatta G, **Odunsi K**, Pabla S, Conroy JM, Glenn ST, DeFedericis HT, Burgher B, Andreas J, Giamo V, Qin M, Wang Y, Kanehira K, Lenzo FL, Frederick P, Lele S, Galluzzi L, Kuvshinoff B, Morrison C. *Treatment recommendations to cancer patients in the context of FDA guidance for next generation sequencing*. BMC Med Inform Decis Mak. 2019 Jan 18;19(1):14. PMID: 30658646
60. Tsuji T, Yoneda A, Matsuzaki J, Miliotto A, Ryan C, Koya RC, **Odunsi K**. *Cancer Immunol Res. Rapid Construction of Antitumor T-cell Receptor Vectors from Frozen Tumors for Engineered T-cell Therapy*. 2018 May;6(5):594-604. doi: 10.1158/2326-6066.CIR-17-0434. Epub 2018 Mar 27. PMID: 29588318

61. Mark J, Argentieri DM, Gutierrez CA, Morrell K, Eng K, Hutson AD, Mayor P, Szender JB, Starbuck K, Lynam S, Blum B, Akers S, Lele S, Paragh G, **Odunsi K**, de Leon-Casasola O, Frederick PJ, Zsiros E. *JAMA Ultrarestrictive Opioid Prescription Protocol for Pain Management After Gynecologic and Abdominal Surgery*. *Netw Open*. 2018 Dec 7;1(8): e185452. doi: 10.1001/jamanetworkopen.2018.5452. PMID: 30646274
62. Singel KL, Grzankowski KS, Khan ANMNH, Grimm MJ, D'Auria AC, Morrell K, Eng KH, Hylander B, Mayor PC, Emmons TR, Lénárt N, Fekete R, Környei Z, Muthukrishnan U, Gilthorpe JD, Urban CF, Itagaki K, Hauser CJ, Leifer C, Moysich KB, **Odunsi K**, Dénes Á, Segal BH. *Br J Cancer. Mitochondrial DNA in the tumour microenvironment activates neutrophils and is associated with worse outcomes in patients with advanced epithelial ovarian cancer*. 2018 Dec 6. doi: 10.1038/s41416-018-0339-8. [Epub ahead of print] PMID: 30518816
63. Barger CJ, Zhang W, Sharma A, Chee L, James SR, Kufel CN, Miller A, Meza J, Drapkin R, **Odunsi K**, Klinkebiel D, Karpf AR. *Sci Rep. Expression of the POTE gene family in human ovarian cancer*. 2018 Nov 20;8(1):17136. doi: 10.1038/s41598-018-35567-1. PMID: 30459449
64. Starbuck KD, Szender JB, Duncan WD, Morrell K, Etter JL, Zsiros E, **Odunsi K**, Moysich K, Eng KH. *PLoS One. Prognostic impact of adjuvant chemotherapy treatment intensity for ovarian cancer*. 2018 Nov 12;13(11): e0206913. doi: 10.1371/journal.pone.0206913. eCollection 2018. PMID: 30418985
65. Chodon T, Lugade AA, Battaglia S, **Odunsi K**. *Hematol Oncol Clin North Am. Emerging Role and Future Directions of Immunotherapy in Advanced Ovarian Cancer*. 2018 Dec;32(6):1025-1039. doi: 10.1016/j.hoc.2018.07.011. Epub 2018 Oct 1. Review. PMID: 30390758
66. Kelemen LE, Earp M, Fridley BL, Chenevix-Trench G; Australian Ovarian Cancer Study Group, Fasching PA, Beckmann MW, Ekici AB, Hein A, Lambrechts D, Lambrechts S, Van Nieuwenhuysen E, Vergote I, Rossing MA, Doherty JA, Chang-Claude J, Behrens S, Moysich KB, Cannioto R, Lele S, **Odunsi K**, et al. *rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology*. *Int J Mol Sci* 2018 Aug 21;19(9). pii: E2473. doi: 10.3390/ijms19092473. PMID: 30134598
67. Lonez C, Hendlisz A, Shaza L, Aftimos P, Vouche M, Donckier V, Machiels JH, Van Den Eynde M, Canon JL, Carrasco J, **Odunsi K**, Sahebjam S, Rottey S, Braun N, Verma B, Gilham DE, Lehmann FF. *Celyad's novel CAR T-cell therapy for solid malignancies*. *Curr Res Transl Med*. 2018 May;66(2):53-56. doi: 10.1016/j.retram.2018.03.001. Epub 2018 Apr 4. PMID: 29625833
68. Shenoy GN, Loyall J, Berenson CS, Kelleher RJ Jr, Iyer V, Balu-Iyer SV, **Odunsi K**, Bankert RB. *J Immunol. Sialic Acid-Dependent Inhibition of T Cells by Exosomal Ganglioside GD3 in Ovarian Tumor Microenvironments*. 2018 Dec 15;201(12):3750-3758. doi: 10.4049/jimmunol.1801041. Epub 2018 Nov 16. PMID: 30446565
69. Earp M, Tyrer JP, Winham SJ, Lin HY, Chornokur G, Dennis J, Modugno F, Moysich KB, Ness RB, Nevanlinna H, **Odunsi K**, Olson SH, Orlow I, Orsulic S, Pearce CL, Berchuck A,

Schildkraut JM, Ramus SJ, Monteiro ANA, Narod SA, Sellers TA, Gayther SA, Kelemen LE, Chenevix-Trench G, Risch HA, Pharoah PDP, Goode EL, Phelan CM. *Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility*. PloS One. 2018 Jul 6;13(7): e0197561. PMID:29979793

70. Want MY, Lugade AA, Battaglia S, **Odunsi K**. *Nature of tumour rejection antigens in ovarian cancer*. Immunology. 2018 May 17. PMID: 29772069
71. Lonez C, Hendlisz A, Shaza L, Aftimos P, Vouche M, Donckier V, Machiels JH, Van Den Eynde M, Canon JL, Carrasco J, **Odunsi K**, Sahebjam S, Rottey S, Braun N, Verma B, Gilham DE, Lehmann FF. *Celyad's novel CAR T-cell therapy for solid malignancies*. Curr Res Transl Med. 2018 May;66(2):53-56.
72. Tsuji T, Yoneda A, Matsuzaki J, Miliotto A, Ryan C, Koya RC, **Odunsi K**. *Rapid Construction of Antitumor T-cell Receptor Vectors from Frozen Tumors for Engineered T-cell Therapy*. Cancer Immunol Res. 2018 May;6(5):594-604.
73. Dixon-Suen SC, Nagle CM, Thrift AP, Pharoah PDP, Ewing A, Pearce CL, Zheng W; Australian Ovarian Cancer Study Group, Chenevix-Trench G, Fasching PA, Beckmann MW, Lambrechts D, Vergote I, Lambrechts S, Van Nieuwenhuysen E, Rossing MA, Doherty JA, Wicklund KG, Chang-Claude J, Jung AY, Moysich KB, **Odunsi K**, et al. *Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study*. Ovarian Cancer Association Consortium. Br J Cancer. 2018 Apr;118(8):1123-1129. PMID: 29555990
74. Etter JL, Eng K, Cannioto R, Kaur J, Almohanna H, Alqassim E, Szender JB, Joseph JM, Lele S, **Odunsi K**, Moysich KB. *Hereditary association between testicular cancer and familial ovarian cancer: A Familial Ovarian Cancer Registry study*. Cancer Epidemiol. 2018 Apr; 53:184-186. PMID: 29499525
75. Mayor PC, Eng KH, Singel KL, Abrams SI, **Odunsi K**, Moysich KB, Fuleihan R, Garabedian E, Lugar P, Ochs HD, Bonilla FA, Buckley RH, Sullivan KE, Ballas ZK, Cunningham-Rundles C, Segal BH. *Cancer in primary immunodeficiency diseases: Cancer incidence in the United States Immune Deficiency Network Registry*. J Allergy Clin Immunol. 2018 Mar;141(3):1028-1035.
76. Mayor PC, Eng KH, Singel KL, Abrams SI, **Odunsi K**, Moysich KB, Fuleihan R, Garabedian E, Lugar P, Ochs HD, Bonilla FA, Buckley RH, Sullivan KE, Ballas ZK, Cunningham-Rundles C, Segal BH. *Cancer in primary immunodeficiency diseases: Cancer incidence in the United States Immune Deficiency Network Registry*. J Allergy Clin Immunol. 2018 Mar;141(3):1028-1035. PMID: 28606585
77. Griffiths EA, Srivastava P, Matsuzaki J, Brumberger Z, Wang ES, Kocent J, Miller A, Roloff GW, Wong HY, Paluch BE, Lutgen-Dunckley LG, Martens BL, **Odunsi K**, Karpf AR, Hourigan CS, Nemeth MJ. *NY-ESO-1 Vaccination in Combination with Decitabine Induces Antigen-Specific T-lymphocyte Responses in Patients with Myelodysplastic Syndrome*. Clin Cancer Res. 2018 Mar 1;24(5):1019-1029. PMID: 28947565

78. Eng KH, Szender JB, Etter JL, Kaur J, Poblete S, Huang RY, Zhu Q, Grzesik KA, Battaglia S, Cannioto R, Krolewski JJ, Zsiros E, Frederick PJ, Lele SB, Moysich KB, **Odunsi K**. *Paternal lineage early onset hereditary ovarian cancers: A Familial Ovarian Cancer Registry study*. PLoS Genet. 2018 Feb 15;14(2): e1007194. PMID: 29447163
79. **Odunsi K**. *Immunotherapy in ovarian cancer*. Ann Oncol. 2017 Nov 1;28(suppl_8): viii1-viii7. doi: 10.1093/annonc/mdx444. Review. PMID: 29232467
80. AN, Moysich KB, Mayor PC, Etter JL, Cannioto RA, Ness RB, Starbuck K, Edwards RP, Segal BH, Lele S, **Odunsi K**, Diergaarde B, Modugno F. *Anthropometric characteristics and ovarian cancer risk and survival*. Minlikeeva. Cancer Causes Control. 2018 Feb;29(2):201-212. PMID: 29327114
81. Shenoy GN, Loyall J, Maguire O, Iyer V, Kelleher RJ Jr, Minderman H, Wallace PK, **Odunsi K**, Balu-Iyer SV, Bankert RB. *Exosomes Associated with Human Ovarian Tumors Harbor a Reversible Checkpoint of T-cell Responses*. Cancer Immunol Res. 2018 Feb;6(2):236-247. PMID: 29301753
82. Szender JB, Kaur J, Clayback K, Hutton ML, Mikkelsen J, **Odunsi K**, Dresbold C. *Breadth of Genetic Testing Selected by Patients at Risk of Hereditary Breast and Ovarian Cancer*. Int J Gynecol Cancer. 2018 Jan;28(1):26-33. PMID: 28930807
83. Lonez C, Verma B, Hendlisz A, Aftimos P, Awada A, Van Den Neste E, Catala G, Machiels JH, Piette F, Brayer JB, Sallman DA, Kerre T, **Odunsi K**, Davila ML, Gilham DE, Lehmann FF. *Study protocol for THINK: a multinational open-label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour types*. BMJ Open. 2017 Nov 12;7(11): e017075. PMID: 29133316
84. Thaker PH, Brady WE, Lankes HA, **Odunsi K**, Bradley WH, Moore KN, Muller CY, Anwer K, Schilder RJ, Alvarez RD, Fracasso PM. *A phase I trial of intraperitoneal GEN-1, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer, administered with pegylated liposomal doxorubicin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancers: An NRG Oncology/Gynecologic Oncology Group study*. Gynecol Oncol. 2017 Nov;147(2):283-290. PMID: 28802766
85. Griffiths EA, Srivastava P, Matsuzaki J, Brumberger Z, Wang ES, Kocent J, Miller A, Roloff GW, Wong HY, Paluch BE, Lutgen-Dunckley LG, Martens BL, **Odunsi K**, Karpf AR, Hourigan CS, Nemeth MJ. *NY-ESO-1 Vaccination in Combination with Decitabine Induces Antigen-Specific T-lymphocyte Responses in Patients with Myelodysplastic Syndrome*. Clin Cancer Res. 2018 Mar 1;24(5):1019-1029. PMID: 28947565
86. Minlikeeva AN, Freudenheim JL, Eng KH, Cannioto RA, Friel G, Szender JB, Segal B, **Odunsi K**, Mayor P, Diergaarde B, Zsiros E, Kelemen LE, Köbel M, Steed H, deFazio A, Jordan SJ, Fasching PA, Beckmann MW, Risch HA, Rossing MA, Doherty JA, Chang-Claude J, Goodman MT, Dörk T, Edwards R, Modugno F, Ness RB, Matsuo K, Mizuno M, Karlan BY, Goode EL, Kjør SK, Høgdall E, Schildkraut JM, Terry KL, Cramer DW, Bandera EV, Paddock LE, Kiemeny LA, Massuger LFAG, Sutphen R, Anton-Culver H, Ziogas A, Menon U, Gayther SA, Ramus SJ, Gentry-Maharaj A, Pearce CL, Wu AH,

- Kupryjanczyk J, Jensen A, Webb PM, Moysich KB; Ovarian Cancer Association Consortium; Australian Ovarian Cancer Study Group. *History of Comorbidities and Survival of Ovarian Cancer Patients, Results from the Ovarian Cancer Association Consortium*. *Cancer Epidemiol Biomarkers Prev*. 2017 Sep;26(9):1470-1473. PMID: 28864456
87. Minlikeeva AN, Freudenheim JL, Cannioto RA, Eng KH, Szender JB, Mayor P, Etter JL, Cramer DW, Diergaard B, Doherty JA, Dörk T, Edwards R, deFazio A, Friel G, Goodman MT, Hillemanns P, Høgdall E, Jensen A, Jordan SJ, Karlan BY, Kjær SK, Klapdor R, Matsuo K, Mizuno M, Nagle CM, **Odunsi K**, Paddock L, Rossing MA, Schildkraut JM, Schmalfeldt B, Segal BH, Starbuck K, Terry KL, Webb PM, Zsiros E, Ness RB, Modugno F, Bandera EV, Chang-Claude J, Moysich KB. *History of thyroid disease and survival of ovarian cancer patients: results from the Ovarian Cancer Association Consortium, a brief report*. *Br J Cancer*. 2017 Sep 26;117(7):1063-1069. PMID: 28817835
88. Singh AK, Winslow TB, Kermany MH, Goritz V, Heit L, Miller A, Hoffend NC, Stein LC, Kumaraswamy LK, Warren GW, Bshara W, **Odunsi K**, Matsuzaki J, Abrams SI, Schwaab T, Muhitch JB. *A Pilot Study of Stereotactic Body Radiation Therapy Combined with Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma*. *Clin Cancer Res*. 2017 Sep 1;23(17):5055-5065. PMID: 28630212
89. Grabosch S, Tseng G, Edwards RP, Lankes HA, Moore K, **Odunsi K**, Vlad A, Ma T, Strange M, Brozick J, Lugade A, Omilian A, Bshara W, Stuckey AR, Walker JL, Birrer M. *Gynecol Oncol. Multiplex profiling identifies distinct local and systemic alterations during intraperitoneal chemotherapy for ovarian cancer: An NRG Oncology/Gynecologic Oncology Group Study*. 2017 Jul;146(1):137-145. doi: 10.1016/j.ygyno.2017.04.008. Epub 2017 May 5. PMID: 28483269
90. Eng KH, Morrell K, Starbuck K, Spring-Robinson C, Khan A, Cleason D, Akman L, Zsiros E, **Odunsi K**, Szender JB. *Prognostic value of miliary versus non-miliary sub-staging in advanced ovarian cancer*. *Gynecol Oncol*. 2017 Jul;146(1):52-57. PMID: 28495239.
91. Szender JB, Emmons T, Belliotti S, Dickson D, Khan A, Morrell K, Khan ANMN, Singel KL, Mayor PC, Moysich KB, **Odunsi K**, Segal BH, Eng KH. *Impact of ascites volume on clinical outcomes in ovarian cancer: A cohort study*. *Gynecol Oncol*. 2017 Jun 14. pii: S0090-8258(17)30937-X. doi: 10.1016/j.ygyno.2017.06.008. [Epub ahead of print] PubMed PMID: 28624153.
92. Mayor PC, Eng KH, Singel KL, Abrams SI, **Odunsi K**, Moysich KB, Fuleihan R, Garabedian E, Lugar P, Ochs HD, Bonilla FA, Buckley RH, Sullivan KE, Ballas ZK, Cunningham-Rundles C, Segal BH. *Cancer in primary immunodeficiency diseases: Cancer incidence in the United States Immune Deficiency Network Registry*. *J Allergy Clin Immunol*. 2017 Jun 9. PubMed PMID: 28606585.
93. Phelan CM, Kuchenbaecker KB, Tyrer JP, Kar SP, Lawrenson K, Winham SJ, Dennis J, Pirie A, Riggan MJ, Chornokur G, Musinsky J, Nathanson KL, Nedergaard L, Ness RB, Neuhausen SL, Nevanlinna H, Niederacher D, Nussbaum RL, **Odunsi K**, Olah E, Olopade OI, Olsson H, Olswold C, O'Malley DM, Berchuck A, Chenevix-Trench G, Goode EL, Sellers TA, Gayther SA, Antoniou AC, Pharoah PDP. *Identification of 12 new*

susceptibility loci for different histotypes of epithelial ovarian cancer. Nat Genet. 2017 May;49(5):680-691. doi: 10.1038/ng.3826. Epub 2017 Mar 27. PMID: 28346442

94. Szender JB, Papanicolau-Sengos A, Eng KH, Miliotto AJ, Lugade AA, Gnjatic S, Matsuzaki J, Morrison CD, **Odunsi K**. *NY-ESO-1 expression predicts an aggressive phenotype of ovarian cancer.* Gynecol Oncol. 2017 Apr 6. pii: S0090-8258(17)30726-6. doi: 10.1016/j.ygyno.2017.03.509. PMID: 28392127
95. Minlikeeva AN, Freudenheim JL, Cannioto RA, Szender JB, Eng KH, Modugno F, Ness RB, LaMonte MJ, Friel G, Segal BH, **Odunsi K**, Mayor P, Zsiros E, Schmalfeldt B, Klapdor R, Dörk T, Hillemanns P, Kelemen LE, Köbel M, Steed H, de Fazio A; Australian Ovarian Cancer Study Group., Jordan SJ, Nagle CM, Risch HA, Rossing MA, Doherty JA, Goodman MT, Edwards R, Matsuo K, Mizuno M, Karlan BY, Kjær SK, Høgdall E, Jensen A, Schildkraut JM, Terry KL, Cramer DW, Bandera EV, Paddock LE, Kiemeny LA, Massuger LF, Kupryjanczyk J, Berchuck A, Chang-Claude J, Diergaarde B, Webb PM, Moysich KB; Ovarian Cancer Association Consortium. *History of hypertension, heart disease, and diabetes and ovarian cancer patient survival: evidence from the ovarian cancer association consortium.* Cancer Causes Control. 2017 Mar 14. PMID: 28293802
96. Downs-Canner S, Berkey S, Delgoffe GM, Edwards RP, Curiel T, **Odunsi K**, Bartlett DL, Obermayer N. *Suppressive IL-17A⁺Foxp3⁺ and ex-Th17 IL-17A^{neg}Foxp3⁺ Treg cells are a source of tumour-associated Treg cells.* Nat Commun. 2017 Mar 14; 8:14649. PMID: 28290453
97. Dicks E, Song H, Ramus SJ, Van Oudenhove E, Tyrer JP, Intermaggio MP, Kar S, Harrington P, Bowtell DD, Study Group A, Cicek MS, Cunningham JM, Fridley BL, Alsop J, Jimenez-Linan M, Piskorz A, Goranova T, Kent E, Siddiqui N, Paul J, Crawford R, Poblete S, Lele S, Sucheston-Campbell L, Moysich KB, Sieh W, McGuire V, Lester J, **Odunsi K**, Whittemore AS, Bogdanova N, Dürst M, Hillemanns P, Karlan BY, Gentry-Maharaj A, Menon U, Tischkowitz M, Levine D, Brenton JD, Dörk T, Goode EL, Gayther SA, Pharoah PD. *Germline whole exome sequencing and large-scale replication identifies FANCM as a likely high grade serous ovarian cancer susceptibility gene.* Oncotarget. 2017 Mar 3. PMID: 28881617
98. Danaher P, Warren S, Dennis L, D'Amico L, White A, Disis ML, Geller MA, **Odunsi K**, Beechem J, Fling SP. *Gene expression markers of Tumor Infiltrating Leukocytes.* J Immunother Cancer. 2017 Feb 21; 5:18. PMCID: PMC5319024
99. Andersen CL, Sikora MJ, Boisen MM, Ma T, Christie A, Tseng G, Park YS, Luthra S, Chandran U, Haluska P, Mantia-Smaldone G, **Odunsi K**, McLean K, Lee AV, Elishaev E, Edwards RP, Oesterreich S. *Active estrogen receptor-alpha signaling in ovarian cancer models and clinical specimens.* Clin Cancer Res. 2017 Jan 10. PMID: 28073843
100. Komorowski MP, McGray AR, Kolakowska A, Eng K, Gil M, Opyrchal M, Litwinska B, Nemeth MJ, **Odunsi KO**, Kozbor D. *Reprogramming antitumor immunity against chemoresistant ovarian cancer by a CXCR4 antagonist-armed viral oncotherapy.* Mol Ther Oncolytics. 2016 Dec 14; 3:16034. PMCID: PMC5155641

101. Huang R, Francois A, McGray AJ, Miliotto A, Kunle **Odunsi K**. *Compensatory upregulation of PD-1, LAG-3 and CTLA-4 limits the efficacy of single agent checkpoint blockade in metastatic ovarian cancer*. *OncoImmunology*. 2016 Oct 28;6(1): e1249561. PMID: PMC5283642
102. Paluch BE, Glenn ST, Conroy JM, Papanicolau-Sengos A, Bshara W, Omilian AR, Brese E, Nesline M, Burgher B, Andreas J, **Odunsi K**, Eng K, He J, Qin M, Gardner M, Galluzzi L, Morrison CD. *Robust detection of immune transcripts in FFPE samples using targeted RNA sequencing*. *Oncotarget*. 2017 Jan 10;8(2):3197-3205. PMID:27911273
103. Brightwell RM, Grzankowski KS, Lele S, Eng K, Arshad M, Chen H, **Odunsi K**. *The CD47 "don't eat me signal" is highly expressed in human ovarian cancer*. *Gynecol Oncol*. 2016 Nov;143(2):393-397. PMID: PMC5077667
104. Klinkebiel D, Zhang W, Akers SN, **Odunsi K**, Karpf AR. *DNA Methylome Analyses Implicate Fallopian Tube Epithelia as the Origin for High-grade Serous Ovarian Cancer*. *Mol Cancer Res*. 2016 Sep;14 (9):787-94. PMID: 27259716
105. Szender JB, Eng K, Matsuzaki J, Miliotto A, Gnjjatic S, Tsuji T, **Odunsi K**. *HLA superfamily assignment is a predictor of immune response to cancer testis antigens and survival in ovarian cancer*. *Gynecol Oncol*. 2016 Jul;142(1):158-62. PMID: PMC4917411. PMID: 27103177
106. Zhang W, Barger CJ, Eng KH, Klinkebiel D, Link PA, Omilian A, Bshara W, **Odunsi K**, Karpf AR. *PRAME expression and promoter hypomethylation in epithelial ovarian cancer*. *Oncotarget*. 2016 Jul 19;7(29):45352-45369. PMID: PMC5216727 PMID: 27322684
107. Cannioto RA, Sucheston-Campbell LE, Hampras S, Goode EL, Knutson K, Ness R, Modugno F, Wallace PK, Szender JB, Mayor P, Hong CC, Joseph JM, Friel G, Davis W, Nesline M, Eng KH, Edwards RP, Kruszka B, Schmitt K, **Odunsi K**, Moysich KB. *The Association of Peripheral Blood Regulatory T-Cell Concentrations with Epithelial Ovarian Cancer: A Brief Report*. *Int J Gynecol Cancer*. 2017 Jan;27(1):11-16. PMID: PMC5177489 PMID: 27759594
108. Pharoah PD, Song H, Dicks E, Intermaggio MP, Harrington P, Baynes C, Alsop K; Australian Ovarian Cancer Study Group, Bogdanova N, Cicek MS, Cunningham JM, Fridley BL, Gentry-Maharaj A, Hillemanns P, Lele S, Lester J, McGuire V, Moysich KB, Pobleto S, Sieh W, Sucheston-Campbell L, Widschwendter M; Ovarian Cancer Association Consortium, Whittemore AS, Dörk T, Menon U, **Odunsi K**, Goode EL, Karlan BY, Bowtell DD, Gayther SA, Ramus SJ. *PPM1D Mosaic Truncating Variants in Ovarian Cancer Cases May Be Treatment-Related Somatic Mutations*. *J Natl Cancer Inst*. 2016 Jan 27;108(3). PMID: PMC5072371 PMID: 26823519
109. Grzankowski KS, Szender JB, Spring-Robinson CL, Lele SB, **Odunsi KO**, Frederick PJ. *Evaluation of Metachronous Breast and Endometrial Cancers: Preroutine and Postroutine Adjuvant Tamoxifen Use*. *Int J Gynecol Cancer*. 2016 Oct;26(8):1440-7. PMID: PMC5077667. PMID: 27648713

110. Brightwell R, Handel E, Eng K, Grzankowski K, Frederick P, **Odunsi K**, Lele S. Eur J Gynaecol Oncol. *Docetaxel and nab-paclitaxel are safe alternative options for patients with gynecologic malignancies following hypersensitivity reaction to paclitaxel.* 2016;37(6):800-802. PMID: 29943924
111. Strohl A, Mori K, Akers S, Bshara W, Buttin B, Frederick PJ, Helenowski IB, Morrison CD, **Odunsi K**, Schink JC, Scholtens DM, Wei JJ, Kim JJ. *Synuclein- γ (SNCG) expression in ovarian cancer is associated with high-risk clinicopathologic disease.* J Ovarian Res. 2016 Nov 3;9(1):75. PMCID: PMC5094138.
112. Sucheston-Campbell LE, Cannioto R, Clay AI, Etter JL, Eng KH, Liu S, Battaglia S, Hu Q, Szender JB, Minlikeeva A, Joseph J, Mayor P, Abrams SI, Segal B, Wallace PK, Soh KT, Zsiros EZ, Anton-Culver H, Bandera EV, Beckmann MW, Berchuck A, Bjørge L, Bruegl A, Campbell IG, Campbell SP, Chenevix-Trench G, Cramer D, Dansonka-Mieszkowska A, Dao F, Diergaarde B, Doerk T, Doherty JA, du Bois A, Eccles D, Engelholm SA, Fasching PA, Gayther SA, Gentry-Maharaj A, Glasspool RM, Goodman MT, Gronwald J, Harter P, Hein A, Heitz F, Hillemanns P, Hogdall C, Høgdall EV, Huzarski T, Jensen A, Johnatty SE, Jung A, Karlan B, Klapdor R, Kluz T, Konopka B, Krüger Kjær S, Kupryjanczyk J, Lambrechts D, Lester J, Lubiński J, Levine DA, Lundvall L, McGuire V, McNeish IA, Menon U, Modugno F, Ness RB, Orsulic S, Paul J, Pearce CL, Pejovic T, Pharoah P, Ramus SJ, Rothstein J, Rossing MA, Rübner M, Schildkraut JM, Schmalfeldt B, Schwaab I, Siddiqui N, Sieh W, Sobiczewski P, Song H, Terry KL, Van Nieuwenhuysen E, Vanderstichele A, Vergote I, Walsh CS, Webb PM, Wentzensen N, Whittemore AS, Wu AH, Ziogas A, **Odunsi K**, Chang-Claude J, Goode EL, Moysich KB. *No evidence that genetic variation in the myeloid-derived suppressor cell pathway influences ovarian cancer survival.* Cancer Epidemiol Biomarkers Prev. 2016Sep27.PMID:27677730
113. Lawrenson K, Kar S, McCue K, Kuchenbaecker K, Michailidou K, Tyrer J, Beesley J, Ramus SJ, Li Q, Delgado MK, Moysich KB, Muir K, Mulligan AM, Nathanson KL, Ness RB, Neuhausen SL, Nevanlinna H, Nord S, Nussbaum RL, **Odunsi K**, Offit K, Olah E, Olopade OI, Olson JE, Olswold C, O'Malley D, Monteiro AN, French JD, Couch FJ, Freedman ML, Easton DF, Dunning AM, Pharoah PD, Edwards SL, Chenevix-Trench G, Antoniou AC, Gayther SA. *Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus.* Nat Commun. 2016 Sep 7; 7:12675. PMCID: PMC5023955
114. Southey MC, Goldgar DE, Winqvist R, Pylkäs K, Couch F, Tischkowitz M, Foulkes WD, Dennis J, Michailidou K, Vergote I, Lambrechts S, Doherty JA, Rossing MA, Nickels S, Eilber U, Wang-Gohrke S, **Odunsi K**, Sucheston-Campbell LE, Friel G, Lurie G, Killeen JL, Wilkens LR, Goodman MT, Runnebaum I, Hillemanns PA, Pelttari LM, Butzow R, Modugno F, Edwards RP, Ness RB, Moysich KB, Gayther SA, Ramus SJ, Menon U, Wu AH, Pearce CL, Van Den Berg D, Pike MC, Dansonka-Mieszkowska A, Plisiecka-Halasa J, Moes-Sosnowska J, Kupryjanczyk J, Pharoah PD, Song H, Winship I, Chenevix-Trench G, Giles GG, Tavtigian SV, Easton DF, Milne RL. *PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS.* J Med Genet. 2016 Dec;53(12):800-811. PMCID: PMC5200636

115. Permuth JB, Reid B, Earp M, Chen YA, Monteiro AN, Chen Z, Aocs Study Group, Chenevix-Trench G, Fasching PA, Beckmann MW, Lambrechts D, Vanderstichele A, Van Niewenhuyse E, Vergote I, Rossing MA, Doherty JA, Chang-Claude J, Moysich K, **Odunsi K**, Goodman MT, Shvetsov YB, Wilkens LR, Thompson PJ, Dörk T, Bogdanova N, Narod S, McLaughlin J, Anton-Culver H, Ziogas A, Menon U, Gayther S, Ramus SJ, Gentry-Maharaj A, Pearce CL, Wu AH, Kupryjanczyk J, Dansonka-Mieszkowska A, Schildkraut JM, Cheng JQ, Goode EL, Sellers TA. *Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility: results from a large-scale collaboration*. *Oncotarget*. 2016 Nov 8;7(45):72381-72394. PMID: 27533245
116. Hampras SS, Sucheston-Campbell LE, Cannioto R, Chang-Claude J, Modugno F, Dörk T, Hillemanns P, Preus L, Knutson KL, Wallace PK, Hong CC, Friel G, Davis W, Nesline M, Pearce CL, Vergote I, Vierkant RA, Walsh C, Wang-Gohrke S, Wentzensen N, Whittemore AS, Wicklund KG, Wilkens LR, Wu AH, Wu X, Woo YL, Yang H, Zheng W, Ziogas A, Gayther SA, Ramus SJ, Sellers TA, Schildkraut JM, Phelan CM, Berchuck A, Chenevix-Trench G, Cunningham JM, Pharoah PP, Ness RB, **Odunsi K**, Goode EL, Moysich KB. *Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer*. *Oncotarget*. 2016 Oct 25;7(43):69097-69110. PMID: 27533245
117. Mikucki ME, Skitzki JJ, Frelinger JG, **Odunsi K**, Gajewski TF, Luster AD, Evans SS. *Unlocking tumor vascular barriers with CXCR3: Implications for cancer immunotherapy*. *Oncoimmunology*. 2016 Feb 11;5(5): e1116675. PMID: 27467928
118. Kar SP, Beesley J, Amin Al Olama A, Michailidou K, Tyrer J, Kote-Jarai Z, Lawrenson K, Lindstrom S, Ramus SJ, Matsuo K, Muir K, Offitt K, Chen K, Moysich KB, Aittomäki K, **Odunsi K**, Kiemeny LA, Massuger LF, Fitzgerald LM, Cook LS, Sellers TA, Hunter DJ, Henderson BE, Kraft P, Chanock SJ, Couch FJ, Hall P, Gayther SA, Easton DF, Chenevix-Trench G, Eeles R, Pharoah PD, Lambrechts D. *Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types*. *Cancer Discov*. 2016 Sep;6(9):1052-67. doi: 10.1158/2159-8290.CD-15-1227 PMID: 27432226
119. Dixon SC, Nagle CM, Thrift AP, Pharoah PD, Pearce CL, Zheng W, Painter JN; AOCs Group & Australian Cancer Study (Ovarian Cancer), Chenevix-Trench G, Fasching PA, Beckmann MW, Lambrechts D, Vergote I, Lambrechts S, Van Nieuwenhuysen E, Rossing MA, Doherty JA, Wicklund KG, Chang-Claude J, Rudolph A, Moysich KB, **Odunsi K**, Goodman MT, Wilkens LR, Thompson PJ, Shvetsov YB, Dörk T, Park-Simon TW, Menon U, Gayther SA, Ramus SJ, Gentry-Maharaj A, Wu AH, Pike MC, Tseng CC, Kupryjanczyk J, Dansonka-Mieszkowska A, Budzilowska A, Spiewankiewicz B, Webb PM; Ovarian Cancer Association Consortium. *Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study*. *Int J Epidemiol*. 2016 Jun;45(3):884-95. PMID: 27401727.
120. Szender JB, Grzankowski KS, Eng KH, **Odunsi K**, Frederick PJ. *Evaluation of satisfaction with work-life balance among U.S. Gynecologic Oncology fellows: A cross-*

sectional study. Gynecol Oncol Rep. 2016 Mar 9;16:17-20. PMID: 27331129
PMCID: PMC4899516. PMID: 27088113

121. Cannioto RA, LaMonte MJ, Kelemen LE, Risch HA, Eng KH, Minlikeeva AN, Hong CC, Szender JB, Sucheston-Campbell L, Joseph JM, Berchuck A, Chang-Claude J, Cramer DW, DeFazio A, Diergaard B, Dörk T, Doherty JA, Edwards RP, Fridley BL, Friel G, Goode EL, Goodman MT, Hillemanns P, Hogdall E, Hosono S, Kelley JL, Kjaer SK, Klapdor R, Matsuo K, **Odunsi K**, Nagle CM, Olsen CM, Paddock LE, Pearce CL, Pike MC, Rossing MA, Schmalfeldt B, Segal BH, Szamreta EA, Thompson PJ, Tseng CC, Vierkant R, Schildkraut JM, Wentzensen N, Wicklund KG, Winham SJ, Wu AH, Modugno F, Ness RB, Jensen A, Webb PM, Terry K, Bandera EV, Moysich KB. *Recreational physical inactivity and mortality in women with invasive epithelial ovarian cancer: evidence from the Ovarian Cancer Association Consortium*. Br J Cancer. 2016 Jun 28;115(1):95-101. PMID: 27299959. PMCID: PMC4931371.
122. Szender JB, Cannioto R, Gulati NR, Schmitt KL, Friel G, Minlikeeva A, Platek A, Gower EH, Nagy R, Khachatryan E, Mayor PC, Kasza KA, Lele SB, **Odunsi K**, Moysich KB. *Impact of Physical Inactivity on Risk of Developing Cancer of the Uterine Cervix: A Case-Control Study*. J Low Genit Tract Dis. 2016 Apr 22. PMID: 27105330. PMCID: PMC4920713
123. Turkoglu O, Zeb A, Graham S, Szyperski T, Szender JB, **Odunsi K**, Bahado-Singh R. *Metabolomics. Metabolomics of biomarker discovery in ovarian cancer: a systematic review of the current literature*. 2016 Apr;12(4). pii: 60. doi: 10.1007/s11306-016-0990-0. Epub 2016 Mar 8. PMID:28819352
124. Kohrt HE, Tumeh PC, Benson D, Bhardwaj N, Brody J, Formenti S, Fox BA, Galon J, June CH, Kalos M, Kirsch I, Kleen T, Kroemer G, Lanier L, Levy R, Lysterly HK, Maecker H, Marabelle A, Melenhorst J, Miller J, Melero I, **Odunsi K**, Palucka K, Peoples G, Ribas A, Robins H, Robinson W, Serafini T, Sondel P, Vivier E, Weber J, Wolchok J, Zitvogel L, Disis ML, Cheever MA; Cancer Immunotherapy Trials Network (CITN). *Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials*. J Immunother Cancer. 2016 Mar 15; 4:15. PMID: 26981245. PMCID: PMC4791805.
125. Seagle BL, Eng KH, Yeh JY, Dandapani M, Schiller E, Samuelson R, **Odunsi K**, Shahabi S. *Discovery of candidate tumor biomarkers for treatment with intraperitoneal chemotherapy for ovarian cancer*. Sci Rep. 2016 Feb 17; 6:21591. PMID: 26883286. PMCID: PMC4756718.
126. Wong JL, Obermajer N, **Odunsi K**, Edwards RP, Kalinski P. *Synergistic COX2 Induction by IFN γ and TNF α Self-Limits Type-1 Immunity in the Human Tumor Microenvironment*. Cancer Immunol Res. 2016 Apr;4(4):303-11. PMID: 26817996. PMCID: PMC4877699.
127. Jim HS, Lin HY, Tyrer JP, Lawrenson K, Dennis J, Chornokur G, Chen Z, Chen AY, Permeth-Wey J, Aben KK, Anton-Culver H, McNeish I, Menon U, Milne RL, Modugno F, Thomsen L, Moysich KB, Ness RB, Nevanlinna H, Eilber U, **Odunsi K**, Olson SH, Orlow I, Orsulic S, Palmieri Weber R, Paul J, Pearce CL, Pejovic T, Amankwah E, Berchuck A; Georgia Chenevix-Trench on behalf of the AOCSS

management group 95,96, Schildkraut JM, Kelemen LE, Ramus SJ, Monteiro AN, Goode EL, Narod SA, Gayther SA, Pharoah PD, Sellers TA, Phelan CM. *Common Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC)*. J Genet Genome Res. 2015;2(2). PMCID: PMC4722961. PMID: 26807442

128. Bolton KL, Tyrer J, Song H, Ramus SJ, Notaridou M, Jones C, Sher T, Gentry-Maharaj A, Wozniak E, Tsai YY, Weidhaas J, Paik D, Van Den Berg DJ, Stram DO, Pearce CL, Wu AH, Brewster W, Anton-Culver H, Ziogas A, Narod SA, Levine DA, Kaye SB, Karlan BY, Ness RB, Edwards RP, **Odunsi K**, Moyisch KB, Baker JA, Modugno F, Birrer MJ, Terry KL, Hernandez D, Cramer DW, Vergote I, Amant F, Lambrechts D, Despierre E, Fasching PA, Beckmann MW, Thiel FC, Ekici AB, Chen X; Australian Ovarian Cancer Study Group, Johnatty SE, Webb PM, Beesley J, Chanock S, Garcia-Closas M, Sellers T, Easton DF, Berchuck A, Chenevix-Trench G, Pharoah PD, Gayther SA. *Corrigendum: Common variants at 19p13 are associated with susceptibility to ovarian cancer*. Nat Genet. 2016 Jan;48(1):101. PMID: 26711112.
129. Lee AW, Templeman C, Stram DA, Beesley J, Tyrer J, Berchuck A, Pharoah PP, Chenevix-Trench G, Pearce CL; Ovarian Cancer Association Consortium; Fertil Steril. *Evidence of a genetic link between endometriosis and ovarian cancer*. 2016 Jan;105(1):35-43.e1-10. doi: 10.1016/j.fertnstert.2015.09.023. Epub 2015 Oct 23. PMID: 26477498
130. Eng KH, Weir I, Tsuji T, **Odunsi K**. *Immuno-stimulatory/regulatory gene expression patterns in advanced ovarian cancer*. Genes Cancer. 2015 Sep;6(9-10):399-407. PMCID: PMC4633167 PMID: 26622942
131. Chodon T, Koya R, **Odunsi K**. *Active Immunotherapy of Cancer*. Immunol Invest. 2015 Nov; 44(8): 817-836. PMID: 26575466
132. Matsuzaki J, Tsuji T, Luescher IF, Shiku H, Mineno J, Okamoto S, Old LJ, Shrikant P, Gnjatic S, **Odunsi K**. *Direct tumor recognition by a human CD4(+) T-cell subset potently mediates tumor growth inhibition and orchestrates anti-tumor immune responses*. Sci Rep. 2015 Oct 8;5:14896. PMCID: PMC4597193. PMID: 26447332
133. Huang RY, Eppolito C, Lele S, Shrikant P, Matsuzaki J, **Odunsi K**. *LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model*. Oncotarget. 2015 Sep 29;6(29):27359-77. PMCID: PMC4694995 PMID: 26318293
134. Kelleher RJ Jr, Balu-Iyer S, Loyall J, Sacca AJ, Shenoy GN, Peng P, Iyer V, Fathallah AM, Berenson CS, Wallace PK, Tario J, **Odunsi K**, Bankert RB. *Extracellular Vesicles Present in Human Ovarian Tumor Microenvironments Induce a Phosphatidylserine-Dependent Arrest in the T-cell Signaling Cascade*. Cancer Immunol Res. 2015 Nov; 3(11):1269-78. PMCID: PMC4636911 PMID: 26112921
135. Mikucki ME, Fisher DT, Matsuzaki J, Skitzki JJ, Gaulin NB, Muhitch JB, Ku AW, Frelinger JG, **Odunsi K**, Gajewski TF, Luster AD, Evans SS. *Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints*. Nat Commun. 2015 Jun 25; 6:7458. PMCID: PMC4605273 PMID: 26109379

136. Khan AN, Kolomeyevskaya N, Singel KL, Grimm MJ, Moysich KB, Daudi S, Grzankowski KS, Lele S, Ylagan L, Webster GA, Abrams SI, **Odunsi K**, Segal BH. *Targeting myeloid cells in the tumor microenvironment enhances vaccine efficacy in murine epithelial ovarian cancer*. *Oncotarget*. 2015 May 10;6(13):11310-26. PMID: 25888637
137. Kelemen LE, Lawrenson K, Tyrer J, Li Q, Lee JM, Seo JH, Phelan CM, Beesley J, Chen X, Spindler TJ, Aben KK, Anton-Culver H, Antonenkova N; Australian Cancer Study; Australian Ovarian Cancer Study Group; Ovarian Cancer Association Consortium. *Genome-wide significant risk associations for mucinous ovarian carcinoma*. *Nat Genet*. 2015 Aug;47(8):888-97. PMID: 26075790
138. Ramus SJ, Song H, Dicks E, Tyrer JP, Rosenthal AN, Intermaggio MP, Fraser L, Gentry-Maharaj A, Hayward J, Philpott S, Anderson C, Edlund CK, Conti D, Harrington P, Barrowdale D, Bowtell DD, Alsop K, Mitchell G; AOCS Study Group, Cicek MS, Cunningham JM, Fridley BL, Alsop J, Jimenez-Linan M, Poblete S, Lele S, Sucheston-Campbell L, Moysich KB, Sieh W, McGuire V, Lester J, Bogdanova N, Dürst M, Hillemanns P; Ovarian Cancer Association Consortium, **Odunsi K**, Whittemore AS, Karlan BY, Dörk T, Goode EL, Menon U, Jacobs IJ, Antoniou AC, Pharoah PD, Gayther SA. *Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women with Ovarian Cancer*. *J Natl Cancer Inst*. 2015 Aug 27;107(11). PMID: 26315354
139. Obermajer N, Wong J, **Odunsi K**, Edwards R, and Kalinski P. *Synergistic COX2 induction by IFN γ and TNF α self-limits type-1 immunity in cancer tissues*. *Cancer Immunol Res*. 2016 Apr;4(4):303-11. PMID: 26877699
140. Apetoh L, Smyth MJ, Drake CG, Abastado JP, Apte RN, Ayyoub M, Blay JY, Bonneville M, Butterfield LH, Caignard A, Castelli C, Cavallo F, Celis E, Chen L, Colombo MP, Comin-Anduix B, Coukos G, Dhodapkar MV, Dranoff G, Frazer IH, Fridman WH, Gabrilovich DI, Gilboa E, Gnjatic S, Jäger D, Kalinski P, Kaufman HL, Kiessling R, Kirkwood J, Knuth A, Liblau R, Lotze MT, Lugli E, Marincola F, Melero I, Melief CJ, Mempel TR, Mittendorf EA, **Odunsi K**, Overwijk WW, Palucka AK, Parmiani G, Ribas A, Romero P, Schreiber RD, Schuler G, Srivastava PK, Tartour E, Valmori D, van der Burg SH, van der Bruggen P, van den Eynde BJ, Wang E, Zou W, Whiteside TL, Speiser DE, Pardoll DM, Restifo NP, Anderson AC. *Consensus nomenclature for CD8 $^{+}$ T cell phenotypes in cancer*. *Oncoimmunology*. 2015 Feb 25;4(4):e998538 PMID: 26485711
141. Brightwell RM, Grzankowski KS, Kaur J, Poblete S, Miller A, Lele SB, Sucheston-Campbell L, Moysich K, **Odunsi K**. *Higher than expected frequencies of non-ovarian cancers within a large familial ovarian cancer registry*. *Am J Clin Exp Obstet Gynecol* 2015;2(1):39-44. PMID: 26605374
142. Lee AW, Templeman C, Stram DA, Beesley J, Tyrer J, Berchuck A, Pharoah PP, Chenevix-Trench G, Pearce CL, Ness RB, Moysich KB, Wicklund KG, **Odunsi K**, Kiemeny LA, Sucheston-Campbell L, Lundvall L, Massuger LF,Lele S, Tworoger SS, Gayther SA, Missmer SA, Narod SA, Ramus SJ, Kjaer SK, Pejovic T, Dörk T, Eilber U, Menon U, McGuire V, Sieh W, Wu X, Bean Y, Shvetsov YB. *Evidence of a genetic link between endometriosis and ovarian cancer*. *Fertil Steril*. 2015 Oct 23. *Fertil Steril*. 2015 Oct 23.

PMCID: PMC5068352

143. Lawrenson K, Iversen ES, Tyrer J, Weber RP, Concannon P, Hazelett DJ, Li Q, Marks JR, Berchuck A, Lee JM, Aben KK, Anton-Culver H, Antonenkova N; Australian Cancer Study (Ovarian Cancer); Australian Ovarian Cancer Study Group, Bandera EV, . McNeish I, Menon U, Modugno F, Moysich KB, Narod SA, Nedergaard L, Ness RB, Noor Azmi MA, **Odunsi K**, Olson SH, Orlow I, Orsulic S, Pearce CL, Pejovic T, Pelttari LM, Permuth-Wey J, Phelan CM, Ziogas A, Coetzee GA, Freedman ML, Monteiro AN, Moes-Sosnowska J, Kupryjanczyk J, Pharoah PD, Gayther SA, Schildkraut JM. *Common variants at the CHEK2 gene locus and risk of epithelial ovarian cancer*. Carcinogenesis. 2015 Nov;36(11):1341-53. PMCID: PMC4635670. PMID: 26424751
144. Song H, Dicks E, Ramus SJ, Tyrer JP, Intermaggio MP, Hayward J, Edlund CK, Conti D, Harrington P, Fraser L, Philpott S, Anderson C, Rosenthal A, Gentry-Maharaj A, Bowtell DD, Alsop K, Cicek MS, Cunningham JM, Fridley BL, Alsop J, Jimenez-Linan M, Høgdall E, Høgdall CK, Jensen A, Kjaer SK, Lubiński J, Huzarski T, Jakubowska A, Gronwald J, Poblete S, Lele S, Sucheston-Campbell L, Moysich KB, **Odunsi K**, Goode EL, Menon U, Jacobs IJ, Gayther SA, Pharoah PD. *Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population*. J Clin Oncol. 2015 Sep 10;33(26):2901-7. PMCID: PMC4554751 PMID: 26261251
145. Berinstein NL, Karkada M, Oza AM, **Odunsi K**, Vilella JA, Nemunaitis JJ, Morse MA, Pejovic T, Bentley J, Buyse M, Nigam R, Weir GM, MacDonald LD, Quinton T, Rajagopalan R, Sharp K, Penwell A, Sammatur L, Burzykowski T, Stanford MM, Mansour M. *Survivin-targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients*. Oncoimmunology. 2015 May 7;4(8): e1026529 PMCID: PMC4570133
146. Amankwah EK, Lin HY, Tyrer JP, Lawrenson K, Dennis J, Chornokur G, Aben KK, Anton-Culver H, Antonenkova N, Bruinsma F, Bandera EV, Modugno F, Moysich KB, Ness RB, Nevanlinna H, Eilber U, **Odunsi K**, Olson SH, Orlow I, Orsulic S, Weber RP, Paul J, Pearce CL, Pejovic T, Pelttari LM, Permuth-Wey J, Ziogas A, Kelemen LE, Berchuck A; Georgia Chenevix-Trench on behalf of the AOCS management group, Schildkraut JM, Ramus SJ, Goode EL, Monteiro AN, Gayther SA, Narod SA, Pharoah PD, Sellers TA, Phelan CM. *Epithelial-Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk*. Genet Epidemiol. 2015 Sep 24. PMCID: PMC4721602. PMID: 26399219
147. Lawrenson K, Li Q, Kar S, Seo JH, Tyrer J, Spindler TJ, Lee J, Chen Y, Karst A, Drapkin R, Modugno F, Moysich KB, Narod SA, Nedergaard L, Ness RB, Azmi MA, **Odunsi K**, Olson SH, Orlow I, Orsulic S, Weber RP, Pearce CL, Woo YL, Wu X, Wu AH, Yang H, Zheng W, Ziogas A, Monteiro A, Pharoah PD, Gayther SA, Freedman ML. *Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer*. Nat Commun. 2015 Sep 22; 6:8234. PMCID: PMC4580986 PMID: 26391404
148. Minlikeeva AN, Freudenheim JL, Lo-Ciganic WH, Eng KH, Friel G, Diergaarde B, Modugno F, Cannioto R, Gower E, Szender JB, Grzankowski K, **Odunsi K**, Ness RB, Moysich KB. *Use of Common Analgesics Is Not Associated with Ovarian Cancer Survival*.

Cancer Epidemiol Biomarkers Prev. 2015 Aug;24(8):1291-4. PMCID: PMC4526413.
PMID: 26063476

149. Knutson KL, Maurer MJ, Preston CC, Moysich KB, Goergen K, Hawthorne KM, Cunningham JM, **Odunsi K**, Hartmann LC, Kalli KR, Oberg AL, Goode EL. *Regulatory T cells, inherited variation, and clinical outcome in epithelial ovarian cancer*. Cancer Immunol Immunother. 2015 Aug 23. PMCID: PMC4651184. PMID: 26298430
150. Zhang W, Barger CJ, Link PA, Mhawech-Fauceglia P, Miller A, Akers SN, **Odunsi K**, Karpf AR. *DNA hypomethylation-mediated activation of Cancer/Testis Antigen 45 (CT45) genes is associated with disease progression and reduced survival in epithelial ovarian cancer*. Epigenetics. 2015 Aug 3;10(8):736-48. PMCID: PMC4622579 PMID: 26098711
151. Kar SP, Tyrer JP, Li Q, Lawrenson K, Aben KK, Anton-Culver H, Antonenkova N, Chenevix-Trench G, Baker H, Bandera EV, McNeish IA, Menon U, Modugno F, Moysich KB, Narod SA, Nedergaard L, Ness RB, Nevanlinna H, **Odunsi K**, Olson SH, Orlow I, Orsulic S, Weber RP, Pearce CL, Wentzensen N, Whittemore AS, Wicklund KG, Wilkens LR, Woo YL, Wu X, Wu A, Yang H, Zheng W, Ziogas A, Sellers TA, Monteiro AN, Freedman ML, Gayther SA, Pharoah PD. *Network-Based Integration of GWAS and Gene Expression Identifies a HOX-Centric Network Associated with Serous Ovarian Cancer Risk*. Cancer Epidemiol Biomarkers Prev. 2015 Oct;24(10): 1574-84. PubMed PMID: 26209509.
152. Seagle BL, Yang CP, Eng KH, Dandapani M, Odunsi-Akanji O, Goldberg GL, **Odunsi K**, Horwitz SB, Shahabi S. *TP53 hot spot mutations in ovarian cancer: selective resistance to microtubule stabilizers in vitro and differential survival outcomes from The Cancer Genome Atlas*. Gynecol Oncol. 2015 Jul;138(1):159-64. PMID: 25958320.
153. Ajenifuja K, Kolomeyevskaya N, Habib F, **Odunsi K**, Lele S. Phyllodes tumor of the breast metastasizing to the vulva. Case Rep Oncol Med. 2015; 589547. PMID: 25960902.
154. Seagle BL, Eng KH, Dandapani M, Yeh JY, **Odunsi K**, Shahabi S. *Survival of patients with structurally grouped TP53 mutations in ovarian and breast cancers*. Oncotarget. 2015 Jul 30;6(21):18641-52. PMID: 26215675.
155. Friel G, Liu CS, Kolomeyevskaya NV, Hampras SS, Kruszka B, Schmitt K, Cannioto RA, Lele SB, **Odunsi KO**, Moysich KB. *Aspirin and Acetaminophen Use and the Risk of Cervical Cancer*. J Low Genit Tract Dis. 2015 Jul;19(3):189-93. PubMed PMID: 25856123.
156. Liu B, Conroy JM, Morrison CD, **Odunsi KO**, Qin M, Wei L, Trump DL, Johnson CS, Liu S, Wang J. *Structural variation discovery in the cancer genome using next generation sequencing: computational solutions and perspectives*. Oncotarget. 2015 Mar 20;6(8):5477-89. PMID: 25849937.
157. Qin M, Liu B, Conroy JM, Morrison CD, Hu Q, Cheng Y, Murakami M, **Odunsi KO**, Johnson CS, Wei L, Liu S, Wang J. *SCNVSim: somatic copy number variation and structure variation simulator*. BMC Bioinformatics. 2015 Feb 28; 16:66. PMID: 25886838.
158. Barger CJ, Zhang W, Hillman J, Stablewski AB, Higgins MJ, Vanderhyden BC, **Odunsi K**, Karpf AR. *Genetic determinants of FOXM1 overexpression in epithelial ovarian cancer and*

functional contribution to cell cycle progression. *Oncotarget*. 2015 Sept 29;6(29):27613-27. PMID: 26243836.

159. Chornokur G, Lin HY, Tyrer JP, Lawrenson K, Dennis J, Amankwah EK, Qu X, Tsai YY, Jim HS, Chen Z, Chen AY, Modugno F, Moysich KB, Ness RB, Nevanlinna H, Eilber U, **Odunsi K**, Olson SH, Orlow I, Orsulic S, Weber RP, Paul J, Pearce CL, Berchuck A; Georgia Chenevix-Trench; AOCs management group, Iversen ES, Schildkraut JM, Ramus SJ, Goode EL, Monteiro AN, Gayther SA, Narod SA, Pharoah PD, Sellers TA, Phelan CM. *Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk*. *PLoS One*. 2015 Jun 19;10(6): e0128106. PMID: 26091520.
160. Zsiros E, Tsuji T, **Odunsi K**. *Adoptive T-cell therapy is a promising salvage approach for advanced or recurrent metastatic cervical cancer*. *J Clin Oncol*. 2015 May 10;33(14):1521-2. Epub 2015 Apr 6. PMID: 25847926.
161. Coetzee SG, Shen HC, Hazelett DJ, Lawrenson K, Kuchenbaecker K, Tyrer J, Rhie SK, Levanon K, Karst A, Drapkin R, Ramus SJ; Ovarian Cancer Association Consortium, The Consortium of Investigators of Modifiers of BRCA1/2, Couch FJ, Offit K, Chenevix-Trench G, Monteiro AN, Antoniou A, McNeish I, Menon U, Modugno F, Moysich KB, Narod SA, Nedergaard L, Ness RB, Azmi MA, **Odunsi K**, Olson SH, Orlow I, Orsulic S, Weber RP, Pearce CL, Pejovic T, Vergote I, Vierkant RA, Wang-Gohrke S, Walsh C, Wentzensen N, Whittemore AS, Wicklund KG, Wilkens LR, Woo YL, Wu X, Wu AH, Yang H, Zheng W, Ziogas A. *Cell-type-specific enrichment of risk-associated regulatory elements at ovarian cancer susceptibility loci*. *Hum Mol Genet*. 2015 Jul 1;24(13):3595-607. PMID: 25804953.
162. Ovarian Cancer Association Consortium, Breast Cancer Association Consortium, and Consortium of Modifiers of BRCA1 and BRCA2, Hollestelle A, van der Baan FH, Berchuck A, Johnatty SE, Aben KK, Agnarsson BA, Aittomäki K, Alducci E, Andrulis IL, Anton-Culver H, Antonenkova NN, Antoniou AC, Narod SA, Nathanson KL, Ness RB, Neuhausen SL, Nevanlinna H, Neven P, Nielsen FC, Nielsen SF, Nordestgaard BG, Nussbaum RL, **Odunsi K**, Offit K, Olah E, Olopade OI, Olson JE, Olson SH, Oosterwijk JC, Orlow I, Orr N, Orsulic S, Osorio A, Ottini L, Paul J, Pearce CL,Whittemore AS, Wilkens LR, Winqvist R, Wu AH, Wu X, Yang HP, Zaffaroni D, Pilar Zamora M, Zheng W, Ziogas A, Chenevix-Trench G, Pharoah PD, Rookus MA, Hooning MJ, Goode EL. *No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer*. *Gynecol Oncol*. 2016 May;141(2):386-401. doi: 10.1016/j.ygyno.2015.04.034. Epub 2015 May 2; PubMed PMID: 25940428. PubMed Central PMCID: PMC4630206
163. Berinstein NL, Karkada M, Oza AM, **Odunsi K**, Vilella JA, Nemunaitis JJ, Morse MA, Pejovic T, Bentley J, Buyse M, Nigam R, Weir GM, MacDonald LD, Quinton T, Rajagopalan R, Sharp K, Penwell A, Sammatour L, Burzykowski T, Stanford MM, Mansour M. *Survivin-targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients*. *Oncoimmunology*. 2015 May 7;4(8): e1026529. PMID: 26405584
164. Rebbeck TR, Mitra N, Wan F, Sinilnikova OM, Healey S, McGuffog L, Mazoyer S, Chenevix-Trench G, Easton DF, Antoniou AC, Olopade OI, Seldon J, Ganz PA, Nussbaum RL, Chan SB, **Odunsi K**, Gayther SA, Domchek SM, Arun BK, Lu KH, Mitchell G, Karlan BY, Senter L, Bojesen A, Pedersen IS, Skytte AB, Sunde L, Thomassen M, Moeller ST,

Kruse TA, Jensen UB, Caligo MA, Aretini P, Teo SH, Selkirk CG, Hulick PJ, Andrulis I. *Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer*. JAMA. 2015 Apr 7;313(13):1347-61. PMID: PMC4537700.

165. Lee AW, Tyrer JP, Doherty JA, Stram DA, Kupryjanczyk J, Dansonka-Mieszkowska A, Plisiecka-Halasa J, Spiewankiewicz B, Myers EJ; Australian Cancer Study (Ovarian Cancer); Australian Ovarian Cancer Study Group, Chenevix-Trench G, Fasching PA, Beckmann MW, Ekici AB, Hein A, Vergote I, Van Nieuwenhuysen E, Lambrechts D, Wicklund KG, Eilber U, Wang-Gohrke S, Chang-Claude J, Rudolph A, Sucheston L, **Odunsi K**, Moysich KB, Shvetsov YB, Thompson PJ, Goodman MT, Ziogas A, Menon U, Ramus SJ, Gentry-Maharaj A, Harrington P, Pike MC, Modugno F, Rossing MA, Ness RB, Pharoah PD, Stram DO, Wu AH, Pearce CL. *Evaluating the ovarian cancer gonadotropin hypothesis: a candidate gene study*. Gynecol Oncol. 2015 Mar;136(3):542-8. PMID: 25528498
166. Szender JB, Frederick PJ, Eng KH, Akers SN, Lele SB, **Odunsi K**. *Evaluation of the National Surgical Quality Improvement Program Universal Surgical Risk Calculator for a gynecologic oncology service*. Int J Gynecol Cancer. 2015 Mar;25(3):512-20. PubMed PMID: 25628106
167. Kolomeyevskaya NV, Lele SB, Miller A, Riebandt GC, Blum BL, **Odunsi KO**, Frederick PJ. *Oxaliplatin Is a Safe Alternative Option for Patients with Recurrent Gynecologic Cancers After Hypersensitivity Reaction to Carboplatin*. Int J Gynecol Cancer. 2015;25(1):42-8.
168. Kuchenbaecker KB, Ramus SJ, Tyrer J, Lee A, Shen HC, Beesley J, Lawrenson K, McGuffog L, Healey S, Lee JM, Spindler TJ, Vergote I, Lambrechts S, Dicks E, Doherty JA, Wicklund KG, Rossing MA, Rudolph A, Chang-Claude J, Wang-Gohrke S, Eilber U, Moysich KB, **Odunsi K**, Sucheston L, Lele S, Wilkens LR, Goodman MT, Thompson PJ, Menon U, Harrington P, Lee AW, Wu AH, Pearce CL, Coetzee G, Pike MC, Dansonka-Mieszkowska A, Timorek A, Rzepecka IK, Kupryjanczyk J, Freedman M, Noushmehr H, Easton DF, Offit K, Couch FJ, Gayther S, Pharoah PP, Antoniou AC, Chenevix-Trench G; the Consortium of Investigators of Modifiers of BRCA1 and BRCA2. *Identification of six new susceptibility loci for invasive epithelial ovarian cancer*. Nat Genet. 2015 Feb;47(2):164-71. PMID: PMC4445140
169. Daudi S, Eng KH, Mhawech-Fauceglia P, Morrison C, Miliotto A, Beck A, Matsuzaki J, Tsuji T, Groman A, Gnjatic S, Spagnoli G, Lele S, **Odunsi K**. *Expression and Immune Responses to MAGE Antigens Predict Survival in Epithelial Ovarian Cancer*. PLoS One. 2014 Aug 7;9(8): e104099. PMID: 25101620
170. Gil M, Komorowski MP, Seshadri M, Rokita H, McGray AJ, Opyrchal M, **Odunsi KO**, Kozbor D. *CXCL12/CXCR4 Blockade by Oncolytic Virotherapy Inhibits Ovarian Cancer Growth by Decreasing Immunosuppression and Targeting Cancer-Initiating Cells*. J Immunol. 2014; 193(10):5327-37. PMID: 25320277
171. **Odunsi K**, Matsuzaki J, James SR, Mhawech-Fauceglia P, Tsuji T, Miller A, Zhang W, Akers S, Griffiths E, Miliotto A, Beck A, Batt CA, Ritter G, Lele S, Gnjatic S, Karpf AR. *Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian cancer*. Cancer

Immunol Res. 2014;2(1):37-49. PMID: 24535937

172. Zsiros E, **Odunsi K**. *Tumor-associated macrophages: Co-conspirators and orchestrators of immune suppression in endometrial adenocarcinoma*. Gynecol Oncol. 2014 Nov;135(2):173-5. PMID: 25457976.
173. Matsuaki J, Tsuji T, Luescher I, Old LJ, Shrikant P, Gnjjatic S, **Odunsi K**. *Non-classical antigen processing pathways are required for MHC class II-restricted direct tumor recognition by NY-ESO-1-specific CD4+ T cells*. Cancer Immunol Res. 2014 Apr;2(4):341-50. PMID: 24764581
174. Liao J, Qian F, Tchabo N, Mhaweche-Fauceglia P, Beck A, Qian Z, Wang X, Huss WJ, Lele SB, Morrison CD, **Odunsi K**. *Ovarian Cancer Spheroid Cells with Stem Cell-Like Properties Contribute to Tumor Generation, Metastasis and Chemotherapy Resistance through Hypoxia-Resistant Metabolism*. PLoS One. 2014 Jan;9(1): e84941 PMID: 24409314
175. Akers SN, Moysich K, Zhang W, Collamat Lai G, Miller A, Lele S, **Odunsi K**, Karpf AR. *LINE1 and Alu repetitive element DNA methylation in tumors and white blood cells from epithelial ovarian cancer patients*. Gynecol Oncol. 2014 Feb;132(2):462-7. PMID: 24374023
176. Ma Y, Sun Z, de Matos R, Zhang J, **Odunsi K**, Lin B. *Towards an animal model of ovarian cancer: Cataloging Chicken Blood Proteins Using Combinatorial Peptide Ligand Libraries Coupled with Shotgun Proteomics Analysis for Translational Research*. OMICS: A Journal of Integrative Biology. 2014 May;18(5):280-97. PMID: 24660652
177. Batt RE, Martin DC, **Odunsi K**. *Endometriosis of the retrocervical septum is proposed to replace the anatomically incorrect term endometriosis of the rectovaginal septum*. Hum Reprod. 2014 Dec; 29(12):2603-5. PMID: 25336705
178. Galluzzi L, Vacchelli E, Bravo-San Pedro J, Buqué A, Senovilla L, Baracco EE, Bloy N, Castoldi F, Abastado J, Agostinis P, Apte RN, Aranda F, Ayyoub M, Beckhove P, Blay J, Bracci L, Caignard A, Castelli C, Cavallo F, Celis E, Cerundolo V, Clayton A, Colombo MP, Coussens L, Dhodapkar MV, Eggermont AM, Fearon DT, Fridman WH, Fučíková J, Gabrilovich DI, Galon J, Garg A, Ghiringhelli F, Giaccone G, Gilboa E, Gnjjatic S, Hoos A, Hosmalin A, Jäger D, Kalinski P, Kärre K, Kepp O, Kiessling R, Kirkwood JM, Klein E, Knuth A, Lewis CE, Liblau R, Lotze MT, Lugli E, Mach J, Mattei F, Mavilio D, Melero I, Melief CJ, Middendorf EA, Moretta L, **Odunsi K**, Okada H, Palucka AK, Peter ME, Pienta KJ, Porgador A, Prendergast GC, Rabinovich GA, Restifo NP, Rizvi N, Sautès-Fridman C, Schreiber H, Seliger B, Shiku H, Silva-Santos B, Smyth MJ, Speiser DE, Spisek R, Srivastava PK, Talmadge JE, Tartour E, Van Der Burg SH, Van Den Eynde BJ, Vile R, Wagner H, Weber JS, Whiteside TL, Wolchok JD, Zitvogel L, Zou W, Kroemer G. *Classification of current anticancer immunotherapies*. Oncotarget. 2014 Dec 30;5(24):12472-508. PMID: 25537519
179. Köbel M, Madore J, Ramus SJ, Clarke BA, Pharoah PD, Deen S, Bowtell DD, **Odunsi K**, Menon U, Morrison C, Lele S, Bshara W, Sucheston L, Beckmann MW, Hein A, Thiel FC, Hartmann A, Wachter DL, Anglesio MS, Høgdall E, Jensen A, Høgdall C, Kalli KR,

Fridley BL, Keeney GL, Fogarty ZC, Vierkant RA, Liu S, Cho S, Nelson G, Ghatage P, Gentry-Maharaj A, Gayther SA, Benjamin E, Widschwendter M, Intermaggio MP, Rosen B, Bernardini MQ, Mackay H, Oza A, Shaw P, Jimenez-Linan M, Driver KE, Alsop J, Mack M, Koziak JM, Steed H, Ewanowich C, DeFazio A, Chenevix-Trench G, Fereday S, Gao B, Johnatty SE, George J, Galletta L; AOCs Study Group, Goode EL, Kjær SK, Huntsman DG, Fasching PA, Moysich KB, Brenton JD, Kelemen LE. *Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study.* Br J Cancer. 2014 Dec 9;111(12):2297-307. PMID: 25349970

180. Kelemen LE, Terry KL, Goodman MT, Webb PM, Bandera EV, McGuire V, Rossing MA, Wang Q, Dicks E, Tyrer JP, Song H, Pearce CL, Pike MC, Stram D, Chang-Claude J, Rudolph A, Dörk T, Dürst M, Hillemanns P, Runnebaum IB, Bogdanova N, Antonenkova N, **Odunsi K**, Edwards RP, Kelley JL, Modugno F, Ness RB, Karlan BY, Walsh C, Lester J, Orsulic S, Fridley BL, Vierkant RA, Cunningham JM, Wu X, Lu K, Liang D, Hildebrandt MA, Weber RP, Iversen ES, Tworoger SS, Phelan CM, Moysich KB, Goode EL, Schildkraut JM, Berchuck A, Pharoah PD, Sellers TA, Brooks-Wilson A, Cook LS, Le ND. *Consortium analysis of gene and gene-folate interactions in purine and pyrimidine metabolism pathways with ovarian carcinoma risk.* Mol Nutr Food Res. 2014 Oct;58(10):2023-35. PMID: 25066213
181. Charbonneau B, Moysich KB, Kalli KR, Oberg AL, Vierkant RA, Fogarty ZC, Block MS, Maurer MJ, Goergen KM, Fridley BL, Cunningham JM, Rider DN, Preston C, Hartmann LC, Lawrenson K, Wang C, Tyrer J, Song H, Defazio A, Johnatty SE, Doherty JA, Phelan CM, Sellers TA, Ramirez SM, Vitonis AF, Terry KL, Van Den Berg D, Pike MC, Wu AH, Berchuck A, Gentry-Maharaj A, Ramus SJ, Diergaarde B, Shen H, Jensen A, Menkiszak J, Cybulski C, Lubiński J, Ziogas A, Rothstein JH, McGuire V, Sieh W, Lester J, Walsh C, Vergote I, Lambrechts S, Despierre E, Garcia-Closas M, Yang H, Brinton LA, Spiewankiewicz B, Rzepecka IK, Dansonka-Mieszkowska A, Seibold P, Rudolph A, Paddock LE, Orlow I, Lundvall L, Olson SH, Hogdall CK, Schwaab I, du Bois A, Harter P, Flanagan JM, Brown R, Paul J, Ekici AB, Beckmann MW, Hein A, Eccles D, Lurie G, Hays LE, Bean YT, Pejovic T, Goodman MT, Campbell I, Fasching PA, Konecny G, Kaye SB, Heitz F, Hogdall E, Bandera EV, Chang-Claude J, Kupryjanczyk J, Wentzensen N, Lambrechts D, Karlan BY, Whittemore AS, Culver HA, Gronwald J, Levine DA, Kjaer SK, Menon U, Schildkraut JM, Pearce CL, Cramer DW, Rossing MA, Chenevix-Trench G; AOCs group; ACS, Pharoah PD, Gayther SA, Ness RB, **Odunsi K**, Sucheston LE, Knutson KL, Goode EL. *Large-scale evaluation of common variation in regulatory T cell-related genes and ovarian cancer outcome.* Cancer Immunol Res. 2014 Apr;2(4):332-40. PMID: 24764580
182. Charbonneau B, Block MS, Bamlet WR, Vierkant RA, Kalli KR, Fogarty Z, Rider DN, Sellers TA, Tworoger SS, Poole E, Risch HA, Salvesen HB, Kiemeny LA, Baglietto L, Giles GG, Severi G, Trabert B, Wentzensen N, Chenevix-Trench G, Whittemore AS, Sieh W, Chang-Claude J, Bandera EV, Orlow I, Terry K, Goodman MT, Thompson PJ, Cook LS, Rossing MA, Ness RB, Narod SA, Kupryjanczyk J, Lu K, Bützow R, Dork T, Pejovic T, Campbell I, Le ND, Bunker CH, Bogdanova N, Runnebaum IB, Eccles DM, Paul J, Wu AH, Gayther SA, Hogdall E, Heitz F, Kaye SB, Karlan BY, Anton-Culver H, Gronwald J, Hogdall CK, Lambrechts D, Fasching PA, Menon U, Schildkraut J, Pearce CL, Levine DA, Kruger Kjær S, Cramer D, Flanagan JM, Phelan CM, Brown R, Massuger LF, Song H,

- Doherty JA, Krakstad C, Liang D, **Odunsi K**, Berchuck A, Jensen A, Lubinski J, Nevanlinna H, Bean YT, Lurie G, Ziogas A, Walsh C, Despierre E, Brinton L, Hein A, Rudolph A, Dansonka-Mieszkowska A, Olson SH, Harter P, Tyrer J, Vitonis AF, Brooks-Wilson A, Aben KK, Pike MC, Ramus SJ, Wik E, Cybulski C, Lin J, Sucheston L, Edwards R, McGuire V, Lester J, du Bois A, Lundvall L, Wang-Gohrke S, Szafron LM, Lambrechts S, Yang HP, Beckmann MW, Pelttari LM, van Altena AM, Van Den Berg D, Halle M, Gentry-Maharaj A, Schwaab I, Chandran U, Menkiszak J, Ekici AB, Wilkens LR, Leminen A, Modugno F, Friel G, Rothstein JH, Vergote I, Garcia-Closas M, Hildebrandt MA, Sobiczewski P, Kelemen LE, Pharoah PD, Moysich K, Knutson KL, Cunningham JM, Fridley BL, Goode EL. *Risk of Ovarian Cancer and the NF- κ B Pathway: Genetic association with IL1A and TNFSF10*. *Cancer Res*. 2014 Feb;74(3):852-61. PMID: 24272484
183. Earp MA, Kelemen LE, Magliocco AM, Swenerton KD, Chenevix-Trench G; Australian Cancer Study; Australian Ovarian Cancer Study Group, Lu Y, Hein A, Ekici AB, Beckmann MW, Fasching PA, Lambrechts D, Despierre E, Vergote I, Lambrechts S, Doherty JA, Rossing MA, Chang-Claude J, Rudolph A, Friel G, Moysich KB, **Odunsi K**, Sucheston-Campbell L, Lurie G, Goodman MT, Phelan CM, Risch HA, McLaughlin JR, Narod SA, Ziogas A, Anton-Culver H, Gentry-Maharaj A, Menon U, Gayther SA, Ramus SJ, Wu AH, Pearce CL, Pike MC, Dansonka-Mieszkowska A, Rzepecka IK, Szafron LM, Kupryjanczyk J, Cook LS, Le ND, Brooks-Wilson A; On behalf of the Ovarian Cancer Association Consortium. *Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA*. *Hum Genet*. 2014 May;133(5):481-97. [Epub 2013 Nov 5] PMID: 24190013
184. Sieh W, Köbel M, Longacre TA, Bowtell DD, Defazio A, Goodman MT, Høgdall E, Deen S, Wentzensen N, Moysich KB, Brenton JD, Clarke BA, Menon U, Gilks CB, Kim A, Madore J, Fereday S, George J, Galletta L, Lurie G, Wilkens LR, Carney ME, Thompson PJ, Matsuno RK, Kjær SK, Jensen A, Høgdall C, Kalli KR, Fridley BL, Keeney GL, Vierkant RA, Cunningham JM, Brinton LA, Yang HP, Sherman ME, García-Closas M, Lissowska J, **Odunsi K**, Morrison C, Lele S, Bshara W, Sucheston L, Jimenez-Linan M, Driver K, Alsop J, Mack M, McGuire V, Rothstein JH, Rosen BP, Bernardini MQ, Mackay H, Oza A, Wozniak EL, Benjamin E, Gentry-Maharaj A, Gayther SA, Tinker AV, Prentice LM, Chow C, Anglesio MS, Johnatty SE, Chenevix-Trench G, Whittemore AS, Pharoah PD, Goode EL, Huntsman DG, Ramus SJ. *Hormone-receptor expression and ovarian cancer survival: An Ovarian Tumor Tissue Analysis consortium study*. *Lancet Oncol*. 2013 Aug;14(9):853-62
185. Godoy H, Mhawech-Fauceglia P, Beck A, Miliotto A, Miller A, Lele S, **Odunsi K**. *Developmentally Restricted Differentiation Antigens Are Targets for Immunotherapy in Epithelial Ovarian Carcinoma*. *Int J Gynecol Pathol*. 2013 Nov;32(6):536-540. PMID: 24071868
186. Simpson-Abelson MR, Loyall JL, Lehman HK, Barnas JL, Minderman H, O'Loughlin KL, Wallace PK, George TC, Peng P, Kelleher RJ Jr, **Odunsi K**, Bankert RB. *Human ovarian tumor ascites fluids rapidly and reversibly inhibit T cell receptor-induced NF- κ B and NFAT signaling in tumor-associated T cells*. *Cancer Immun*. 2013; Jul 15; 13:14. PMCID: PMC3718770. PMID: 23882159

187. Janetzki S, Hoos A, Melief CJ, **Odunsi K**, Romero P, Britten CM. *Structured reporting of T cell assay results*. *Cancer Immun*. 2013 Jul 15;13:13. PMID: 23882158.
188. James SR, Cedeno CD, Sharma A, Zhang W, Mohler JL, **Odunsi K**, Wilson EM, Karpf AR. *DNA methylation and nucleosome occupancy regulate the cancer germline antigen gene MAGEA11*. *Epigenetics*. 2013 Aug;8(8):849-63. PMID: 23839233.
189. Obermajer N, Wong JL, Edwards RP, Chen K, Scott M, Khader S, Kolls JK, **Odunsi K**, Billiar TR, Kalinski P. *Induction and stability of human Th17 cells require endogenous NOS2 and cGMP-dependent NO signaling*. *J Exp Medicine*. 2013 Jul 1;210(7):1433-445. PMID: 23797095.
190. Yokota SJ, Facciponte JG, Kelleher RJ Jr, Shultz LD, Loyall JL, Parsons RR, **Odunsi K**, Frelinger JG, Lord EM, Gerber SA, Balu-Iyer SV, Bankert RB. *Changes in ovarian tumor cell number, tumor vasculature, and T cell function monitored in vivo using a novel xenograft model*. *Cancer Immun*. 2013 May 31; 13:11. PMID: 23885217.
191. McNeil LK, Price L, Britten CM, Jaimes M, Maecker H, **Odunsi K**, Matsuzaki J, Staats JS, Thorpe J, Yuan J, Janetzki S. *A Harmonized Approach to Intracellular Cytokine Staining Gating: Results from an International Multiconsortia Proficiency Panel Conducted by the Cancer Immunotherapy Consortium (CIC/CRI)*. *Cytometry Part A*. Aug;83(8):728-38. PMID: 23788464.
192. Goode EL, Derycke M, Kalli KR, Oberg AL, Cunningham JM, Maurer MJ, Fridley BL, Armasu SM, Serie DJ, Ramar P, Goergen K, Vierkant RA, Rider DN, Sicotte H, Wang C, Winterhoff B, Phelan CM, Schildkraut JM, Weber RP, Iversen E, Berchuck A, Sutphen R, Birrer MJ, Hampras S, Preus L, Gayther SA, Ramus SJ, Wentzensen N, Yang HP, Garcia-Closas M, Song H, Tyrer J, Pharoah PP, Konecny G, Sellers TA, Ness RB, Sucheston LE, **Odunsi K**, Hartmann LC, Moysich KB, Knutson KL. *Inherited variants in regulatory T cell genes and outcome of ovarian cancer*. *PLoS One*. 2013;8(1): e53903.
193. Akers SN, Riebandt G, Miller A, Groman A, **Odunsi K**, Lele S. *Bevacizumab for the treatment of recurrent ovarian cancer: A retrospective cohort study*. *Eur J Gyn Oncol*. 2013;34(2):113-119.
194. Cohn DE, Leitao M, Levenback C, Berkowitz R, Roman L, Lucci J, Kim S, Lancaster J, **Odunsi K**, Wakabayashi M, Goff BA. *Reporting of Quality Measures in Gynecologic Oncology Programs at Prospective Payment System (PPS)-Exempt Cancer Hospitals: An Early Glimpse into a Challenging Initiative*. *Gynecol Oncol*. 2013 May 26. [Epub ahead of print]
195. Ayyoub M, Pignon P, Classe JM, **Odunsi K**, Valmori D. *CD4+ T Effectors Specific for the Tumor Antigen NY-ESO-1 Are Highly Enriched at Ovarian Cancer Sites and Coexist with, but Are Distinct from, Tumor-Associated Treg*. *Cancer Immunol Res*. 2013;1(5):303-8. PMID: 24777968.
196. Budzinski EE, Patrzyc HB, Dawidzik JB, Freund HG, Frederick P, Godoy HE, Voian NC, **Odunsi K**, Box HC. *Pyrimidine base damage is increased in women with BRCA mutations*. *Cancer Lett*. 2013;338(2):267-70.

197. Shen H, Fridley BL, Song H, Lawrenson K, Cunningham JM, Ramus SJ, Cicek MS, Tyrer J, Stram D, Larson MC, Kobel M, Ziogas A, Phelan CM, Pelttari LM, Pejovic T, Paul J, Orlow I, Zawiah Omar S, Olson SH, **Odunsi K**, Nickels S, Nevanlinna H, Ness RB, Narod SA, Nakanishi T, Moysich KB, Monteiro AN, Moes-Sosnowska J, Modugno F, Menon U, Anton-Culver H, Aben KK, Liang D, Wu X, Lu K, Hildebrandt MA, Schildkraut JM, Sellers TA, Huntsman D, Berchuck A, Chenevix-Trench G, Gayther SA, Pharoah PD, Laird PW, Goode EL, Leigh Pearce C. *Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer*. Nature Communications. 2013; 4:1628.
198. Pharoah PD, Tsai YY, Ramus SJ, Phelan CM, Goode EL, Lawrenson K, Buckley M, Fridley BL, Tyrer JP, Shen H, Weber R, Menon U, Modugno F, Moysich KB, Nakanishi T, Narod SA, Ness RB, Nevanlinna H, Nickels S, Noushmehr H, **Odunsi K**, Olson S, Orlow I, Paul J, Pejovic T, Pelttari LM, Permut-Wey J, Ziogas A, Zulkifli F, Goodman MT, Hall P, Easton DF, Pearce CL, Berchuck A, Chenevix-Trench G, Iversen E, Monteiro AN, Gayther SA, Schildkraut JM, Sellers TA. *GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer*. Nature Genetics. 2013;45(4):362.
199. Permut-Wey J, Lawrenson K, Shen HC, Velkova A, Tyrer JP, Chen Z, Lin HY, Ann Chen Y, Tsai YY, Qu X, Ramus SJ, Karevan R, Lee J, Lee N, Larson MC, Aben KK, Anton-Culver H, Menon U, Modugno F, Moysich KB, Nakanishi T, Narod SA, Nedergaard L, Ness RB, Nevanlinna H, Nickels S, Noushmehr H, **Odunsi K**, Olson SH, Orlow I, Paul J, Pearce CL, Pejovic T, Pelttari LM, Phelan CM, Iversen E, Schildkraut JM, Berchuck A, Fridley BL, Goode EL, Pharoah PD, Monteiro AN, Sellers TA, Gayther SA. *Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31*. Nature Communications. 2013;4:1627.
200. Mach CM, Kim J, Soibam B, Creighton CJ, Hawkins SM, Zigelboim I, Goodfellow P, Gunaratne PH, **Odunsi K**, Salem PA, Anderson ML. *Novel MicroRNAs regulating proliferation and apoptosis in uterine papillary serous carcinomas*. Cancer letters. 2013;335(2):314.
201. Faber MT, Kjaer SK, Dehlendorff C, Chang-Claude J, Andersen KK, Hogdall E, Webb PM, Jordan SJ, Rossing MA, Doherty JA, Lurie G, Thompson PJ, Carney ME, Goodman MT, Ness RB, Modugno F, Edwards RP, Bunker CH, Goode EL, Fridley BL, Vierkant RA, Larson MC, Schildkraut J, Cramer DW, Terry KL, Vitonis AF, Bandera EV, Olson SH, King M, Chandran U, Kiemeny LA, Massuger LF, van Altena AM, Vermeulen SH, Brinton L, Wentzensen N, Lissowska J, Yang HP, Moysich KB, **Odunsi K**, Kasza K, Odunsi-Akanji O, Song H, Pharoah P, Shah M, Whittemore AS, McGuire V, Sieh W, Sutphen R, Menon U, Gayther SA, Ramus SJ, Gentry-Maharaj A, Pearce CL, Wu AH, Pike MC, Risch HA, Jensen A. *Cigarette smoking and risk of ovarian cancer: a pooled analysis of 21 case-control studies*. Cancer Causes & Control: CCC. 2013; 24(5):989.
202. Bojesen SE, Pooley KA, Johnatty SE, Beesley J, Michailidou K, Tyrer JP, Edwards SL, Pickett HA, Shen HC, Smart CE, Hillman KM, Wang-Gohrke S, Andrulis IL, Moysich KB, Hopper JL, **Odunsi K**, Lindblom A, Giles GG, Brenner H, Simard J, Lurie G, Fasching PA, Carney ME, Radice P, Wilkens LR, Swerdlow A, Goodman MT, Savage SA, Lester J, Soucy P, Kuchenbaecker KB, Olswold C, Cunningham JM, Slager S, Pankratz VS, Dicks E,

Lakhani SR, Couch FJ, Hall P, Monteiro AN, Gayther SA, Pharoah PD, Reddel RR, Goode EL, Greene MH, Easton DF, Berchuck A, Antoniou AC, Chenevix-Trench G, Dunning AM. *Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer.* Nature Genetics. 2013;45(4):371.

203. Link PA, Zhang W, **Odunsi K**, Karpf AR. *BORIS/CTCF mRNA isoform expression and epigenetic regulation in epithelial ovarian cancer.* Cancer Immunity. 2013; 13:6.
204. Mhaweche-Fauceglia P, Wang D, Ali L, Lele S, Huba MA, Liu S, **Odunsi K**. *Intraepithelial T cells and tumor-associated macrophages in ovarian cancer patients.* Cancer Immun. 2013; 13:1.
205. Peng M, Bakke JL, DiCioccio RA, Gille JJ, Zhao H, **Odunsi K**, Sucheston L, Jaafar L, Mivechi NF, Waisfisz Q, Ko L. *Inactivating mutation in GT198 in familial and early-onset breast and ovarian cancers.* Genes Cancer. 2013 Jan;4(1-2):15-25. PMID: 23946868.
206. Godoy H, Khan AN, Vethanayagam RR, Grimm MJ, Singel KL, Kolomeyevskaya N, Sexton KJ, Parameswaran A, Abrams SI, **Odunsi K**, Segal BH. *Myeloid-derived suppressor cells modulate immune responses independently of NADPH oxidase in the ovarian tumor microenvironment in mice.* PLoS One. 2013 Jul 26;8(7): e69631. PMID: 23922763.
207. Godoy H, Vaddadi P, Cooper M, Frederick PJ, **Odunsi K**, Lele S. *Photodynamic therapy effectively palliates gynecologic malignancies.* Eur J Gynaecol Oncol. 2013;34(4):300-2. PMID: 24020133.
208. Olawaiye AB, Godoy HE, Shahzad MM, Rauh-Hain JA, Lele SB, **Odunsi K**. *Comparison of outcomes in patients treated with multi-agent regimens of cisplatin, adriamycin, and VP-16 versus carboplatin and paclitaxel for advanced and recurrent endometrial cancer.* Eur J Gynaecol Oncol 2012;33(5):477-9.
209. Zhao H, Shen J, Wang D, Gregory S, Medico L, Hu Q, Yan L, **Odunsi K**, Lele S, Liu S. *Associations between Gene Expression Variations and Ovarian Cancer Risk Alleles Identified from Genome Wide Association Studies.* PLoS One. 2013;8(5).
210. **Odunsi K**, Mhaweche-Fauceglia P, Andrews C, Beck A, Amuwo O, Lele S, Black JD, Huang R-Y. *Elevated expression of the Serine-Arginine Protein Kinase 1 gene in Ovarian Cancer and its Role in Cisplatin Cytotoxicity in vitro.* PLoS ONE. 2012;7(12): e51030
211. Obermajer N, Wong JL, Edwards RP, **Odunsi K**, Moysich K, Kalinski P. *PGE (2)-Driven Induction and Maintenance of Cancer-Associated Myeloid-Derived Suppressor Cells.* Immunol Invest. 2012;41(6-7):635-57.
212. Akers S, Groman A, **Odunsi K**, Lele S, Frederick PJ. *Adjuvant treatment for uterine leiomyosarcoma.* Eur J Gynaecol Oncol. 2013;34(5):409-14. PMID: 24475573
213. Hampras SS, Nesline M, Wallace PK, **Odunsi K**, Furlani N, Davis W, Moysich KB. *Predictors of immunosuppressive regulatory T lymphocytes in healthy women.* J Cancer Epidemiol. 2012;191090

214. Berinstein NL, Karkada M, Morse MA, Nemunaitis JJ, Chatta G, Kaufman H, **Odunsi K**, Nigam R, Sammatur L, Macdonald LD, Weir GM, Stanford MM, Mansour M. *First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients*. J Transl Med. 2012;10(1):156.
215. Britten CM, Janetzki S, Butterfield LH, Ferrari G, Gouttefangeas C, Huber C, Kalos M, Levitsky HI, Maecker HT, Melief CJ, O'Donnell-Tormey J, **Odunsi K**, Old LJ, Ottenhoff TH, Ottensmeier C, Pawelec G, Roederer M, Roep BO, Romero P, van der Burg SH, Walter S, Hoos A, Davis MM. *T Cell Assays and MIATA: The Essential Minimum for Maximum Impact*. Immunity. 2012;27;37(1):1-2.
216. Sirugo G, Edwards DR, Ryckman K, Bisseye C, White, M, Kebbeh B, Morris G, Adegbola R, Tacconelli A, Predazzi I, Novelli G, Vannberg F, **Odunsi K**, Page G, Williams SM. *PTX3 genetic variation and dizygotic twinning in The Gambia: could pleiotropy with innate immunity explain common dizygotic twinning in Africa?* Ann Hum Genet. 2012;76(6):454-463.
217. Redjimi N, Raffin C, Raimbaud I, Pignon P, Matsuzaki J, **Odunsi K**, Valmori D, Ayyoub M. *CXCR3+ T regulatory cells selectively accumulate in human ovarian carcinomas to limit type I immunity*. Cancer Res. 2012;72(17):4351.
218. Ademuyiwa FO, Bshara W, Attwood K, Morrison C, Edge SB, Ambrosone CB, O'Connor, TL, Levine EG, Miliotto A, Ritter E, Ritter G, Gnjatic S, **Odunsi K**. *NY-ESO-1 Cancer Testis Antigen Demonstrates High Immunogenicity in Triple Negative Breast Cancer*. PLoS One. 2012;7(6): e38783.
219. Kim KM, Song MH, Kim MJ, Daudi S, Miliotto A, Old L, **Odunsi K**, Lee SY. *A novel cancer/testis antigen KP-OVA-52 identified by SEREX in human ovarian cancer is regulated by DNA methylation*. Int J Oncol. 2012;41(3):1139-47.
220. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho, LH, Kauh J, **Odunsi K**, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthi S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta A, Wigginton JM. *Safety and activity of anti-PD-L1 antibody in patients with advanced cancer*. N Engl J Med. 2012;366(26):2455-65.
221. Shan W, Akinfenwa PY, Savannah KB, Kolomeyevskaya N, Laucirica R, Thomas DG, **Odunsi K**, Creighton CJ, Lev DC, Anderson ML. *A small molecule inhibitor targeting the mitotic spindle checkpoint impairs the growth of uterine leiomyosarcoma*. Clin Cancer Res. 2012;18(12):3352-65.
222. Qian F, Liao J, VILLELLA J, Edwards R, Kalinski P, Lele S, Shrikant P, **Odunsi K**. *Effects of 1-methyltryptophan stereoisomers on IDO2 enzyme activity and IDO2 mediated arrest of human T cell proliferation*. Cancer Immunol Immunother. 2012;61(11):2013-20. PMID:22527253
223. **Odunsi K**, Matsuzaki J, Karbach J, Neumann A, Mhaweche-Fauceglia P, Miller A, Beck A, Morrison C, Ritter G, Godoy H, Lele S, duPont N, Edwards R, Shrikant P, Old LJ, Gnjatic

S, Jager E. *Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients.* Proc Natl Acad Sci U S A. 2012; 109 (15) 5797-5802.

224. Tsuji, T, Matsuzaki J, Caballero OL, Jungbluth AA, Ritter G, **Odunsi K**, Old LJ, Gnjjatic S. *Heat Shock Protein 90-mediated peptide-selective presentation of cytosolic tumor antigen for direct recognition of tumors by CD4+ T cells.* J Immunol. 2012;188(8):3851-8.
225. Li Q, Rao R, Vazzana J, Goedegeburre P, **Odunsi K**, Gillanders W, Shrikant PA. *Regulation mammalian target of rapamycin to tune vaccination induced CD8+ T cell responses for tumor immunity.* J Immunol. 2012;188(7):3080.
226. Couch FJ, Gaudet MM, Antoniou AC, Ramus SJ, Kuchenbaecker KB, Soucy P, Beesley J, Chen X, Wang X, Kirchoff T, McGuffog L, Barrowdale D, Lee A, Healey S, Sinilnikova OM, Andrulis IL, Ozelik H, Mulligan AM, Thomassen M, Gerdes AM, Boggess J, Wakeley K, Ewart-Toland A, Montagna M, Agata S, Imyanitov EN, Isaacs C, Janavicius R, Lazaro C, Blanco I, Feliubadalo L, Brunet J, Gayther SA, Pharoah PP, **Odunsi KO**, Karlan BY, Walsh CS, Olah E, Teo SH, Ganz PA, Beattie MS, Ding YC, Lindor NM, Fredericksen Z, Pankratz VS, Peterlongo P, Manoukian S, Peissel B, Zaffaroni D, Barile M, Bernard L, Viel A, Giannini G, Varesco L, Radice P, Greene MH, Mai PL, Easton DF, Chenevix-Trench G, Offit K, Simard J. *Common Variants at the 19p13.1 and ZNF365 Loci Are Associated with ER Subtypes of Breast Cancer and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers.* Cancer Epidemiol Biomarkers Prev. 2012;21(4):645-57.
227. Shen J, Wang D, Gregory S, Medico L, Hu Q, Yan L, **Odunsi K**, Lele SB, Ambrosone CB, Liu S, Zhao H. *Evaluation of microRNA expression profiles and their associations with risk alleles in lymphoblastoid cell lines of familial ovarian cancer.* Carcinogenesis. 2012; 33(3):604-12.
228. Mavaddat N, Barrowdale D, Andrulis IL, Domchek SM, Eccles D, Nevanlinna H, Ramus SJ, Spurdle A, Robson M, Sherman M, Mulligan AM, Couch FJ, Singer CF, Tea MK, Rappaport C, Mai PL, Greene MH, Sokolenko A, Imyanitov E, Toland AE, Senter L, Sweet K, Thomassen M, Gerdes AM, Kruse T, Caligo M, Aretini P, Rantala J, von Wachenfeld A, Henriksson K, Steele L, Neuhausen S. L, Nussbaum R, Beattie M, **Odunsi K**, Sucheston L, Gayther SA, Nathanson K, Gross J, Walsh C, Karlan B, Chenevix-Trench G, Easton DF, Antoniou AC. *Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA).* Cancer Epidemiol Biomarkers Prev. 2012;21(1):134-147.
229. Antoniou AC, Kuchenbaecker KB, Soucy P, Beesley J, Chen X, McGuffog L, Lee A, Barrowdale D, Healey S, Sinilnikova OM, Caligo MA, Loman N, Montagna M, Olini C, Imyanitov E, Isaacs C, Tihomirova L, Blanco I, Lazaro C, Teule A, Del Valle J, Gayther SA, **Odunsi K**, Gross J, Karlan BY, Olah E, Teo SH, Ganz PA, Beattie MS, Dorfling CM, Jansen van Rensburg E, Diez O, Kwong A, Schmutzler RK, Wappenschmidt B,Mulligan AM, Glendon G, Thomassen M, Gerdes AM, Jensen UB, Skytte AB, Kruse TA, Chenevix-Trench G, Couch FJ, Simard J, Easton DF, Swedish Breast Cancer Study SB, Research Facility H, Study E, Study Collaborators G, Investigators K. *Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers.* Breast

Cancer Res, 2012;14(1): R33.

230. Mhaweche-Fauceglia P, Wang D, Syriac S, Godoy H, Dupont N, Liu S, **Odunsi K**. *Synuclein-gamma (SNCG) protein expression is associated with poor outcome in endometrial adenocarcinoma*. Gynecol Oncol. 2012;124(1):148-52.
231. Fox BA, Schendel DJ, Butterfield LH, Aamdal S, Allison JP, Ascierto PA, Atkins MB, Bartunkova J, Bergmann L, Berinstein N, Bonorino CC, Borden E, Bramson JL, Britten CM, Cao X, Carson WE, Chang AE, Characiejus D, Choudhury AR, Coukos G, de Gruijl T, Dillman RO, Dolstra H, Dranoff G, Durrant LG, Finke JH, Galon J, Gollob JA, Gouttefangeas C, Grizzi F, Guida M, Hakansson L, Hege K, Herberman RB, Hodi FS, Hoos A, Huber C, Hwu P, Imai K, Jaffee EM, Janetzki S, June CH, Kalinski P, Kaufman HL, Kawakami K, Kawakami Y, Keilholtz U, Khleif SN, Kiessling R, Kotlan B, Kroemer G, Lapointe R, Levitsky HI, Lotze MT, Maccalli C, Maio M, Marschner JP, Mastrangelo MJ, Masucci G, Melero I, Nelief C, Murphy WJ, Nelson B, Nicolini A, Nishimura MI, **Odunsi K**, Ohashi PS, O'Donnell-Tormey J, Old LJ, Ottensmeier C, Papamichail M, Parmiani G, Pawelec G, Proietti E, Qin S, Rees R, Ribas A, Ridolfi R, Ritter G, Rivoltini L, Romero PJ, Salem ML, Scheper RJ., Seliger B, Sharma P, Shiku H, Singh-Jasuja H, Song W, Straten PT, Tahara H, Tian Z, van Der Burg SH, von Hoegen P, Wang E, Welters MJ, Winter H, Withington T, Wolchok JD, Xiao W, Zitvogel L, Zwierzina H, Marincola FM, Gajewski TF, Wigginton JM, Disis ML. *Defining the Critical Hurdles in Cancer Immunotherapy*. J Transl Med. 2011; (9) 1:214.
232. Obermajer N, Muthuswamy R, **Odunsi K**, Edwards R, Kalinski P. *PGE₂-Dependent CXCL12 Production and CXCR4 Expression Control the Accumulation of Human MDSCs in Ovarian Cancer Environment*. Cancer Res. 2011 Dec 15;71(24):7463-7470. PMID: PMC4993027
233. Agnani D, Camacho-Vanegas O, Camacho C, Lele S, **Odunsi K**, Cohen S, Dottino P, Martignetti JA. *Decreased levels of serum glutathione peroxidase 3 are associated with papillary serous ovarian cancer and disease progression*. J Ovarian Res. 2011; 4(1):18.
234. Mhaweche-Fauceglia P, Wang D, Kesterson J, Beck A, de Mesy Bentley KL, Shroff S, Syriac S, Frederick PJ, Liu, **Odunsi K**. *Aldolase mRNA expression in endometrial cancer and the role of clotrimazole in endometrial cancer cell viability and morphology*. Histopathology. 2011;59(5):1015-8.
235. Tsuji T, Matsuzaki J, Ritter E, Miliotto A, Ritter G, **Odunsi K**, Old LJ, Gnjatic S. *Split T cell tolerance against a self/tumor antigen: spontaneous CD4⁺ but not CD8⁺ T cell responses against p53 in cancer patients and healthy donors*. PLoS One. 2011. 6(8): e23651.
236. Attig S, Price L, Janetzki S, Kalos M, Pride M, McNeil L, Clay T, Yuan J, **Odunsi K**, Hoos A, Romero P, Britten CM, Assay Working Group CC. *A critical assessment for the value of markers to gate-out undesired events in HLA-peptide multimer staining protocols*. J Transl Med. 2011; 9(1):108.
237. Huang RS, Johnatty SE, Gamazon ER, Im HK, Ziliak D, Duan S, Zhang W, Kistner EO, Chen P, Beesley J, Mi S, O'Donnell P, Fraiman YS, Das S, Cox NJ, Lu Y, Macgregor S,

- Goode EL, Vierkant RA, Fridley BL, Hogdall EV, Kjaer SK, Jensen A, Moysich KB, Grasela M, **Odunsi KO**, Brown R, Paul J, Lambrechts D, Despierre E, Vergote I, Gross J, Karlan BY, Defazio A, Chenevix-Trench G, Dolan ME. *Platinum sensitivity-related germline polymorphism discovered via a cell-based approach and analysis of its association with outcome in ovarian cancer patients*. Clin Cancer Res. 2011;17(16):5490-500.
238. Li Q, Rao RR, Araki K, Pollizzi K, **Odunsi K**, Powell JD, Shrikant PA. *A Central Role for mTOR Kinase in Homeostatic Proliferation Induced CD8(+) T Cell Memory and Tumor Immunity*. Immunity. 2011;34(4):541-53.
239. Woloszynska-Read A , Zhang W, Yu J , Link PA , Mhaweche-Fauceglia P, Collamat G, Akers SN, Ostler KR, Godley LA , **Odunsi KO**, Karpf AR. *Coordinated cancer germline antigen promoter and global DNA hypomethylation in ovarian cancer: association with BORIS/CTCF expression ratio and advanced stage*. Clin Cancer Res. 2011; 17:2170-80.
240. Tsuji T, Matsuzaki J, Kelly MP, Ramakrishna V, Vitale L, He LZ, Keler T, **Odunsi K**, Old LJ, Ritter G, Gnjatic S. *Antibody-Targeted NY-ESO-1 to Mannose Receptor or DEC-205 In Vitro Elicits Dual Human CD8+ and CD4+ T Cell Responses with Broad Antigen Specificity*. J Immunol. 2011;186:1218-27.
241. Bankert RB, Balu-Iyer SV, **Odunsi K**, Shultz LD, Kelleher RJ, Jr, Barnas JL, Simpson-Abelson M, Parsons R, Yokota SJ. *Humanized mouse model of ovarian cancer recapitulates patient solid tumor progression, ascites formation, and metastasis*. PLoS One. 2011. 6(9): e24420.
242. Godoy H, Mhaweche-Fauceglia P, Beck A, Miller A, Lele S, **Odunsi K**. *Expression of Poly (Adenosine Diphosphate-Ribose) Polymerase and p53 in Epithelial Ovarian Cancer and Their Role in Prognosis and Disease Outcome*. Int J Gynecol Pathol. 2011;30:139-44.
243. Garcia E, Andrews C, Hua J, Kim H, Sukumaran DK, Szyperski TA, **Odunsi K**. *Diagnosis of early stage ovarian cancer by 1H NMR metabonomics of serum explored by use of a micro-flow NMR probe*. J Proteome Res. 2011 Apr 1;10(4):1765-71.
244. Britten CM, Janetzki S, van der Burg SH, Huber C, Kalos M, Levitsky HI, Maecker HT, Melief CJ, O'Donnell-Tormey J, **Odunsi K**, Old LJ, Pawelec G, Roep BO, Romero P, Hoos A, Davis MM. *Minimal information about T cell assays: the process of reaching the community of T cell immunologists in cancer and beyond*. Cancer Immunol Immunother. 2011; 60:15-22.
245. Mhaweche-Fauceglia P, Wang D, Kesterson J, Clark K, Monhollen L, **Odunsi K**, Lele S, Liu S. *Microarray analysis reveals distinct gene expression profiles among different tumor histology, stage and disease outcomes in endometrial adenocarcinoma*. PLoS One. 2010;5: e15415.
246. Caballero OL, Zhao Q, Rimoldi D, Stevenson BL, Svobodová S, Devalle S, Röhrig UF, Pagotto A, Michielin O, Speiser D, Wolchok JD, Liu C, Pejovic T, **Odunsi K**, Brasseur F, Van den Eynde BJ, Old LJ, Lu X, Cebon J, Strausberg RL, Simpson AJ. *Frequent MAGE mutations in human melanoma*. PLoS One. 2010;5: e12773.

247. Bolton KL, Tyrer J, Song H, Ramus SJ, Notaridou M, Jones C, Sher T, Gentry-Maharaj A, Wozniak E, Tsai YY, Weidhaas J, Paik D, Van Den Berg DJ, Stram DO, Pearce CL, Wu AH, Brewster W, Anton-Culver H, Ziogas A, Narod SA, Levine DA, Kaye SB, Brown R, Paul J, Flanagan J, Sieh W, McGuire V, Whittemore AS, Campbell I, Gore ME, Lissowska J, Yang HP, Medrek K, Gronwald J, Lubinski J, Jakubowska A, Le ND, Cook LS, Kelemen LE, Brook-Wilson A, Massuger LF, Kiemeny LA, Aben KK, van Altena AM, Houlston R, Tomlinson I, Palmieri RT, Moorman PG, Schildkraut J, Iversen ES, Phelan C, Vierkant RA, Cunningham JM, Goode EL, Fridley BL, Kruger-Kjaer S, Blaeker J, Hogdall E, Hogdall C, Gross J, Karlan BY, Ness RB, Edwards RP, **Odunsi K**, Moyisch KB, Baker JA, Modugno F, Heikkinen T, Butzow R, Nevanlinna H, Leminen A, Bogdanova N, Antonenkova N, Doerk T, Hillemanns P, Dürst M, Runnebaum I, Thompson PJ, Carney ME, Goodman MT, Lurie G, Wang-Gohrke S, Hein R, Chang-Claude J, Rossing MA, Cushing-Haugen KL, Doherty J, Chen C, Rafnar T, Besenbacher S, Sulem P, Stefansson K, Birrer MJ, Terry KL, Hernandez D, Cramer DW, Vergote I, Amant F, Lambrechts D, Despierre E, Fasching PA, Beckmann MW, Thiel FC, Ekici AB, Chen X; the Australian Ovarian Cancer Study Group; the Australian Cancer Study (Ovarian Cancer); on behalf of the Ovarian Cancer Association Consortium, Johnatty SE, Webb PM, Beesley J, Chanock S, Garcia-Closas M, Sellers T, Easton DF, Berchuck A, Chenevix-Trench G, Pharoah PD, Gayther SA. *Common variants at 19p13 are associated with susceptibility to ovarian cancer*. Nat Genet. 2010; 42:880-4
248. Matsuzaki J, Gnjatic S, Mhawech-Fauceglia P, Beck A, Miller A, Tsuji T, Eppolito C, Qian F, Lele S, Shrikant P, Old LJ, **Odunsi K**. *Tumor-infiltrating NY-ESO-1-specific CD8⁺ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer*. Proc Natl Acad Sci U S A. 2010; 107:7875-80.
249. Gnjatic S, Ritter E, Büchler M, Giese N, Brors B, Frei C, Murray A, Halama N, Zörnig I, Chen Y-T, Andrews A, Ritter G, Old L, **Odunsi K**, Jäger D. *Seromic profiling of ovarian and pancreatic cancer*. Proc Natl Acad Sci U S A. 2010; 107:5088-93.
250. Wadle A, Mischo A, Strahl S, Nishikawa H, Held G, Neumann F, Wullner B, Fischer E, Kleber S, Karbach J, Jager E, Shiku H, **Odunsi K**, Shrikant PA, Knuth A, Cerundolo V, Renner C. *NY-ESO-1 protein glycosylated by yeast induces enhanced immune responses*. Yeast. 2010; 27:919-31.
251. Woloszynska-Read A, James SR, Song C, Jin B, **Odunsi K**, Karpf AR. *BORIS/CTCF expression is insufficient for cancer-germline antigen gene expression and DNA hypomethylation in ovarian cell lines*. Cancer Immun. 2010; 10:6.
252. duPont NC, Guru KA, Iskander GB, **Odunsi K**, Lele S, Rodabaugh K. *Instituting a robot-assisted surgery programme at a tertiary cancer care center*. Int J Med Robot. 2010 Sep;6(3):330-3.
253. Rao RR, Li Q, **Odunsi K**, Shrikant PA. *The mTOR kinase determines effector versus memory cell fate of CD8⁺ T cells by regulating T-bet and eomesodermin expression*. Immunity. 2010; 32:67-78.
254. Mhawech-Fauceglia P, Herrmann RF, Kesterson J, Izevbaye I, Lele S, **Odunsi K**. *Prognostic factors in stages II/III/IV and stages III/IV endometrioid and serous adenocarcinoma of the endometrium*. Eur J Surg Oncol. 2010 Dec;36:1195-201.

255. Mhaweche-Fauceglia P, Herrmann FR, Rai H, Tchabo N, Lele S, Izevbaye I, **Odunsi K**, Cheney RT. *IMP3 Distinguishes Uterine Serous Carcinoma from Endometrial Endometrioid Adenocarcinoma*. Am J Clin Pathol. 2010; 133:899-908.
256. Kesterson J, **Odunsi K**, Lele S. *High Cumulative Doses of Pegylated Liposomal Doxorubicin Are Not Associated with Cardiac Toxicity in Patients with Gynecologic Malignancies*. Chemotherapy. 2010 Apr 20;56(2):108-111.
257. Batt R, Mhaweche-Fauceglia P, **Odunsi K**, Yeh J. *Pathogenesis of mediastinal paravertebral müllerian cysts of Hattori: Developmental endosalpingiosis - Müllerianosis*. Int J Gynecol Pathol. 2010 Nov;29:546-51.
258. Cheng L, Lu W, Kulkarni B, Pejovic T, Yan X, Chiang J-H, Hood L, **Odunsi K**, Lin B. *Analysis of chemotherapy response programs in ovarian cancers by the next generation sequencing technologies*. Gynecol Oncol. 2010; 117:159-69.
259. Paczos TA, Ackers S, **Odunsi K**, Lele S, Mhaweche-Fauceglia P. *Primary Vaginal Adenocarcinoma Arising in Vaginal Adenosis After CO2 Laser Vaporization and 5-Fluorouracil Therapy*. Int J Gynecol Pathol. 2010; 29:193-6.
260. Shen J, DiCioccio R, **Odunsi K**, Lele SB, Zhao H. *Novel genetic variants in miR-191 gene and familial ovarian cancer*. BMC Cancer. 2010; 10:47.
261. Akers S, **Odunsi K**, Karpf AR. *Regulation of cancer germline antigen gene expression: implications for cancer immunotherapy*. Future Oncology 2010; 6:717-32.
262. Ferchichi I, Stambouli N, Marrackchi R, Arlot Y, Prigent C, Fadiel A, **Odunsi K**, Ben Ammar Elgaaied A, Hamza A. *Experimental and Computational Studies Indicate Specific Binding of pVHL Protein to Aurora-A Kinase*. J Phys Chem B. 2010;14: 1486-97.
263. Li Q, Eppolito C, **Odunsi K**, Shrikant P. *Antigen induced Erk1/2 activation regulates Ets-1 mediated sensitization of CD8+ T cells for IL-12 responses*. J Leukoc Biol. 2010; 87:257-63.
264. McCloskey S, Tchabo N, Malhotra H, **Odunsi K**, Rodabaugh K, Singhal P, Lele S, Jaggernaut W. *Adjuvant vaginal brachytherapy alone for high risk localized endometrial cancer as defined by the three major randomized trials of adjuvant pelvic radiation*. Gynecol Oncol. 2010; 116:404-7.
265. Pejovic T, Pande NT, Mori M, Mhaweche-Fauceglia P, Harrington C, Mongoue-Tchokote S, Dim D, Andrews C, Beck A, Tarumi Y, Djilas J, Cappuccini F, Caballero O, Huang J, Levy S, Tsiamouri A, Cain J, Bagby G, Strausberg R, Simpson AJ, **Odunsi K**. *Expression Profiling of the Ovarian Surface Kinome Reveals Candidate Genes for Early Neoplastic Changes*. Transl Oncol 2009; 2:341-9.
266. Tchabo NE, Mhaweche-Fauceglia P, Caballero OL, Vilella J, Beck A, Miliotto AJ, Liao J, Andrews C, Lele S, Old LJ, **Odunsi K**. *Expression and serum immunoreactivity of developmentally restricted differentiation antigens in epithelial ovarian cancer*. Cancer

Immun. 2009; 9:6.

267. Qian F, Villella J, Wallace PK, Mhawech-Fauceglia P, Tario, Jr. JD, Andrews C, Matsuzaki J, Valmori D, Ayyoub M, Frederick PJ, Beck A, Liao J, Cheney R, Moysich K, Lele S, Shrikant P, Old LJ, **Odunsi K**. *Efficacy of levo-1-methyl tryptophan and dextro-1-methyl tryptophan in reversing indoleamine-2,3-dioxygenase-mediated arrest of T- cell proliferation in human epithelial ovarian cancer*. Cancer Research. 2009; 69:5498-5504.
268. Leveque L, Deknuydt F, Bioley G, Old L, Matsuzaki J, **Odunsi K**, Ayyoub M, Valmori D. *Interleukin 2-mediated conversion of ovarian cancer associated CD4+ regulatory T cells into pro-inflammatory interleukin 17-producing helper T cells*. J Immunother. 2009; 32:101-108.
269. Tayo BO, DiCioccio RA, Liang Y, Trevisan M, Cooper RS, Lele S, Sucheston L, Piver SM, **Odunsi K**. *Complex segregation analysis of pedigrees from the Gilda Radner Familial Ovarian Cancer Registry reveals evidence for mendelian dominant inheritance*. PloS ONE. 2009;4: e5939.
270. Simpson-Abelson MR, Purohit VS, Pang WM, Iyer V, **Odunsi K**, Demmy TL, Yokota SJ, Loyall JL, Kelleher Jr. RJ, Balu-Iyer S, Bankert RB. *IL-12 delivered intratumorally by multilamellar liposomes reactivates memory T cells in human tumor microenvironments*. Clinical Immunol. 2009; 132:71-82.
271. Lin B, White JT, Wu J, Lele S, Old LJ, Hood L, **Odunsi K**. *Deep depletion of abundant serum proteins reveals low abundant proteins as biomarker for human ovarian cancer*. Proteomics Clin App, 2009;3:853-61.
272. Britten CM, Janetzki S, Ben-Porat L, Clay TM, Kalos M, Maecker H, **Odunsi K**, Pride M, Old LJ, Hoos A, Romero P. for the HLA-peptide Multimer Proficiency panel of the CVC-CRI Immune Assay Working Group. *Harmonization guidelines for HLA-peptide multimer assays derived from results of a large-scale international proficiency panel of the Cancer Vaccine Consortium (CVC)*. Cancer Immunol Immunother. 2009; 58:1701-13.
273. Chen YT, Hsu M, Lee P, Shin SJ, Mhawech-Fauceglia P, **Odunsi K**, Altorki NK, Song CJ, Jin BQ, Simpson AJ, Old LJ. *Cancer/testis antigen CT45: Analysis of mRNA and protein expression in human cancer*. Int J Cancer. 2009; 124:2893-8.
274. Mhawech-Fauceglia P, Herrmann FR, Wagner H, Godoy H, **Odunsi K**, Cheney RT, Lele S. *Submission of the entire lymph node dissection for histologic examination in gynecologic-oncology specimens*. Gynecol Oncol. 2009; 115:354-6.
275. Sukumaran D, Garcia E, Hua J, Tabaczynski W, **Odunsi K**, Andrews C, Szyperki T. *Standard operating procedure for metabolomics studies of blood serum and plasma samples using a 1H-NMR micro-flow probe*. Magn Reson Chem. 2009; 47, S81–S85.
276. Tchabo NA, McCloskey S, Mashtare TL, Andrews C, Singh AK, **Odunsi K**, Lele S, Jaggernauth W. *Treatment of early stage uterine papillary serous carcinoma at Roswell Park Cancer Institute, 1992-2006*. Gyne Onc. 2009; 115:249-256.

277. Mhaweche-Fauceglia P, Herrmann FR, Andrews C, South S, Beck A, Lele S, **Odunsi K**. *14-3-3 β Expression and prognostic value in patients with epithelial ovarian carcinoma: A high throughput tissue microarray analysis*. Eur J Surg Oncol. 2009; 35:763-7.
278. Rai H, **Odunsi K**, Kesterson J, Morrison C, Chan A, Mhaweche-Fauceglia P. *Epithelioid sarcoma of the vulva in a 17-year-old pregnant woman*. Appl Immunohistochem Mol Morphol. 2009; 17:270-273.
279. Miyahara Y, **Odunsi K**, Chen W, Peng G, Matsuzaki J, Wang RF. *Generation and regulation of human CD4+ IL-17-producing T cells in ovarian cancer*. Proc Natl Acad Sci U S A. 2008; 105:15505-10.
280. Tosello V, **Odunsi K**, Souleimanian NE, Lele S, Shrikant P, Old LJ, Valmori D, Ayyoub M. *Differential expression of CCR7 defines two distinct subsets of human memory CD4(+) CD25(+) Tregs*. Clin Immunol. 2008; 126:291-302.
281. Woloszynska-Read A, Mhaweche-Fauceglia P, Yu J, **Odunsi K**, Karpf A. *Intertumor and intratumor NY-ESO-1 expression heterogeneity is associated with promoter-specific and global DNA methylation status in ovarian cancer*. Clin Cancer Res. 2008; 14:3283-90.
282. Yin B, Kiyamova R, Chua R, Caballero OL, Gout I, Gryshkova V, Bhaskaran N, Souchelnytskyi S, Hellman U, Filonenko V, Jungbluth AA, **Odunsi K**, Lloyd KO, Old LJ, Ritter G. *Monoclonal antibody MX35 detects the membrane transporter NaPi2b (SLC34A2) in human carcinomas; a new target for cancer immunotherapy*. Cancer Immunity. 2008; 8:3.
283. Mhaweche-Fauceglia P, Smiraglia DJ, Bshara W, Andrews C, Schwaller J, South S, Higgs D, Lele S, Herrmann F, **Odunsi K**. *Prostate-Specific Membrane Antigen expression is a potential prognostic marker in endometrial adenocarcinoma*. Cancer Epidemiol Biomarkers Prev. 2008; 17:571-7.
284. Mhaweche-Fauceglia P, **Odunsi K**, Dim D, Nowak N, Lele S, Cheney RT, Pejovic, T. *Array-comparative genomic hybridization analysis of primary endometrial and ovarian high-grade neuroendocrine carcinoma associated with adenocarcinoma: Mystery resolved?* Int J Gynecol Pathol. 2008; 27:539-46.
285. Mhaweche-Fauceglia P, Allal A, **Odunsi K**, Andrews C, Herrmann FR, Huard B. *Role of the tumour necrosis family ligand APRIL in solid tumour development: Retrospective studies in bladder, ovarian and head and neck carcinomas*. Eur J Cancer. 2008; 44:2097-100.
286. Shen J, Ambrosone CB, Dicioccio R, **Odunsi K**, Lele SB, Zhao H. *A Functional Polymorphism in the miR-146a Gene and Age of Familial Breast/Ovarian Cancer Diagnosis*. Carcinogenesis. 2008; 29:1963-6.
287. Matsuzaki J, Qian F, Luescher I, Lele S, Ritter G, Shrikant PA, Gnjatich S, Old LJ, **Odunsi K**. *Recognition of naturally processed and ovarian cancer reactive CD8+ T cell epitopes within a promiscuous HLA class II T-helper region of NY-ESO-1*. Cancer Immunol Immunother. 2008;57(8):1185-95.

288. Ghadersohi A, **Odunsi K**, Fayazi Z, Zhang S, Azruk RG, Bundy BN, Manjili MH, Rustum YM, Li F. *Prostate-derived Ets transcription Factor as a favorable prognostic marker on ovarian cancer patients*. Int J Cancer. 2008; 123:1376-84.
289. Mhaweche-Fauceglia P, Pejovic T, Dim D, Fang X, Conroy J, Lele S, Cheney R, **Odunsi K**. *Array-based comparative genomic hybridization (aCGH) analysis is a useful tool for distinguishing primary pulmonary from metastatic neuroendocrine carcinoma to the lung*. Appl Immunohistochem Mol Morphol. 2008; 16:291-295.
290. Mhaweche-Fauceglia P, Rai H, Nowak N, Cheney RT, Rodabaugh K, Lele S, **Odunsi K**. *The use of array-based comparative genomic hybridization (a-CGH) to distinguish metastatic from primary synchronous carcinomas of the ovary and the uterus*. Histopathology. 2008; 53:490-495.
291. Mhaweche-Fauceglia P, Herrman F, Bshara W, Zhang S, Penetrante R, Lele S, **Odunsi K**, Rodabaugh K. *Intraobserver and interobserver variability in distinguishing between endocervical and endometrial adenocarcinoma on problematic cases of cervical curetings*. Int J Gynecol Path. 2008; 27:431-6.
292. Woloszynska-Read A, James SR, Link PA, Yu J, **Odunsi K**, Karpf AR. *DNA methylation-dependent regulation of BORIS/CTCF expression in ovarian cancer*. Cancer Immun. 2007 Dec 21; 7:21.
293. **Odunsi K**, Qian F, Matsuzaki J, Mhaweche-Fauceglia P, Andrews C, Hoffman EW, Pan L, Ritter G, Vilella J, Thomas B, Rodabaugh K, Lele S, Shrikant P, Old LJ, Gnjatich S. *Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T-cell responses in ovarian cancer*. Proc Natl Acad Sci U S A. 2007; 104:12837-42.
294. Sharma S, Tammela J, Wang X, Arnouk H, Driscoll D, Mhaweche-Fauceglia P, Lele S, Kazim AL, **Odunsi K**. *Characterization of a Putative Ovarian Oncogene, Elongation Factor 1{alpha}, Isolated by Panning a Synthetic Phage Display Single-Chain Variable Fragment Library with Cultured Human Ovarian Cancer Cells*. Clin Cancer Res. 2007; 13:5889-96.
295. Aikhionbare FO, Mehrabi S, Kumaresan K, Zavareh M, Olatinwo M, **Odunsi K**, Partridge E. *Mitochondrial DNA sequence variants in epithelial ovarian tumor subtypes and stages*. J Carcinog. 2007 26;6(1):1.
296. Moysich KB, Baker JA, Menezes RJ, Jayaprakash V, Rodabaugh KJ, **Odunsi K**, Beehler GP, Zirpoli G, McCann SE, Vilella JA. *Usual Adult Body Mass Index is Not Predictive of Ovarian Cancer Survival*. Cancer Epidemiol Biomarkers Prev. 2007; 16:626-8.
297. Shamshirsaz AA, Withiam-Leitch M, **Odunsi K**, Baker T, Frederick P, Lele S. *Young patients with endometrial carcinoma selected for conservative treatment: A need for vigilance for synchronous ovarian carcinomas, case report and literature review*. Gynecol Oncol. 2007; 104:757-60.
298. Sabbatini P, **Odunsi K**. *Immunologic approaches to ovarian cancer treatment*. J Clin.

- Oncol. 2007; 25:2884-93.
299. Singhal P, Tchabo N, **Odunsi K**. *Immunologic markers of cancer progression and prognosis*. Exp Opin Med Diagn. 2007; 1:439-450.
300. **Odunsi K**, Sabbatini P. *Harnessing the immune system for ovarian cancer therapy*. Amer J Reprod Immunol. 2007; 59:62-74.
301. **Odunsi K**, Old LJ. *Tumor infiltrating lymphocytes: indicators of tumor-related immune responses*. Cancer Immun [serial online] 2007; 7:3.
302. Li Q, Eppolito C, **Odunsi K**, Shrikant P. *IL-12-Programmed long-term CD8+ T responses require STAT4*. J Immunol. 2006; 177:7618-25.
303. Sabbatini P, Dupont J, Aghajanian C, Derosa F, Poynor E, Anderson S, Hensley M, Livingston P, Iosonos A, Spriggs D, McGuire W, Reinartz S, Schnieder S, Grande C, Lele S, Rodabaugh K, Kepner J, Ferrone S, **Odunsi K**. *Phase I study of the antibody abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer*. Clin Cancer Res. 2006; 12:5503-10.
304. Nishikawa H, Qian F, Tsuji T, Ritter G, Old LJ, Gnjatic S, **Odunsi K**. *Influence of CD4⁺CD25⁺ regulatory T cells on low/ high-avidity CD4⁺ T cells following peptide vaccination*. J Immunol. 2006; 176:6340-6.
305. Mhaweche-Fauceglia P, Herrmann FR, Bshara W, **Odunsi K**, Terracciano L, Sauter G, Cheney RT, Groth J, Penetrante R, Mhaweche-Fauceglia P. *Friend leukaemia integration-1 expression in malignant and benign tumours: a multiple tumour tissue microarray analysis using polyclonal antibody*. J Clin Pathol. 2007;60(6):694-700.
306. Valmori D, Qian F, Ayyoub M, Renner C, Merlo A, Gnjatic S, Stockert E; Driscoll D, Lele S, Old LJ, **Odunsi K**. *Expression of SSX antigen in epithelial ovarian cancer and identification of SSX-4 epitopes recognized by CD4⁺ cells*. Clin Cancer Res. 2006;12(2)398-404.
307. Mhaweche-Fauceglia P, Herrmann F, Penetrante R, Beck A, Sait S, Block AM, Malik D, **Odunsi K**, Fisher J, Balos L, Cheney RT. *Diagnostic Utility Of FLI-1 Monoclonal Antibody And Dual-Color, Break-Apart Probe Fluorescence In Situ (FISH) Analysis In Ewing's Sarcoma/ Primitive Neuroectodermal Tumor (EWS/PNET) A comparative Study to CD99 and FLI-1 Polyclonal Antibodies*. Histopathology. 2006; 49:569-75.
308. Collins Y, DiCioccio R, Keitz B, Lele S, **Odunsi K**. *Methylation of Death Associated Protein (DAP) kinase in ovarian carcinomas*. Int J Gynecol Cancer. 2006;16 (Suppl 1):195-9.
309. Hylander B, Repasky E, Shirkant P, Intengan M, Beck A, Driscoll D, Singhal P, Lele S, **Odunsi K**. *Expression of Wilm's tumor gene (WT1) in epithelial ovarian cancer*. Gynecol Oncol. 2006;101(1):12-7.
310. VILLELLA J, Herrmann FR, Kaul S, Lele S, Marchetti D, Natiella J, **Odunsi K**, Mhaweche-

Fauceglia P. *Clinical and Pathologic Predictive Factors in Women with Adult-Type Granulosa Cell Tumor of the Ovary*. Int J Gynecol Path. 2007; 26:154-9.

311. Sharma S, Rezai K, Driscoll D, **Odunsi K**, Lele S. *Characterization of neutropenic fever in patients receiving first-line adjuvant chemotherapy for epithelial ovarian cancer*. Gynecol Oncol. 2006; 103:181-5.
312. Fischer G, **Odunsi K**, Lele S, Mhaweche P. *Ovarian primary primitive neuroectodermal tumor (PNET) co-existing with endometrioid adenocarcinoma: A case report*. Int J Gynecol Path. 2006; 25:151-4.
313. Fisher D, Chen Q, Appenheimer M, Skitzki J, Wang W-C, **Odunsi K**, Evans S. *Hurdles to Lymphocyte Trafficking in the Tumor Microenvironment: Implications for Effective Immunotherapy*. Immunol Invest. 2006; 35:251-77.
314. Singhal P, **Odunsi K**, Driscoll D, Rodabaugh K, Lele S. *Primary fallopian tube carcinoma restrospective clinicopathologic study*. Eur J Gynaec Oncol. 2006;27(1):16-8.
315. Tammela J, Uenaka A, Ono T, Noguchi Y, Jungbluth A, Mhaweche-Fauceglia P, Qian F, Schneider S, Driscoll D, Lele S, Old L, Nakayama E, **Odunsi K**. *OY-TES-1 Expression and Serum Immunoreactivity in Epithelial Ovarian Cancer*. Int J Oncol. 2006; 29:903-10.
316. Kidd K, Pakstis A, Speed WC, Grigorenko E, Kajuna S, Karoma NJ, Kungulilo S, Kim J, Lu R, **Odunsi K**, Okonofua F, Parnas J, Schulz L, Zhukova O, Kidd J. *Developing a SNP panel for forensic identification of individuals*. Forensic Sci Int. 2006; 164:20-32.
317. Vilella J, **Odunsi K**, Lele S. *The role of IDO in immune system evasion of malignancy: Another piece to the tolerance puzzle*. Cancer Therapy. 2006;4A:427-34. [Epub]
318. Sato E, Olson SH, Ahn J, Jungbluth AA, Frosina D, Bundy B, Qian F, Gnjjatic S, Ambrosone C, Kepner J, Keitz B, Odunsi T., Ritter G, Lele S, Chen Y, Ohtani H, Old LJ, **Odunsi K**. *Intraepithelial CD8+ Tumor infiltrating lymphocytes and high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer*. Proc Natl Acad Sci U S A. 2005; 102:18538-43
319. Sharma S, Driscoll D, **Odunsi K**, Venkatadri A, Lele S. *Safety and efficacy of cytoreductive surgery for epithelial ovarian cancer in elderly and high-risk surgical patients*. Am J Obstet Gynecol. 2005; 193:2077-82.
320. Han Y, Oota H, Osier MV, Pakstis AJ, Speed WC, **Odunsi K**, Okonofua F, Kajuna SLB, Nganyirwa, Karoma J, Kungulilo S, Grigorenko E, Zhukova OV, Bonne-Tamir B, Lu RB, Parnas J, Schulz LO, Kidd JR, Kidd KK. *Considerable Haplotype Diversity within the 23kb Encompassing the ADH7 Gene*. Alcohol Clin Exp Res. 2005; Dec;29(12):2091-2100.
321. Menakaya U, Otoide V, Agboja LO, **Odunsi K**, Okonofua F. *Experience with misoprostol in the management of missed abortion in the second trimester*. J Obstet Gynaecol.2005;25:583-5.
322. Sharma S, Qian F, Driscoll D, Scanlan MJ, Skipper J, Rodabaugh KJ, Lele S, Old LJ,

Odunsi K. *A-kinase anchoring protein 3 messenger rna expression correlates with poor prognosis in epithelial ovarian cancer.* Gynecol Oncol. 2005; 99:183-8.

323. **Odunsi K,** Wollman R, Ambrosone C, Hutson A, McCann S, Tammela J, Geisler JP, Miller G, Sellers T, Cliby W, Qian F, Keitz B, Intengan M, Lele S, Alderfer JL. *Detection of epithelial ovarian cancer using ¹H-NMR- based metabonomics.* Int J Cancer. 2005; 113:782-788.
324. Qian F, **Odunsi K,** Blatt L, Scanlan M, Mannan M, Shah N, Montgomery J, Haddad F, Taylor M. *Tumor associated antigen recognition by autologous serum in patients with breast cancer.* Int J Mol Med. 2005; 15:137-144.
325. Sharma S, **Odunsi K,** Driscoll D, Lele S. *Pelvic extenterations for gynecologic malagancies: 20 years experience at Roswell Park Cancer Institute.* Int J Gynecol Cancer. 2005; 15:475-482.
326. Singhal P, Spiegel G, Driscoll D, **Odunsi K,** Lele S, Rodabaugh K. *Cyclooxygenase 2 expression in serous tumors of the ovary.* Int J Gynecol Path. 2005; 24:62-66.
327. Sharma S, **Odunsi K.** *Targeted therapy for epithelial ovarian cancer.* Expert Opin Ther Targets. 2005;9(3):501-13.
328. Vilella J, Marchetti D, **Odunsi K,** Rodabaugh K, Driscoll DL, Lele S. *Response of combination platinum and gemcitabine chemotherapy for recurrent epithelial ovarian carcinoma.* Gynecol Oncol. 2004; 95:539-545.
329. Qian F, Gnjatic S, Jager E, Darren Santiago D, Jungbluth A, Grande C, Schneider S, Keitz B, Ritter G, Lele S, Sood A, Old LJ, **Odunsi K.** *T Helper Type1 (Th1)/Th2 CD4⁺ Tcell responses against NY-ESO-1 in HLA-DPBI*0401/0402 patients with epithelial ovarian cancer.* Cancer Immun. 2004; 4:12.
330. Pejovic T, Ladner D, Intengan M, Zheng K, Fairchild T, Easley S, Dillon D, Marchetti D, Schwartz P, Lele S, **Odunsi K.** *Somatic D-loop mitochondrial DNA mutations are frequent in uterine serous carcinoma.* Eur J Cancer. 2004; 40:2519-2524.
331. Tammela J, Jungbluth AA, Qian F, Santiago D, Scanlan M, Keitz B, Driscoll D, Rodabaugh K, Lele S, Old LJ, **Odunsi K.** *SCP-1 “Cancer / Testis” antigen is a prognostic indicator and a candidate target for immunotherapy in epithelial ovarian cancer.* Cancer Immun. 2004; 4:10.
332. Collins Y, Tan DF, Pejovic T, Mor G, Rutherford T, Varma R, McQuaid D, Driscoll D, Jiang M, Deeb G, Lele S, Nowak N, **Odunsi K.** *Identification of differentially expressed genes in clinically distinct groups of serous ovarian carcinomas using cDNA microarray.* Int J Mol Med. 2004 Jul; 14:43-53.
333. Olawaiye A, Caesar ML, Walsh D, Lyman M, Yeh J, Rodabaugh R, Marchetti D, Shashikant Lele S, **Odunsi K.** *Analysis of the time interval between diagnoses in women with double primary breast and ovarian or primary peritoneal cancers.* Gynecol Oncol. 2004; 94:796-802.

334. Oota H, Pakstis AJ, Bonne-Tamir B, Goldman D, Grigorenko E, Kajuna SL, Karoma NJ, Kungulilo S, Lu RB, **Odunsi K**, Okonofua F, Zhukova OV, Kidd JR, Kidd KK. The evolution and population genetics of the ALDH2 locus; random genetic drift, selection, and low levels of recombination. *Ann Hum Genet.* 2004; 68:93-109.
335. Tammela J, Bundy B, **Odunsi K**. Reassessment of pelvic lymph node debulking in advanced cervical cancer. *Gynecol Oncol.* 2004; 92:1014-1015.
336. **Odunsi K**, Moneke V, Tammela J, Ghamande S, Seago P, Baker T, Marchetti D, Lele S. Efficacy of Adjuvant CYVADIC chemotherapy in early stage uterine sarcomas: results of long-term follow-up. *Int J Gynecol Cancer.* 2004; 14:659-664.
337. Palmatier MA, Pakstis AJ, Speed W, Paschou P, Goldman D, **Odunsi A**, Okonofua F, Kajuna S, Karoma N, Kungulilo S, Grigorenko E, Zhukova OV, Bonne-Tamir B, Lu R, Parnas J, Kidd JR, DeMille M, Kidd KK. COMT haplotypes suggest P2 promoter region relevance for schizophrenia. *Mol Psychiatry.* 2004; 9:859-870.
338. dos Santos L, **Odunsi K**, Lele S. Clinicopathologic outcome of laser conization for high-grade cervical dysplasia. *Eur J Gynaec Oncol.* 2004; 25:305-307.
339. Sirugo G, Ashenbrenner J, **Odunsi K**, Morakinyo O, Page G. No evidence of association between the genetic predisposition of dizygotic twinning and schizophrenia in West Africa. *Schizophr Res.* 2004; 70:343-344
340. Ghadersohi A, **Odunsi K**, Lele S, Collins Y, Greco WR, Winston JS, Liang P, Sood AK. *Prostate derived Ets transcription factor shows better tumor-association than other cancer-associated molecules.* *Oncol Rep.* 2004; 11:453-58.
341. **Odunsi K**, Olatinwo M, Collins Y, Withiam-Leitch M, Lele S, Spiegel G. *Primary primitive neuroectodermal tumor (PPNET) of the uterus: a report of 2 cases and review of the literature.* *Gynecol Oncol.* 2004; 92:689-696.
342. Tammela J, **Odunsi K**. *Gene expression and prognostic significance in ovarian cancer.* *Minerva Ginecol.* 2004; 56:495-02.
343. **Odunsi K**, Lele S, Savalgi R. Vaccine Therapy for Cancer: Fact or Fiction? *Surg Technol Int.* 2004; 13:39-47
344. **Odunsi K**, Jungbluth A, Stockert E, Qian F, Gnajtlic S, Tammela J, Intengan M, Beck A, Keitz B, Santiago D, Williamson B, Scanlan MJ, Ritter G, Chen YT, Driscoll D, Sood A, Lele S, Old LJ. *NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer.* *Cancer Res.* 2003; 63:6076-6083.
345. Chattopadhyay P, Pakstis AJ, Mukherjee N, Iyengar S, **Odunsi K**, Okonofua F, Bonne-Tamir B, Speed W, Kidd JR, Kidd KK. 2003. *A global survey of haplotype frequencies and linkage disequilibrium at the RET locus.* *Eur J Hum Genet.* 2003; 11:760-769.
346. Ghamande S, Lele S, Marchetti D, Baker T, **Odunsi K**. *Weekly paclitaxel in patients with recurrent or persistent advanced ovarian cancer.* *Int J Gynecol Cancer.* 2003; 13:142-147.

347. Tammela JE, Lele S, **Odunsi K**. *A human papillomavirus type 16 vaccine (letter)*. NEJM. 2003; 348:1402.
348. DeMille MC, Kidd JR, Ruggeri V, Palmatier MA, Goldman D, **Odunsi K**, Okonofua F, Grigorenko E, Schulz LO, Bonne-Tamir B, Lu RB, Parnas J, Pakstis AJ, Kidd KK. *Population variation in linkage disequilibrium across the COMT gene considering promoter region and coding region variation*. Hum Genet. 2002; 111:521-537.
349. **Odunsi K**, Ghamande S, Chandrasekaran EV, Ta A, Moysich KB, Driscoll D, Matta K, Lele S. *Evaluation of beta1,4-galactosyltransferase as a potential biomarker for the detection of subclinical disease after the completion of primary therapy for ovarian cancer*. Am J Obstet Gynecol. 2002; 187:575-580.
350. Osier MV, Pakstis AJ, Soodyall H, Comas D, Goldman D, **Odunsi K**, Okonofua F, Parnas J, Schulz L, Bertranpetit J, Bonne-Tamir B, Lu R, Kidd JR, Kidd K. *A global perspective on genetic variation at the ADH genes reveals unusual patterns of linkage disequilibrium and diversity*. Am J Hum Genet. 2002; 71:84-99.
351. Anupol N, Ghamande S, **Odunsi K**, Driscoll D, Lele S. *Evaluation of prognostic factors and treatment modalities in ovarian cancer patients with brain metastasis*. Gynecol Oncol. 2002; 85:487-492.
352. **Odunsi K**. *A masterpiece on maternity care in developing countries*. Lancet. 2002; 360:1897.
353. Ghadersohi A, Chitta K, Greco WR, Harvey S, Winston J, Slocum H, **Odunsi K**, Sood A. *Tumor antigens and markers for breast and ovarian cancers*. Front Biosci. 2002;7: e48-57.
354. **Odunsi K**, Ganesan TS. *Motif analysis of HLA class II molecules that determine the HPV associated risk of cervical carcinogenesis*. Int J Mol Med. 2001; 8:405-412.
355. **Odunsi K**, Lele S, Ghamande S, Seago P, Driscoll D. *The impact of pre-therapy extraperitoneal surgical staging on the evaluation and treatment of patients with locally advanced cervical cancer*. Eur J Gynecol Oncol. 2001; 5:325-330.
356. Chandrasekaran EV, Chawda R, Piskorz C, Locke RD, Ta A, Ghamande S, **Odunsi K**, Lele S, Matta K. *Human ovarian cancer, lymphoma spleen, and bovine milk GlcNac:β1,4Gal/GalNac transferases: two molecular species in ovarian tumor and induction of GalNacβ1,4Glc synthesis by α-lactalbumin*. Carbohydr Res. 2001; 334:105-118.
357. Pejovic T, **Odunsi K**. *Controversies in ovarian cancer (letter)*. Am J Obstet Gynecol. 2001; 184:1310-1311.
358. **Odunsi K**, Van Ee C, Ganesan TS, Shelling AN. *Evaluation of the possible protective role of adeno-associated virus type II infection in HPV associated cervical neoplasia*. Gynecol Oncol. 2000; 78:342-345.
359. Kidd JR, Pakstis AJ, Ru-Band L, Okonofua FE, **Odunsi K**, Grigorenko E, Batsheva BT,

Kidd KK. *Haplotypes and linkage disequilibrium at the phenylalanine hydroxylase locus (PAH) in a global representation of populations*. Am J of Hum Genet. 2000; 66:1882-1889.

360. **Odunsi K**, Pejovic T, Savalgi R. *Principles of evidence-based screening for cancers*. Surg Technol Int, IX. 2000;318-332.
361. **Odunsi K**, Kidd KK. *A paradigm for finding genes for a complex human trait: Polycystic ovary syndrome and follistatin*. Proc Nat Acad Sci, USA. 1999; 96:8315-8317.
362. Pejovic T, Burki N, **Odunsi K**, Fielder P, Achong N, Schwartz P, Ward DC. *Well differentiated mucinous carcinoma of the ovary and a co-existing Brenner tumor both exhibit amplification of 12q14-21 by comparative genomic hybridization (CGH)*. Gynecol Oncol. 1999; 74:134-137.
363. Johns BJ, **Odunsi K**, Fleischman S, Azodi M, Schwartz P. *Serous adenocarcinoma of the endometrium presenting as paraneoplastic cerebellar degeneration: a case report*. Gynecol Oncol. 1999; 73:326-330.
364. **Odunsi K**, Rutherford TJ, Olive DL, Brown J, Parkash V, Bia F, Zreik TG. *Cryomyolysis in the treatment of uterine fibroids: techniques and complications*. Surg Technol Int, VIII. 1999;171-174.
365. Zreik T, **Odunsi K**, Sarrel P, Olive D. *Fatal pulmonary thromboembolism associated with the use of intravenous premarin therapy for menometrorrhagia: a case Report*. Fertil Steril. 1999; 71:373-375.
366. **Odunsi K.**, Peck LL, Kohorn EI, Parkash V, Cracchiolo B, Chambers JT, Taylor K. *Necrosis of Myometrial Choriocarcinoma with Fulminating Sepsis Complicating Chemotherapy for Trophoblastic Tumor*. Gynecol Oncol. 1998; 70:100-104.
367. **Odunsi K**, Olive D, Rutherford TJ, Zreik TG. *Abscess formation in a uterine fibroid treated with cryomyolysis*. J Gynecol Tech. 1998; 4:115-118.
368. **Odunsi K**, Cooke I, Olive D. *Evidence-based medicine: How do we find the evidence?* J Am Assoc Gynecol Laparosc. 1998; 5:313-318
369. **Odunsi K**, Ganesan TS. *The roles of the Human Major Histocompatibility Complex and Human Papillomavirus in Cervical Intra-epithelial Neoplasia and Cervical Cancer*. Clin Oncol. 1997; 9:4-13.
370. **Odunsi K**, Terry G, Ho L, Bell J, Cuzick J, Ganesan TS. *Susceptibility to Human Papillomavirus associated cervical intra-epithelial neoplasia is determined by specific HLA DR-DQ alleles*. Int J Cancer. 1996; 67:595-602.
371. **Odunsi K**, Bullough CHW, Henzel J, Polanska I. *Fetal bleeding from vasa praevia: evaluation of existing chemical tests*. Int J Gynaecol Obstet. 1996; 55:207-212.
372. **Odunsi K**, Terry G, Ho L, Bell J, Cuzick J, Ganesan TS. *Association between HLA DQB1*03 and cervical intra-epithelial neoplasia*. Mol Med. 1995; 1:161-171.

373. Mehal WZ, Lo YMD, Herrington CS, Evans M, Papadopoulos MC, **Odunsi K**, Ganesan TS, McGee JO'D, Bell JI, Fleming KA. *Role of human papillomavirus in determining the HLA associated risk of cervical carcinogenesis.* J Clin Pathol. 1994; 47:1077-1081.
374. Okonofua FE, Onwudiegwu U, **Odunsi K**. *Illegal Induced Abortion: A study of 74 new cases in Ile-Ife, Nigeria.* Trop Doct. 1992; 22:75-78.
375. Okonofua FE, **Odunsi K**, Hussain S, O'Brien PMS. *Evaluation of the Roll-Over Test as a predictor of gestational hypertension in African Women.* Int J Gynecol Obstet. 1991; 35:37-40.
376. Okonofua FE, Onwudiegwu U, **Odunsi K**. *Preterm Premature Rupture of Fetal Membranes in a low socio-economic population: Results of conservative management.* Int J Gynecol Obstet. 1991; 34:35-39.
377. Okonofua FE, Onwudiegwu U, **Odunsi K**, Hussain S, O'Brien PMS. *Does Standing Up Improve the Predictive Value of the Supine Pressor Test for Gestational Hypertension?* Obstet Gynecol. 1990; 76:332-335.
378. Okonofua FE, Ojo OS, **Odunsi K**, Odesanmi WO. *Ectopic Pregnancy Associated with Tubal Schistosomiasis in a Nigerian Woman.* Int J Gynecol Obstet. 1990; 32:281-284.
379. Sule-Odu AO, Fakoya TA, Odutayo R, **Odunsi K**. *Advanced Abdominal Pregnancy Complicated by Uterine Prolapse: A case report.* Niger Med Pract. 1989; 18:49-50.

BOOKS

1. Okonofua F, Briggs ND, Otubu JA, **Odunsi K.** Editors. *Contemporary Obstetrics and Gynecology for Developing Countries.* Women's Health & Action Research Center, Benin City, Nigeria. 2004.
2. **Odunsi K,** Pejovic T. Editors. *Gynecological Cancers: A Multidisciplinary Approach to Diagnosis and Management* (Current Multidisciplinary Oncology Series). Thomas CR, Series Editor. Demos Medical, New York, NY. 2013.

BOOK CHAPTERS

1. Agyemang A, **Odunsi K**. The use of immunotherapy for treatment of chemoresistant ovarian cancer. In: Overcoming Ovarian Cancer Chemoresistance. Bonavida B, editor. Elsevier Inc., Oxford, UK. 2020; 79-96.
2. **Odunsi K**, Trimble C. Immunotherapy for Gynecologic Malignancies. In: Cancer Immunotherapy Principles and Practice. L. H. Butterfield, H. L. Kaufman, F. M. Marincola, editors. New York, NY. 2017; 684-701
3. Amobi A, Qian F, Lugade A, **Odunsi K**. Tryptophan catabolism and cancer immunotherapy targeting IDO mediated immune suppression. In: The Microenvironment in Cancer Progression and Cancer Therapy. P Kalinski, editor. New York, NY. 2017; 129-144
4. Pejovic T, Birrer MJ, Anderson ML, **Odunsi K**. Molecular Biology of Gynecological Cancers. In: Cancer: Principles and Practice of Oncology (10th Edition). DeVita Jr V, Lawrence TS, Rosenberg SA, editors. Wolters Kluwer Health, Philadelphia, PA. 2015;1005-1012.
5. Daudi S, Godoy H, **Odunsi K**. Genomic and Proteomic Biomarkers for Ovarian Cancer Screening, Prognosis and Individualization of Chemotherapy. In: Gynecologic Cancers: A Multidisciplinary Approach to Diagnosis and Management (Current Multidisciplinary Oncology Series).**Odunsi K**, Pejovic T, Editors, Thomas CR, Series Editor. Demos Medical, New York, NY. 2013; 247-270.
6. Sabbatini P, **Odunsi K**, Pfisterer J, Coukos G. Immunotherapy of Gynecologic Malignancies. In: Principles and Practice of Gynecologic Oncology (6th Edition). Barakat RR, Berchuck A, Markman M, Randall ME, editors. Lippencott, Willilams and Wilkins, Philadelphia, PA. 2013; 434-456.
7. Pejovic T, Anderson M, **Odunsi K**. Ovarian Cancer. In: Genomic and Personalized Medicine (2nd Edition). Ginsburg GS and Willard HF, editors. Elsevier Inc., Oxford, UK. 2013; 714-721.
8. **Odunsi K**, Pejovic T, Anderson M. Molecular Biology of Gynecological Cancers. In: Cancer: Principles and Practice of Oncology (9th Edition). DeVita Jr V, Lawrence T, Rosenberg S, editors. Lippencott Williams & Wilkins, Baltimore, MD. 2011;1302-1310.
9. van den Broek M, von Boehmer L, **Odunsi K**, Knuth A. Cancer Immunity and Clinical Oncology. In: Oxford Textbook of Medicine, 5th Edition Warrell DA, Cox TA, Firth JD, editors. Oxford University Press. USA. 2010; Section 06.04.
10. **Odunsi K**. Oncogenes Meet Metabolism: From Deregulated Genes to a Broader Understanding of Tumour Physiology. In: Ernst Schering Foundation Symposium Proceedings 07.4. Kroemer G, Mumberg D, Keun H, Riefke B, Steger-Hartmann T, Peterson K, editors. Springer-Verlag Berlin Heidelberg, New York. 2008; 205-226.
11. South S, **Odunsi K**. Preventive strategies and non-invasive treatment options for cervical pre-invasive and invasive disorders. In: Non-invasive management of

Gynecologic Disorders. Arici A, Seli E, editors. Informa Healthcare, London, United Kingdom. 2008; 253-269.

12. **Odunsi K**, Pejovic T, Anderson M. Molecular Biology of Gynecological Cancers. In: Cancer: Principles and Practice of Oncology (8th Edition). DeVita Jr V, Lawrence T, Rosenberg S, editors. Lippencott Williams & Wilkins, Baltimore, MD. 2008;1487-1496.
13. **Odunsi K**, Simpson A, Skipper J, Old L. Cancer vaccines: achievements, challenges and perspectives. In: Cancer in Africa. Ly A and Khayat D, editors. Institut National du Cancer, Cedex, France. 2006; 711-730.
14. **Odunsi K**, Odutayo R. Premature rupture of fetal membranes. In: Contemporary Obstetrics and Gynecology for Developing Countries. Okonofua F, Briggs ND, Otubu JA, Odunsi K, editors. Women's Health & Action Research Center, Benin City, Nigeria. 2004:430-453.
15. **Odunsi K**, Gian-Carlo M, Schwartz PES. Radiologic diagnosis of cancer in pregnancy. In: Cancer and Pregnancy. Barnea ER, Jauniaux E, Schwartz PE and Scholfield PE, editors. London: Springer-Verlag. 2001; 81-92.